
<html lang="en"     class="pb-page"  data-request-id="e964e49e-eda9-4aaf-b267-a8e57bb71313"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-9;article:article:10.1021/acs.jmedchem.8b02012"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease" /></meta><meta name="dc.Creator" content="Malin  Lemurell" /></meta><meta name="dc.Creator" content="Johan  Ulander" /></meta><meta name="dc.Creator" content="Hans  Emtenäs" /></meta><meta name="dc.Creator" content="Susanne  Winiwarter" /></meta><meta name="dc.Creator" content="Johan  Broddefalk" /></meta><meta name="dc.Creator" content="Marianne  Swanson" /></meta><meta name="dc.Creator" content="Martin A.  Hayes" /></meta><meta name="dc.Creator" content="Luna  Prieto Garcia" /></meta><meta name="dc.Creator" content="Annika  Westin Eriksson" /></meta><meta name="dc.Creator" content="Johan  Meuller" /></meta><meta name="dc.Creator" content="Johan  Cassel" /></meta><meta name="dc.Creator" content="Gabrielle  Saarinen" /></meta><meta name="dc.Creator" content="Zhong-Qing  Yuan" /></meta><meta name="dc.Creator" content="Christian  Löfberg" /></meta><meta name="dc.Creator" content="Staffan  Karlsson" /></meta><meta name="dc.Creator" content="Monica  Sundqvist" /></meta><meta name="dc.Creator" content="Carl  Whatling" /></meta><meta name="dc.Description" content="5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. However, previous clinical candidates ..." /></meta><meta name="Description" content="5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. However, previous clinical candidates ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 30, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b02012" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b02012" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b02012" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b02012" /></link>
        
    
    

<title>Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b02012" /></meta><meta property="og:title" content="Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0017.jpeg" /></meta><meta property="og:description" content="5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. However, previous clinical candidates have been discontinued and the link between FLAP inhibition and outcome in inflammatory diseases remains to be established. We here describe a novel series of FLAP inhibitors identified from a screen of 10k compounds and the medicinal chemistry strategies undertaken to progress this series. Compound 4i showed good overall properties and a pIC50 hWBfree of 8.1 and an lipophilic ligand efficiency of 5.2. Target engagement for 4i was established in dogs using ex vivo measurement of leukotriene B4 (LTB4) levels in blood with good correlation to in vitro potency. A predicted human dose of 280 mg b.i.d. suggests a wide margin to any identified in vitro off-target effects and sufficient exposure to achieve an 80% reduction of LTB4 levels in humans. Compound 4i is progressed to preclinical in vivo safety studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b02012"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b02012">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b02012&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b02012&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b02012&amp;href=/doi/10.1021/acs.jmedchem.8b02012" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4325-4349</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b02004" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01772" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Malin Lemurell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Malin Lemurell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#2c414d40454202404941595e4940406c4d5f585e4d564942494f4d024f4341"><span class="__cf_email__" data-cfemail="94f9f5f8fdfabaf8f1f9e1e6f1f8f8d4f5e7e0e6f5eef1faf1f7f5baf7fbf9">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Malin++Lemurell">Malin Lemurell</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8718-9421" title="Orcid link">http://orcid.org/0000-0001-8718-9421</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johan Ulander</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johan Ulander</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Ulander">Johan Ulander</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hans Emtenäs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hans Emtenäs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Science IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hans++Emten%C3%A4s">Hans Emtenäs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susanne Winiwarter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susanne Winiwarter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susanne++Winiwarter">Susanne Winiwarter</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9808-1683" title="Orcid link">http://orcid.org/0000-0002-9808-1683</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johan Broddefalk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johan Broddefalk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Broddefalk">Johan Broddefalk</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marianne Swanson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marianne Swanson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marianne++Swanson">Marianne Swanson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin A. Hayes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin A. Hayes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Science IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+A.++Hayes">Martin A. Hayes</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2640-8464" title="Orcid link">http://orcid.org/0000-0002-2640-8464</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luna Prieto Garcia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luna Prieto Garcia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luna++Prieto+Garcia">Luna Prieto Garcia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Annika Westin Eriksson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Annika Westin Eriksson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Safety & Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Annika++Westin+Eriksson">Annika Westin Eriksson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johan Meuller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johan Meuller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Science IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Meuller">Johan Meuller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johan Cassel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johan Cassel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Cassel">Johan Cassel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gabrielle Saarinen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gabrielle Saarinen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gabrielle++Saarinen">Gabrielle Saarinen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhong-Qing Yuan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhong-Qing Yuan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhong-Qing++Yuan">Zhong-Qing Yuan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Löfberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Löfberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++L%C3%B6fberg">Christian Löfberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Staffan Karlsson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Staffan Karlsson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Science IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Staffan++Karlsson">Staffan Karlsson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5302-7157" title="Orcid link">http://orcid.org/0000-0002-5302-7157</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Monica Sundqvist</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Monica Sundqvist</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Monica++Sundqvist">Monica Sundqvist</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Carl Whatling</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carl Whatling</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carl++Whatling">Carl Whatling</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b02012&amp;href=/doi/10.1021%2Facs.jmedchem.8b02012" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4325–4349</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 30, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 December 2018</li><li><span class="item_label"><b>Published</b> online</span>30 March 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b02012" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b02012</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4325%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMalin%2BLemurell%252C%2BJohan%2BUlander%252C%2BHans%2BEmten%25C3%25A4s%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D9%26contentID%3Dacs.jmedchem.8b02012%26title%3DNovel%2BChemical%2BSeries%2Bof%2B5-Lipoxygenase-Activating%2BProtein%2BInhibitors%2Bfor%2BTreatment%2Bof%2BCoronary%2BArtery%2BDisease%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4349%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b02012"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1366</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b02012" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Malin&quot;,&quot;last_name&quot;:&quot;Lemurell&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Ulander&quot;},{&quot;first_name&quot;:&quot;Hans&quot;,&quot;last_name&quot;:&quot;Emtenäs&quot;},{&quot;first_name&quot;:&quot;Susanne&quot;,&quot;last_name&quot;:&quot;Winiwarter&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Broddefalk&quot;},{&quot;first_name&quot;:&quot;Marianne&quot;,&quot;last_name&quot;:&quot;Swanson&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;A. Hayes&quot;},{&quot;first_name&quot;:&quot;Luna&quot;,&quot;last_name&quot;:&quot;Prieto Garcia&quot;},{&quot;first_name&quot;:&quot;Annika&quot;,&quot;last_name&quot;:&quot;Westin Eriksson&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Meuller&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Cassel&quot;},{&quot;first_name&quot;:&quot;Gabrielle&quot;,&quot;last_name&quot;:&quot;Saarinen&quot;},{&quot;first_name&quot;:&quot;Zhong-Qing&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Löfberg&quot;},{&quot;first_name&quot;:&quot;Staffan&quot;,&quot;last_name&quot;:&quot;Karlsson&quot;},{&quot;first_name&quot;:&quot;Monica&quot;,&quot;last_name&quot;:&quot;Sundqvist&quot;},{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;Whatling&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4325-4349&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b02012&quot;},&quot;abstract&quot;:&quot;5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. However, previous clinical candidates have been discontinued and the link between FLAP inhibition and outcome in inflammatory diseases remains to be established. We here describe a novel series of FLAP inhibitors identified from a screen of 10k compounds and the medicinal chemistry strategies undertaken to progress this series. Compound 4i showed good overall properties and a pIC50 hWBfree of 8.1 and an lipophilic ligand efficiency of 5.2. Target engagement for 4i was established in dogs using ex vivo measurement of leukotriene B4 (LTB4) levels in blood with good correlation to in vitro potency. A predicted human dose of 280 mg b.i.d. suggests a wide margin to any identified in vitro off-target effects and sufficient exposure to achieve an 80% reduction of LTB4 levels in humans. Compound 4i is progressed to preclinical in vivo safety studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02012&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02012" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02012&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02012" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b02012&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02012" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b02012&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b02012&amp;href=/doi/10.1021/acs.jmedchem.8b02012" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b02012" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b02012" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b02012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b02012%26sid%3Dliteratum%253Aachs%26pmid%3D30929436%26genre%3Darticle%26aulast%3DLemurell%26date%3D2019%26atitle%3DNovel%2BChemical%2BSeries%2Bof%2B5-Lipoxygenase-Activating%2BProtein%2BInhibitors%2Bfor%2BTreatment%2Bof%2BCoronary%2BArtery%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D9%26spage%3D4325%26epage%3D4349%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290723" title="Solutions">Solutions</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/jmcmar.2019.62.issue-9/20190509/jmcmar.2019.62.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. However, previous clinical candidates have been discontinued and the link between FLAP inhibition and outcome in inflammatory diseases remains to be established. We here describe a novel series of FLAP inhibitors identified from a screen of 10k compounds and the medicinal chemistry strategies undertaken to progress this series. Compound <b>4i</b> showed good overall properties and a pIC<sub>50</sub> hWB<sub>free</sub> of 8.1 and an lipophilic ligand efficiency of 5.2. Target engagement for <b>4i</b> was established in dogs using ex vivo measurement of leukotriene B<sub>4</sub> (LTB<sub>4</sub>) levels in blood with good correlation to in vitro potency. A predicted human dose of 280 mg b.i.d. suggests a wide margin to any identified in vitro off-target effects and sufficient exposure to achieve an 80% reduction of LTB<sub>4</sub> levels in humans. Compound <b>4i</b> is progressed to preclinical in vivo safety studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27728" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27728" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">5-Lipoxygenase (5-LO)-activating protein (FLAP) is critical for the cellular production of leukotrienes, the lipid mediators derived from arachidonic acid that have inflammatory and vasoactive actions and play a role in innate immunity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In leukotriene-producing cells such as neutrophils, macrophages, and mast cells, FLAP is primarily located within the nuclear membrane. Here, it may act as a docking site for 5-LO following cell activation and facilitates the transfer of arachidonic acid released from membrane phospholipids to the active site of 5-LO which initiates the production of leukotrienes (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FLAP facilitates the transfer of arachidonic acid from membrane phospholipids to the active site of 5-LO. Inhibition of FLAP attenuates the production of the leukotriene precursor LTA<sub>4</sub> and the formation of the biologically active leukotrienes LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to playing a role in innate immunity, leukotriene production has been associated with several chronic diseases that have an inflammatory component in their pathophysiology including cardiovascular diseases such as atherosclerotic coronary artery disease (CAD).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">It is possible to block 5-LO pathway activity completely by targeting 5-LO or FLAP, preventing formation of the precursor leukotriene A<sub>4</sub> (LTA<sub>4</sub>) that is required for production of the pro-inflammatory and vasoactive leukotrienes LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Moreover, it has been suggested that FLAP inhibition might deliver a more robust and sustained suppression of the 5-LO pathway activity in vivo than can be achieved by 5-LO inhibition.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Both FLAP and 5-LO inhibitors have been evaluated in human clinical trials and have shown robust target engagement and sustained suppression of the 5-LO pathway as indicated by reduction in ex vivo LTB<sub>4</sub> production in blood and LTE<sub>4</sub> levels in urine.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> In a phase II study in CAD patients who had experienced a recent (within 1 month) acute coronary syndrome event, the 5-LO inhibitor VIA-2291 delivered a reduction in non-calcified atherosclerotic plaque volume and a reduction in the incidence of new coronary artery lesion formation after 6 months dosing during which LTB<sub>4</sub> production was suppressed by over 80%.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Despite these promising results, VIA-2291 has not been progressed into phase III clinical studies.</div><div class="NLM_p">Different chemical series of FLAP inhibitors have been described,<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7−10)</a> and some representative compounds are exemplified in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of the most advanced FLAP inhibitors from previously described chemical series, which have later been discontinued during preclinical toxicology studies or in development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">None of these chemical series have delivered a clinical candidate that has progressed beyond phase II, despite being very potent inhibitors (∼0.5–10 nM). To the best of our knowledge, the reasons for discontinuation were related to either efficacy (DG-031 and AM803) or a variety of safety liabilities, which for the class of compounds leading up to AM803 potentially could be attributed to their highly lipophilic nature (Clog <i>P</i> > 5) and promiscuous in vitro secondary pharmacology profiles.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> We have previously demonstrated that it is possible to generate a FLAP inhibitor with lower lipophilicity, high lipophilic ligand efficiency (LLE), and good in vitro safety profile in AZD6642.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This compound was however stopped because of toxicity in preclinical animal models (unpublished results). Another later generation FLAP inhibitor, BI665915,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> showed testicular toxicological effects.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In light of these challenges, we saw the need to identify and optimize a new, structurally distinct, chemical series of FLAP inhibitors for selection of a candidate drug with the aim to evaluate the benefits of inhibiting the 5-LO pathway in patients with CAD.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06715" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06715" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit Finding</h3><div class="NLM_p">A new hit finding campaign was initiated to identify novel FLAP inhibitors with the aim to open up chemical space with the possibility to identify compounds with improved LLE and safety profiles. A competitive binding assay with <sup>3</sup>H-MK-591 as the ligand was used as primary screening,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and it was assumed that the assay would identify inhibitors which bound to the same site in the transmembrane region of FLAP as MK-591 and other reported FLAP inhibitors.<a onclick="showRef(event, 'ref3 ref14'); return false;" href="javascript:void(0);" class="ref ref3 ref14">(3,14)</a></div><div class="NLM_p">The low throughput of the FLAP-binding assay precluded a full-scale HTS of the AZ compound collection, and a virtual screen was instead performed from which a subset of 10k compounds was selected. The focus was on ligand-based techniques because the large cavity and low-resolution of existing X-ray structures <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q7M">2Q7M</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q7R">2Q7R</a> (4.0, 4.2 Å)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> did limit the use of docking approaches. Some of the features of the putative binding pocket were however incorporated into pharmacophore searches. MOE calculation was used for a pharmacophore/excluded volume search.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> To avoid entropic penalties and to focus attention on bioactive conformations, a Boltzmann-weighted scoring of the conformational ensembles was used for the 3D-scoring metrics (shape/pharmacophoric/Tversky/electrostatic fit tanimotos). Approximately 20% of the selected compounds originated from multi-fingerprint search techniques (Trust, alfi, foyfi, ecfi)<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> and 80% from 3D techniques such as shape or pharmacophore searches.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a></div><div class="NLM_p">More potent compounds were then evaluated in a secondary assay measuring the effect on LTB<sub>4</sub> production in human whole blood (hWB) after calcium ionophore stimulation. In parallel, representative compounds from each chemical cluster identified were subject to in vitro ADME and safety evaluation, for example, solubility, metabolic stability, CYP inhibition, hERG inhibition, and reactive metabolite (RM) formation.</div><div class="NLM_p">A series of highly interesting neutral compounds with a <i>trans</i>-benzoyl cyclohexane carboxamide core was identified, a generic structure of which is shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationship for the Described Series of FLAP Inhibitors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0013.gif" alt="" id="GRAPHIC-d7e490-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0014.gif" alt="" id="gr13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data are given for the (R,R) enantiomer unless denoted (<i>rac</i> or (<i>S</i>,<i>S</i>)).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Defined in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">pIC<sub>50</sub> in the FLAP binding assay.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">pIC<sub>50</sub> in the hWB assay measuring the inhibition of the downstream LTB<sub>4</sub> production with 30 min incubation time of the compound.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">pIC<sub>50</sub> in the hWB assay taking into account the plasma protein binding.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">LLE calculated from pIC<sub>50</sub> hWB<sub>free</sub> – log <i>D</i><sub>7.4</sub>.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">pIC<sub>50</sub> in the hWB assay after 4 h incubation time of the compound, ND = not determined.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemistry</h3><div class="NLM_p">The strategy during the lead generation phase was to design routes which allowed late stage diversification. As a result, early exploration of this series was ideally set up for starting from <i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carboxylic acid (<b>1</b>) followed by routes for the variation of the amines or the Suzuki reagents (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). <i>trans</i>-2-(4-Bromobenzoyl)cyclohexane-1-carboxylic acid (<b>1</b>) was either purchased as racemic material or obtained as the pure enantiomer starting from (1<i>R</i>,2<i>R</i>)-2-(methoxycarbonyl) cyclohexane carboxylic acid.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The final compounds <b>4a–u</b> were made from <b>1</b> either by conversion to the amides <b>2a–k</b> followed by Suzuki reaction or compound <b>1</b> was first used in a Suzuki coupling to construct intermediates (<b>3a–c</b>) followed by amide coupling. The affinity for FLAP was found to reside in the (R,R)-enantiomer of these compounds, and from here on, any compound number will refer to the (R,R)-enantiomer unless denoted (<i>rac</i>) or (<i>S</i>,<i>S</i>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Late-Stage Variation of the Amines and Suzuki Reactants To Provide Compounds <b>4a–u</b> Either as Racemates or Pure Enantiomers<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Commonly used reagents and conditions: (a) R<sub>1</sub>-NH<sub>2</sub>, TBTU, DIPEA, DMF or R<sub>1</sub>-NH<sub>2</sub>, T3P, Et<sub>3</sub>N, 50 °C; (b) R<sub>2</sub>-B(OH)<sub>2</sub>/R<sub>2</sub>-Bpin, Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, DMF-H<sub>2</sub>O, 100 °C or R<sub>2</sub>-B(OH)<sub>2</sub>/R<sub>2</sub>-Bpin, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C.</p><p><span class="fn-label"><sup>b</sup></span>See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for synthesis details. No synthesis details given for <b>4a</b> (<i>rac</i>) and <b>4b</b> (<i>rac</i>) as they were identified as hits during the HTS from the AstraZeneca compound collection.</p><p class="last"><span class="fn-label"><sup>c</sup></span>See <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for the chemical structure and stereochemistry.</p></p></figure><div class="NLM_p">To introduce variation in the aryl moiety, we instead used racemic (3a,7a<i>-trans</i>)-hexahydro-2-benzofuran-1,3-dione as starting material. As a result, this was reacted with the organometallic regents made from either 2,5-dibromo pyridine or 2-iodo-5-bromo toluene to furnish compounds <b>5</b> (<i>rac</i>) and <b>6</b> (<i>rac</i>), respectively. These could then be modified by the chemistry depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> to form compounds <b>7</b> (<i>rac</i>) and <b>8</b> (<i>rac</i>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Variation of the Aryl Ring Introduced by Ring Opening of (3a,7a-<i>trans</i>)-Hexahydro-2-benzofuran-1,3-dione<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (3a,7a<i>-trans</i>)-hexahydro-2-benzofuran-1,3-dione, <i>n</i>-BuLi, Et<sub>2</sub>O and/or THF, −78 °C; 20–32%; (b) 1<i>H</i>-pyrazol-3-ylboronic acid, Pd(dppf), K<sub>3</sub>PO<sub>4</sub> or K<sub>2</sub>CO<sub>3</sub>, DME/EtOH/H<sub>2</sub>O or dioxane/H<sub>2</sub>O, heated in a microwave reactor at 130 °C or reflux, 30–42%; (c) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride, TBTU, NMM or DIPEA, DMF or CH<sub>2</sub>Cl<sub>2</sub>, rt, 6–77%; (d) NH<sub>4</sub>CO<sub>2</sub>H, Pd(OH)<sub>2</sub>, CH<sub>3</sub>OH, heated in a microwave reactor at 100 °C, quant; (e) K<sub>2</sub>CO<sub>3</sub>, PhN(Tf)<sub>2</sub>, DMF, rt, 69%; (f) chiral separation.</p></p></figure><div class="NLM_p">Introduction of an <i>ortho</i>-fluoro substituent in the aryl ring turned out to be problematic using this approach because of instability of the organometallic reagents. Following a similar procedure as previously described,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> compound <b>10</b> (<i>rac</i>) could be obtained in moderate yield by reacting the benzyl protected phenol<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><b>9</b> with the (3a,7a-<i>trans</i>)-hexahydro-2-benzofuran-1,3-dione under lithiation conditions. After amide coupling using standard conditions and de-benzylation, the obtained phenol <b>11</b> (<i>rac</i>) was used in the following Suzuki coupling by first converting the phenol <b>11</b> (<i>rac</i>) to the corresponding triflate followed by direct coupling with heteroaryl boronic acid. The racemic mixture of <b>12</b> (<i>rac</i>) was separated by chiral chromatography to give both individual enantiomers (<b>12</b> and <b>12</b> (<i>S</i>,<i>S</i>)).</div><div class="NLM_p">A limiting factor using the anhydride route was the lack of appropriate commercially available (hetero) aryl halides as starting material. More importantly, the use of anhydrides was considered a safety risk because of the intrinsic allergenic properties of these compounds. Our attention instead turned to develop a Diels–Alder based route (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). β-Acyl acrylic acids of type <b>13</b> are known to perform well in Diels–Alder reactions with dienes.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Thus, compound <b>13</b> was reacted with <i>trans</i>-butadiene to give the cyclohexene <b>14</b> (<i>rac</i>) in high yield.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>ortho</i>-Fluoro Compounds Using a Diels–Alder Approach<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) oxoacetic acid, CH<sub>3</sub>CO<sub>2</sub>H, CH<sub>3</sub>SO<sub>3</sub>H, 130 °C, 73%; (b) buta-1,3-diene, toluene, 60 °C, 90%; (c) chiral separation; (d) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride, T3P, Et<sub>3</sub>N, EtOAc, 80 °C, 70%; (e) 1<i>H</i>-pyrazol-3-ylboronic acid or 1-(tetrahydro-2<i>H</i>-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 85 °C, 52–58%; (f) Pd/C, CH<sub>3</sub>OH, H<sub>2</sub> (g, 1 atm), rt, 56%; (g) 5% Rh/C, THF, H<sub>2</sub> (g, 2 bar), rt, 91%; (h) 4-amino-1-methyl-1<i>H</i>-pyrazole-3-carboxamide, HATU, DIPEA, DMF, rt; (i) 1.25 M HCl in CH<sub>3</sub>OH, 16 °C, 69%.</p></p></figure><div class="NLM_p">To avoid chiral separation of all final compounds in this series, we choose to separate the cyclohexene derivative <b>14</b> (<i>rac</i>). The (+) isomer of <b>14</b> was found to give <b>12</b> (<i>S</i>,<i>S</i>) (the least active enantiomer) by applying the chemistry described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> followed by reducing the double bond by hydrogenation, thus concluding that the (−)-isomer of <b>14</b> had the desired (R,R)-stereochemistry.</div><div class="NLM_p">Moreover, a shorter route to the final compounds was desired, and our strategy aimed to reduce the double bond at an earlier stage. Initial attempts to reduce the double bond of <b>14</b> by hydrogenation with Pd/C turned out to be difficult and gave rise to byproducts such as reduced ketone as well as debromination. After a thorough screen of catalyst and reaction conditions, we found that Rh/C gave a good result. Thus, the cyclohexene <b>14</b> was converted to <b>16</b> by hydrogenation. The final compound <b>17</b> was made by applying similar chemistry as in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> followed by acidic hydrolysis (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><div class="NLM_p">Moreover, to introduce variation in the cyclohexyl ring system, we first choose to react the anhydride with the amine forming the imide <b>18</b>. After hydrogenation of the double bond, the imide <b>19</b> could be reacted with organometallic reagent forming compound <b>20</b> (<i>rac</i>). When applying standard Suzuki conditions, a mixture of our desired screening compound <b>21</b> (<i>rac</i>) together with the cyclized hemi-amidal <b>22</b> was isolated (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Introduction of the Bridged Cyclohexyl Ring System<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride, CDI, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 91%; (b) 5% Pd/C, THF, H<sub>2</sub>, rt, 99%; (c) 2-fluoro-5-bromo-bromobenzene, <i>n</i>-BuLi, THF, −78 °C, 11%; (d) 1<i>H</i>-pyrazol-5-ylboronic acid, Pd(dppf)<sub>2</sub>CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 14%.</p></p></figure><div class="NLM_p">Our attention then turned to functionalizing the double bond further, and we focused on the installation of a cyclopropyl group. In this case, we performed the Diels–Alder reaction with the ester <b>24</b> to give the cyclohexene <b>25</b> (<i>rac</i>). Cyclopropanation using the Furukawa modification of the Simmons–Smith reaction gave compound <b>26</b> (<i>rac</i>) as a mixture of stereoisomers. Finally, the desired compound <b>27</b> could be synthesized by hydrolysis of the ester, followed by standard amine coupling and Suzuki coupling and then by separation of the four stereoisomers by chiral chromatography. The stereochemical arrangement of the cyclopropyl group was assigned by NMR (NOE experiments).</div><div class="NLM_p">To minimize the cumbersome separation of all isomers in the end, we decided to first separate the enantiomers of the cyclohexyl <b>25</b> (<i>rac</i>). The (−)-isomer of the cyclohexyl <b>25</b> was deduced from <b>1</b> and was further converted to <b>26</b> as a mixture of two diastereomers by cyclopropanation. Analogous to <b>27</b>, the desired screening compound <b>28</b> was obtained (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Introduction of the Cyclopropyl-Fused Cyclohexyl Ring System<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) buta-1,3-diene, hydroquinone, toluene, 160 °C, 95%; (b) Et<sub>2</sub>Zn, ClCH<sub>2</sub>I, DCE/heptane, 0 °C → rt; (c) LiOH, CH<sub>3</sub>OH–THF–H<sub>2</sub>O, 60 °C; (d) 1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine, T3P, Et<sub>3</sub>N, 50 °C, 64% (from <b>25</b> (<i>rac</i>)); (e) 1<i>H</i>-pyrazol-3-ylboronic acid, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C, 80%. (f) Chiral separation; (g) 1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine, T3P, Et<sub>3</sub>N, 80 °C, 47% (from <b>25</b>); (h) 1<i>H</i>-pyrazol-3-ylboronic acid, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C, 63%.</p></p></figure><div class="NLM_p">We also wanted to evaluate modifications of the aryl ketone. Initial attempts to introduce the 1,2-benzisoxazole group via a late-stage modification of <i>ortho</i>-fluoro compounds, for example, <b>12</b>, using hydroxylamine proved to be very inefficient and provided poor yield. We therefore decided to introduce the 1,2-benzisoxazole group earlier in the synthetic sequence. In a stepwise procedure, oxime <b>29</b> could be prepared from 4-bromo-2-fluoro cyclohexylarylketone <b>16</b>, and subsequent deprotonation by NaH to facilitate the intramolecular S<sub>N</sub>Ar reaction gave the 1,2-benzisoxazole <b>30</b>. The desired compound <b>32</b> was then prepared by Suzuki coupling to give acid <b>31</b> followed by amide bond formation (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of 1,2-Benzisoxazole Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HONH<sub>2</sub>·HCl, pyridine, 100 °C; (b) NaH, DMF, rt, 59% (over 2 steps); (c) 3-methyl-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 90 °C, 96%; (d) 4-amino-1-methyl-1<i>H</i>-pyrazole-3-carboxamide, HATU, DIPEA, DMF, rt; (e) HCl(aq), dioxane/H<sub>2</sub>O, rt, 74% (over 2 steps); (f) H<sub>2</sub>SO<sub>4</sub>, EtOH, Δ; (g) Et<sub>2</sub>Zn, ClCH<sub>2</sub>I, DCE/heptane, 0 °C → rt; (h) LiOH, CH<sub>3</sub>OH–THF–H<sub>2</sub>O, 50 °C; (i) separation of diastereomers.</p></p></figure><div class="NLM_p last">Finally, <b>35</b>, an analogue of 1,2-benzisoxazole compound <b>32</b> also containing the bicyclo[4.1.0]heptane ring system was prepared. Esterification of cyclohexen derivate <b>14</b> followed by cyclopropanation and ester hydrolysis gave <b>33</b>. The 1,2-benzioxazole moiety of <b>34</b> was installed in a manner analogous to compound <b>32</b>. Suzuki coupling, amide bond formation, and subsequent separation of diastereomers gave the analogue <b>35</b>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Structure–Activity Relationships and in Vitro Data</h3><div class="NLM_p">Early hits from this series demonstrated good affinity to FLAP with binding pIC<sub>50</sub> higher than 6 and hWB pIC<sub>50</sub> close to 6, here exemplified by <b>4a</b> (<i>rac</i>) and <b>4b</b> (<i>rac</i>), <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The structure–activity relationship (SAR) of the series was developed using the competitive binding assay and the hWB assay. In the hWB assay, the standard compound incubation time was 30 min, but as described by Stock et al., a prolonged incubation time (4 h) was required for some compounds to appreciate the full response on LTB<sub>4</sub> reduction as indicated in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The permeability of the compounds was found to be a key parameter influencing the onset to full effect, as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. Further, the IC<sub>50</sub> hWB contains large effects from nonspecific protein binding. The free concentration is what drives the biological response, and the relevant design parameter is therefore the free potency, IC<sub>50u</sub>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> To account for the effect of nonspecific binding, the free potency IC<sub>50</sub> hWB<sub>free</sub> was estimated using the measured compound fraction unbound (<i>f</i><sub>u</sub>) in human plasma. The binding assay contained lipid membranes with some effects from nonspecific partitioning. The correlation between the uncorrected IC<sub>50</sub>’s from the binding assay and IC<sub>50</sub> hWB<sub>free</sub> was however sufficient (<i>R</i><sup>2</sup> = 0.8) to guide prioritization of compounds for further study. LLE<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> was a key optimization parameter to identify compounds with highly specific interactions with FLAP and here derived from pIC<sub>50</sub> hWB<sub>free</sub> – log <i>D</i>.</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds with reduced permeability required prolonged incubation time (4 h vs 30 min) in the hWB assay to attenuate the full response on LTB<sub>4</sub> reduction. The dashed line gives the linear fit (residual standard error = 0.32 log units which corresponds to a factor 2), <i>R</i><sup>2</sup> = 0.44; dotted lines correspond to a ratio 4× difference from the fitted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR for Alternative Central Core Structures of the Described Series of FLAP Inhibitors<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0016.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data are given for the (R,R) enantiomer unless denoted (<i>rac</i>).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Defined in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">pIC<sub>50</sub> in the FLAP binding assay.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">pIC<sub>50</sub> in the hWB assay measuring the inhibition of the downstream LTB<sub>4</sub> production.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">pIC<sub>50</sub> in the hWB assay taking into account the plasma protein binding.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">LLE calculated from pIC<sub>50</sub> hWB<sub>free</sub> – log <i>D</i><sub>7.4</sub>.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">pIC<sub>50</sub> in the hWB assay after for 4 h incubation time of the compound.</p></div></div><div></div></div><div class="NLM_p">The series was expanded using the commercially available racemic <i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carboxylic acid <b>1</b> suitable for library synthesis by amide formation (R<sub>1</sub>) and cross-coupling reactions (R<sub>2</sub>). From compound <b>4c</b> (<i>rac</i>) and <b>4d</b> (<i>rac</i>), it was evident that potency could be improved in this series with a reduction in lipophilicity compared to <b>4a</b> (<i>rac</i>) and <b>4b</b> (<i>rac</i>). Chiral separation of the more active compounds, for example, <b>4d</b> (<i>rac</i>), showed that FLAP inhibition primarily resided in the (R,R)-isomer as shown for the corresponding two enantiomers <b>4d</b> and <b>4d</b> (<i>S</i>,<i>S</i>) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">A set of C–C and C–N cross-coupling reactions of the aryl bromide to introduce various aliphatic and aromatic substituents as R<sub>2</sub> showed a relatively narrow SAR (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The R<sub>2</sub> pyrazole derivative <b>4d</b> (<i>rac</i>) appeared to offer beneficial interactions in this region of the binding site, and matched pair analysis confirmed this group as a preferred aromatic R<sub>2</sub> motif. The R<sub>2</sub> 2-pyridine and 2-pyrrole motifs of <b>4e</b> (<i>rac</i>) and <b>4f</b> (<i>rac</i>) respectively were both tolerated but nonetheless exhibited reduced binding affinity compared to <b>4d</b> (<i>rac</i>). Methylation of the 2-<i>N</i> of the pyrazole (<b>4g</b> (<i>rac</i>)) had a significant negative impact on binding affinity. This suggests that the R<sub>2</sub> pyrazole nitrogens form one or two hydrogen bond interactions at the binding site. Introduction of a methyl substituent in the 4-position of the pyrazole (<b>4h</b> (<i>rac</i>)) resulted in an affinity drop of an order of magnitude compared to <b>4d</b> (<i>rac</i>). More successful was the introduction of a methyl substituent in the 5-position of the pyrazole (<b>4i</b>), while larger groups such as ethyl, iso-propyl, or trifluoro methyl (data not shown) were not well tolerated. The relatively high binding affinity of <b>4i</b> translated into good potency in the hWB assay. The free hWB pIC<sub>50</sub> was as high as 8.1 resulting in an LLE of 5.2.</div><div class="NLM_p">A broad set of amides with various substitutions were synthesized as analogues of <b>4d</b> to explore the SAR of the R<sub>1</sub> region (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This data set suggested a rather high degree of tolerance for structural and electronic variations in this region, and several compounds were identified with sub-100 nM binding affinity. However, to move away from aromatic amides and a potential genotoxic metabolite liability, aliphatic amines were introduced with generally poor success. Two of the more promising compounds with good affinity and high hWB activity were <b>4j</b> and <b>4k</b>. A smaller drop in affinity was observed for the tertiary amide <b>4l</b> in comparison with <b>4d</b>. From this example, it was not apparent that the hydrogen bond donor of the amide bond is important for the compounds’ interaction to the binding site, even though many of the tertiary amides showed reduced affinity to a varying degree. Reversing the amide bond or replacing it with a sulfonamide was detrimental to binding affinity (data not shown).</div><div class="NLM_p">Exploration of a wide range of five-membered and six-membered aromatic amines resulted in highly potent compounds, in particular <b>4m</b>, which exhibited a free hWB pIC<sub>50</sub> of 9.3. It was also found that large substituents elongating out from the vector of the amide in R<sub>1</sub> as shown with the para-substituent in <b>4n</b> (<i>rac</i>) were tolerated. The five-membered amino pyrazole introduced in <b>4d</b> was found to be of particular interest and used as the basis for further exploration. Substitutions in the position next to the amide bond as exemplified by biaryl <b>4o</b> and by <b>4p</b>, <b>4q</b>, <b>4r</b>, <b>4s</b>, <b>4t</b>, and <b>4u</b> resulted in novel FLAP inhibitors which engaged the protein with high LLE between 4.8 and 5.5.</div><div class="NLM_p">It is known that certain amino pyrazoles are genotoxic,<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26−28)</a> and hence, interesting amino pyrazoles were tested in a 2-strain Ames assay (with and without metabolic activation using rat S9 fraction) throughout the optimization of this series. Compounds containing a masked Ames-positive aromatic amine were not progressed. Among the potent compounds highlighted above, only the amine in <b>4s</b> was measured Ames-positive. The amino pyrazole in <b>4r</b> was not chemically stable and therefore could not be reliably tested in the Ames assay. Interestingly, it was observed that the substitution pattern of the amino pyrazole was important, and while the amino pyrazole in <b>4t</b> did not show any Ames liability, its analogue with the methyl moved to the adjacent pyrazole nitrogen was measured Ames-positive.</div><div class="NLM_p">We then turned to explore the core phenyl ring. Introduction of heteroatoms or small substitutions resulted in reduced affinity, as exemplified by <b>7</b> (<i>rac</i>) and <b>8</b> (<i>rac</i>) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) compared to <b>4d</b> (<i>rac</i>), except for the introduction of halogens ortho to the ketone. The high hWB potency and LLE was maintained upon introduction of an <i>ortho</i>-fluoro substituent, for example, <b>12</b> and <b>17</b> compared to <b>4d</b> and <b>4u</b>, respectively.</div><div class="NLM_p">The major metabolic in vitro clearance pathway for compounds in this series was CYP-mediated oxidation in the aliphatic cyclohexyl ring. Significant effort was put into blocking metabolism or reducing lipophilicity in this part of the molecule, though with limited success with respect to simultaneously maintaining binding affinity. Replacement of the cyclohexyl ring with alternative aliphatic three-, four-, five-, or seven-membered rings were unsuccessful. Complete removal of the ring and replacement with an ethylene or ethyl chain was also not tolerated, nor was the introduction of a methylene or ether bridge between the 3- and 6-carbon. The analogue <b>21</b> (<i>rac</i>) with an ethylene bridge showed reasonable affinity but with the penalty of increased lipophilicity and increased metabolic clearance. Overall, small modifications that affected the conformation of the cyclohexyl and the 1,2-substituents led to detrimental effects on affinity, which we hypothesized to be due to distortion of the vectors positioning the 1,2-substituents into a preferred binding mode in the FLAP binding site. Introduction of fluorine in the cyclohexyl ring to block oxidation sites caused issues with chemical or metabolic instability due to HF elimination. However, addition of a cyclopropyl ring in <b>27</b> and <b>28</b> which altered the sp<sup>3</sup> carbons most labile to CYP-mediated oxidation into ones with more sp<sup>2</sup> like character resulted in highly potent compounds with free hWB pIC<sub>50</sub> of 9.0 and 8.5, respectively.</div><div class="NLM_p">Considering the generally reactive and electrophilic nature of a ketone group, we were initially keen to understand if it could be replaced. However, it turned out that the ketone was difficult to replace. Replacing the ketone with the corresponding alcohol and replacement by methylene, ether, thioether, sulfoxide, or sulfone were examples of modifications that resulted in no or poor binding affinity to FLAP. The benzisoxazole in <b>32</b> and <b>35</b> was identified as a tolerated ketone bioisostere which retained potency in the binding and hWB assays, for example <b>32</b> versus <b>4u</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">Initial in vitro ADME and safety evaluation of the early compounds in this series, such as <b>4c</b> (<i>rac</i>) and <b>4d</b> (<i>rac</i>), showed good solubility and medium metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Throughout the advancement of the series, selected compounds were profiled more broadly, and the series was optimized on parameters such as solubility, permeability, and metabolic stability as the combination of these properties along with the compounds’ potency influences the predicted human dose. Additionally, properties that indicated potential risks for adverse effects, for example, CYP inhibition, RM formation, and hERG inhibition were monitored.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Data for Selected Compounds (Solubility, CYP Inhibition, Metabolic Stability in Human Hepatocytes, Caco-2 Permeability, RM Trapping, Contribution of CYP3A4 to Metabolism and hERG Inhibition</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">aq sol.<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" align="center">max pIC<sub>50</sub> CYP inh<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> (isoform)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">HH CL<sub>int</sub><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">Caco-2 <i>P</i><sub>app</sub><a class="ref internalNav" href="#t3fn5" aria-label="e">e</a> (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center">RM trapping (GSH)<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">contr 3A4<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a>/<i>f</i><sub>m,CYP3A4</sub><a class="ref internalNav" href="#t3fn8" aria-label="h">h</a> (%)</th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t3fn9" aria-label="i">i</a> pIC<sub>50</sub>/inh. (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4c</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">5.4 (3A4)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">ND/ND</td><td class="colsep0 rowsep0" align="left"><4.9/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4d</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left"><4.7</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">little</td><td class="colsep0 rowsep0" align="left">ND/ND</td><td class="colsep0 rowsep0" align="left"><4.9/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4i</b></td><td class="colsep0 rowsep0" align="left">225</td><td class="colsep0 rowsep0" align="left"><4.6</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">little</td><td class="colsep0 rowsep0" align="left">89/>32</td><td class="colsep0 rowsep0" align="left"><4.0/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4m</b></td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">5.3 (2C9)</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">69</td><td class="colsep0 rowsep0" align="left">little</td><td class="colsep0 rowsep0" align="left">94/52</td><td class="colsep0 rowsep0" align="left">4.9/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4n</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">111</td><td class="colsep0 rowsep0" align="left">5.0 (1A2)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">ND/ND</td><td class="colsep0 rowsep0" align="left">-/22%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4o</b></td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left"><4.7</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">92/61</td><td class="colsep0 rowsep0" align="left"><4.5/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4p</b></td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">4.7 (3A4)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">94/57</td><td class="colsep0 rowsep0" align="left"><4.5/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4q</b></td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">5.2 (2C9)</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">little</td><td class="colsep0 rowsep0" align="left">94/>54</td><td class="colsep0 rowsep0" align="left">-/32%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4t</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">5.1 (2C9)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">ND/ND</td><td class="colsep0 rowsep0" align="left">-/23%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4u</b></td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">5.0 (2C9)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND/ND</td><td class="colsep0 rowsep0" align="left"><4.5/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left"><4.7</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">97/51</td><td class="colsep0 rowsep0" align="left"><4.9/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">5.2 (3A4)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND/ND</td><td class="colsep0 rowsep0" align="left"><4.5/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">5.4 (3A4)</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="left">little</td><td class="colsep0 rowsep0" align="left">86/53</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">5.3 (2C9)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">little</td><td class="colsep0 rowsep0" align="left">80/>72</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">5.1 (2C9)</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">96/ND</td><td class="colsep0 rowsep0" align="left"><4.5/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">5.5 (3A4)</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">ND/97</td><td class="colsep0 rowsep0" align="left">-/12%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Aqueous solubility.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Inhibition of CYP450, maximum value for a panel of six CYP isoforms (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Specification of CYP isoform associated with the maximum inhibition value.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Intrinsic clearance measured in human hepatocytes.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Apparent permeability measured in Caco-2 cells.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">RM trapping using GSH as a trapping agent.</p></div><div class="footnote" id="t3fn7"><sup><sup>g</sup></sup><p class="last">Contribution of CYP3A4 to CYP-mediated metabolism of a compound considering a panel of six CYP isoforms (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4).</p></div><div class="footnote" id="t3fn8"><sup><sup>h</sup></sup><p class="last">Fraction metabolized by CYP3A4 measured in human hepatocytes with and without the CYP3A4 inhibitor ketoconazole.</p></div><div class="footnote" id="t3fn9"><sup><sup>i</sup></sup><p class="last">Inhibition of the hERG ion channel with data given as pIC<sub>50</sub> or % inhibition at 10 μM concentration. ND, not determined. Experimental details for all assays are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><div class="NLM_p">The more lipophilic compounds in the series, such as <b>4m</b> and <b>27</b>, showed low solubility, whereas <b>28</b>, an isostere of <b>27</b> with similar lipophilicity, demonstrated moderate solubility. The ketone replacement benzisoxazole introduced in <b>32</b> and <b>35</b> had a negative impact on solubility which turned out to be a general disadvantage for this ketone replacement. Some of the modifications in the amino pyrazole such as the introduction of a nitrile group or a primary amide in <b>4t</b> or <b>4u</b> reduced the solubility compared to <b>4i</b>. Despite that the solubility of <b>4u</b> was still moderate, the primary amide likely contributed to the poor solubility of <b>17</b>, <b>32</b>, and <b>35</b> as well.</div><div class="NLM_p">The compounds displayed in general good permeability in Caco-2 cells, often with no or low levels of efflux (data not shown). Introduction of a second amide bond hampered permeability significantly in <b>4n</b> (<i>rac</i>). Also, the <i>P</i><sub>app</sub> of <b>32</b> with the additional amide substituent on the amino pyrazole was relatively low, whereas higher permeability was measured for the analogues <b>4u</b>, <b>17</b>, and <b>35</b>.</div><div class="NLM_p">Only low levels of cytochrome P450 enzyme inhibition were observed across the series from screening a panel of the most common CYP isoforms, and in general, no or only minor levels of RM formation were seen using glutathione (GSH) as a trapping agent in human liver microsome incubations. The higher levels of RM observed could be assigned to oxidation followed by elimination in the R<sub>1</sub> dimethyl oxazole in <b>4c</b> (<i>rac</i>) and in the aromatic biaryl ring of <b>4o</b>.</div><div class="NLM_p">Ketone reactivity was assessed on a subset of compounds using methoxylamine as a trapping agent.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> No or only minimal imine formation was detected for the compounds tested (data not shown).</div><div class="NLM_p">Whilst the series progressed, and it was seen that high pIC<sub>50</sub> hWB<sub>free</sub> could be obtained also for compounds in the lower lipophilic range, the compounds remained to show a medium rate of intrinsic clearance (CL<sub>int</sub>) in both human liver microsomes and human hepatocytes. Strategies beyond reducing lipophilicity to improve the in vitro metabolic stability and thereby lower the predicted human dose were guided by metabolite identification experiments performed in human hepatocytes. Most frequently, the observed metabolic transformations were combinations of cytochrome P450-catalyzed oxidative hydroxylation (M1), ketone reduction (M2), and demethylation (M5), as shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. In general, little or no amide cleavage (M3) was seen for compounds in this series. Glucuronidation took place directly on the parent compound (<i>N</i>-glucuronidation, M6) or after amide cleavage forming the acyl-glucuronide (M4) or after P450 oxidation to form an ether glucuronide (M7). Minor structural modifications many times had a pronounced effect on the metabolic elimination pathways as exemplified in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. For example, compound <b>4p</b> was cleared via P450 oxidation on the cyclohexane ring resulting in three isomeric cyclohexanols and an additional alcohol formed via ketone reduction. No demethylation of the methyl on the R<sub>1</sub> 1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazole was observed. In contrast to <b>4p</b>, for the isomeric compound <b>4q</b>, demethylation was observed to be a major clearance route alongside cyclohexyl oxidation and only little ketone reduction was observed. Despite the structural resemblance, the major clearance route for <b>4i</b> was instead amide hydrolysis followed by conjugation to the acyl glucuronide and cytochrome P450-mediated oxidation. The cyclopropyl substitution in the cyclohexyl ring of <b>27</b> was introduced to alter the sp<sup>3</sup> carbons most labile to CYP-mediated oxidation into ones with more sp<sup>2</sup> like character and to block the dominant site of oxidation. This was a successful strategy with no oxidative metabolites being observed in the cyclohexyl ring, cf. <b>4p</b>. Instead, however, <b>27</b> was cleared via a combination of amide hydrolysis/acyl glucuronidation and ketone reduction pathways. The overall properties and potency of <b>4u</b> with the primary amide in the R<sub>1</sub> amino pyrazole were judged beneficial but the metabolic clearance was still too high. The metabolic pathways observed for <b>4u</b> were the same as observed for <b>4p</b>. The phenyl ketone was replaced by benzisoxazole (<b>32</b>) to eliminate the ketone reduction metabolism resulting in the major clearance route for <b>32</b> to be solely via cyclohexyl oxidation. We then turned to introduce the bicyclo[4.1.0]heptane core containing the cyclopropyl ring (<b>35</b>) with the aim of blocking P450-mediated oxidation. Frustratingly, no improvement in hepatic clearance was measured and from the biotransformation analysis, it was seen that <b>35</b> was cleared mainly via mono-oxidation of the R<sub>2</sub> ring 5-methyl-1<i>H</i>-pyrazole forming the corresponding pyrazol-5-yl methanol metabolite (M8).</div><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Generic Biotransformation Map of the Compound Series in Human Hepatocytes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Metabolic Stability and Metabolites Formed in Human Hepatocytes Demonstrating Structure-Dependent Altering of Metabolic Pathways within Series<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">HH CL<sub>int</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">parent (%)</th><th class="colsep0 rowsep0" align="center">M1 (%)</th><th class="colsep0 rowsep0" align="center">M2 (%)</th><th class="colsep0 rowsep0" align="center">M3 (%)</th><th class="colsep0 rowsep0" align="center">M4 (%)</th><th class="colsep0 rowsep0" align="center">M5 (%)</th><th class="colsep0 rowsep0" align="center">M6 (%)</th><th class="colsep0 rowsep0" align="center">additional metabolites<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4i</b></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M8 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4p</b></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M7 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4q</b></td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M7 (<1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4u</b></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">M7 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">68</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">69</td><td class="colsep0 rowsep0" align="left">6*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">M8 (22)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">M1–M6 defined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Intrinsic clearance measured in human hepatocytes (μL/min/10<sup>6</sup> cells).</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Additional metabolites defined as: M7 = <i>O</i>-glucuronidated metabolite on phenyl R<sub>2</sub>-pyrazole, M8 = oxidation on the methyl of the R<sub>2</sub>-methylpyrazole, NA = not applicable. * = oxidation on bicyclo[4.1.0]heptane. If no values are given the metabolite level was not detectable by ultra HPLC/MS.</p></div></div></div><div class="NLM_p last">As shown above, oxidation via cytochrome P450 isoforms was a major metabolic pathway in this series. CYP reaction phenotyping showed that the isoform CYP3A4 was responsible for more than 80% (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) of the CYP-mediated metabolism considering a panel of six CYP isoforms (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), indicating a potential risk for drug–drug interactions when co-medicated with a CYP3A4 inhibitor. However, as also non-CYP-mediated metabolism was seen, such as ketone reduction, amide cleavage or direct glucuronidation, the contribution of CYP3A4-mediated oxidation in relation to total metabolism was investigated in hepatocytes as fraction metabolized by CYP3A4 (<i>f</i><sub>m,CYP3A4</sub>; see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> For most compounds, a significant reduction of this value down to roughly 50% was seen and the risk for drug–drug-interactions was considered low.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Profiles</h3><div class="NLM_p">The compounds with the most promising in vitro profiles, <b>4i</b>, <b>4p</b>, <b>4q</b>, <b>4u</b>, <b>12</b>, and <b>28</b>, were tested in rat in vivo pharmacokinetic (PK) studies (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These compounds showed low to medium clearance (mostly below 25% of rat liver blood flow), often good bioavailability and a rather low volume of distribution with half-life not much longer than 2 hours. <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> also shows early dose to man (eD2M) predictions based on the in vitro potency from the hWB FLAP assay. Standard procedures following in vitro to in vivo extrapolation of CL<sub>int</sub> measured in human hepatocytes, considering both fraction unbound in the incubation and plasma protein binding were utilized. Initially, an average steady-state concentration model based on target concentration defined as 3× IC<sub>50</sub> hWB<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and in vitro data supplemented by in silico data<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> was used to guide design and rank compounds (eD2M average concn in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Later, a refined eD2M prediction utilized a one-compartment PK model assuming fast absorption to target the minimum effective concentration (eD2M MEC in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), thus aiming at 80% inhibition of LTB<sub>4</sub> production in the circulation during the whole dosing interval. Human volume of distribution was predicted from the rat PK study, considering species differences in protein binding. Bioavailability was estimated from first pass clearance only because the compounds had high Caco-2 <i>P</i><sub>app</sub> values, indicating likely good absorption, which was confirmed by the good bioavailability in rats. (Details and equations can be found in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>). Compound <b>4i</b> was ranked to have the most beneficial dose estimate based on both these models from in vitro parameters and rat PK.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Rat in Vivo PK Data and Early Human Dose Prediction Based on Primarily in Vitro Data</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">CL mL/min/kg<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> L/kg<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> h<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>F</i> %<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">rat PPB % free<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">hu PPB % free<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">eD2M average concn mg/day<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">eD2M MEC mg/day<a class="ref internalNav" href="#t5fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4i</b></td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0.83</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4p</b></td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="left">150 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4q</b></td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">0.97</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">6800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4u</b></td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">0.64</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">285</td><td class="colsep0 rowsep0" align="left">14 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">13.3</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">210</td><td class="colsep0 rowsep0" align="left">1 000 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">9.8</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">175</td><td class="colsep0 rowsep0" align="left">140 000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Rat in vivo clearance.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Rat in vivo volume of distribution.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Rat in vivo half-life.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Rat in vivo bioavailabilty.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Rat plasma protein binding.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Human plasma protein binding.</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">eD2M prediction considering 3× IC<sub>50</sub> as target for the average steady state concentration.</p></div><div class="footnote" id="t5fn8"><sup><sup>h</sup></sup><p class="last">eD2M prediction considering 3× IC<sub>50</sub> as target for the MEC. Experimental details for dose predictions and experimental data are described in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><div class="NLM_p">The compounds in this series showed limited rodent activity but were potent in dogs, and hence dogs were utilized for an initial PK/pharmacodynamic (PK/PD) analysis. Compound <b>4i</b> was progressed and administered as single and multiple doses and as either intravenous (IV) infusion or per oral (po) to the dog (IV dose: 0.004–0.1 μmol/kg; po dose: 0.1–1 μmol/kg). The collected blood samples were used to determine both the compounds’ plasma concentration and to measure ex vivo levels of LTB<sub>4</sub> production following ionophore stimulation (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>). Thus, enabling a modeling approach to define the PK and PK/PD properties of compound <b>4i</b> (details on PK/PD modeling approach, observed data and results can be found in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>). First, the PK parameters were estimated simultaneously for IV and po administration. The absorption of compounds <b>4i</b> was rapid in the dog, exhibiting good apparent oral bioavailability of 51%, and the plasma shows a monophasic decline over time. Clearance estimated at 0.2 L/h/kg and the volume of distribution at 0.98 L/kg, rendering a half-life in the dog of about 3.4 h (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Drug plasma concentration vs time (left) and the absolute LTB<sub>4</sub> values vs compound <b>4i</b> exposure (right) is shown for oral repeated dosing (IV data in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>). The circles represent observed PK and mean individual LTB<sub>4</sub> (<i>n</i> = 5, per time point) data from po dosing, and filled and empty circles represent 1 and 0.1 μmol/kg doses, respectively. To the left, the solid and dash blue lines represent the population model fit of 1 and 0.1 μmol/kg po dosing, respectively, and to the right, the black line represents the population model fit including all data from the different oral and IV studies (more information in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The time-matched PK and LTB<sub>4</sub> samples were used to quantitatively describe the exposure–response relationship for compounds <b>4i</b> in the dog. The observed values cover a wide range of concentrations and LTB<sub>4</sub> inhibition (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). These studies indicated that LTB<sub>4</sub> production was inhibited in a concentration-dependent manner, and no time delay was observed. A sigmodal <i>E</i><sub>max</sub> model was fitted to the data and the IC<sub>50</sub> value was estimated to be 26 nM in blood after correction of the plasma/blood ratio, in keeping with the potency as determined in vitro from dog whole blood, IC<sub>50</sub> = 28 nM.</div><div class="NLM_p last">The preliminary human dose prediction for <b>4i</b> targeting the MEC (eD2M MEC, see <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) was refined based on dog PK/PD data with the aim to reach 80% LTB<sub>4</sub> inhibition during the whole dosing time. The human CL (0.3 L/kg/h) was based on scaling in vitro human hepatocyte CL<sub>int</sub> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>) as well as scaling dog and rat CL using the liver blood flow method with plasma protein binding correction.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The blood/plasma ratio for all species was assumed to be the same as measured in humans (0.74). Volume of distribution (<i>V</i><sub>ss</sub>) in human was predicted to be 1.5 L/kg from rat and dog PK data using the Øie–Tozer method.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Human bioavailability and constant of absorption were assumed to be the same as estimated from dog PK data, 52% and 5.3 h<sup>–1</sup>, respectively. A human PK/PD model was developed based on these PK parameters and the exposure–response data were generated in the dog. In vitro human IC<sub>50</sub> was used as approximation for the in vivo value because we demonstrated a good in vitro–in vivo potency correlation in dogs. The model predicts that a twice-daily dose of 280 mg of compound <b>4i</b> is sufficient to achieve an exposure level above the defined minimum inhibitory concentration and would correspond to a maximum free concentration of 0.38 μM.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Safety Profiling</h3><div class="NLM_p">Compounds in the series were in general found to have low hERG inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Based on the promising PK/PD and a dose predicted to be suitable for b.i.d. dosing of <b>4i</b>, a thorough in vitro safety assessment was conducted. Across a panel of seven human cardiac ion channels (hERG, IK<sub>s</sub>, Kv1.5, I<sub>to</sub>, HCN4, Cav3.2, and Nav1.5), <b>4i</b> was measured to have pIC<sub>50</sub> < 4. In a liver panel investigating cell toxicity in THLE cells, mitochondrial impairment in HepG2 cell and inhibition of hBSEP and hMrp2 <b>4i</b> showed no activity part from activity in the hBSEP assay with an IC<sub>50</sub> value of 120 μM, which still leaves a wide margin to predicted total <i>C</i><sub>max</sub> of 3.5 μM. Compound <b>4i</b> demonstrated activity in a phospholipidosis assay with an EC<sub>50</sub> value of 32 μM, which still yields good margin to predict exposure in man. No activity was observed in an hAhR assay and no genotoxic liabilities were observed for <b>4i</b> based on a 5-strain Ames test and in vitro micronucleus assessment in mouse lymphoma cells. In a broad secondary pharmacology screen of 180 targets (Cerep, France), activity was only observed for a limited number of targets and all at low pIC<sub>50</sub>, resulting in good margin predicted for any off-target effect of <b>4i</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</div><figure id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Secondary pharmacology activity of <b>4i</b> was assessed in a screening panel of 180 targets. A margin of >30-fold was predicted for any off-target effects based on the predicted human free <i>C</i><sub>max</sub> of 0.38 μM corresponding to a dose of 280 mg b.i.d. to reach the target of 80% LTB<sub>4</sub> suppression over 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The selectivity of compound <b>4i</b> against key lipoxygenases was assessed using isolated enzyme assays and the compound demonstrated no significant inhibitory effect on the activity of 5-LO, platelet 12-lipoxygenase, or 15-lipoxygenase. The lack of activity against isolated 5-LO provides additional confirmation that <b>4i</b> inhibits 5-LO pathway activity through interaction with FLAP. Compound <b>4i</b> was also profiled in human blood assays to assess whether it had any effect on eicosanoid (prostanoid) production by the COX-1 or COX-2 pathways, biochemical pathways similar to the 5-LO pathway that also uses arachidonic acid as a substrate. No significant activity on the production of either thromboxane B<sub>2</sub> or prostaglandin E<sub>2</sub>, markers of COX-1 and COX-2 pathway activity, respectively, was observed indicating ≥100-fold selectivity of the compound for the 5-LO pathway.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FLAP inhibition has been shown to be an efficient way to reduce the formation of leukotrienes in humans. Leukotrienes have a role as inflammation mediators and inhibitors of the 5-LO pathway in which FLAP is a key regulator, which have been hypothesized to have a beneficial effect in both asthma and CAD,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> diseases with a strong inflammatory component to their pathophysiology. Despite years of efforts and several series developed into clinical candidates for human studies, no FLAP inhibitor has progressed beyond phase II clinical studies.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The reasons for discontinuation have either been undisclosed, lack of efficacy, or various safety liabilities. We here report the discovery of a novel series of FLAP inhibitors identified from a focused screen where we set strict criteria to identify and develop low lipophilic compounds with a wide therapeutic margin to identifiable safety liabilities and off-target effects. A defined SAR is being described around the (R,R)-enantiomer of the <i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carboxylic acid core <b>1</b>. The series has been optimized using LLE to reach high free hWB pIC<sub>50</sub> values in the range of 8–9. Overall, the compounds show good solubility and permeability and no in vitro safety liabilities. The metabolic stability was moderate in vitro in human hepatocytes and in vivo after oral administration into both rats and dogs. The dose prediction was set from previous clinical data showing that an 80% inhibition of leukotriene production over 24 h can have efficacy on surrogate endpoints in CAD patients. Major efforts were put into reducing the metabolic clearance, while maintaining high potency and overall good properties. A thorough analysis of metabolic pathways was undertaken to guide the design and strategies to reduce or block these metabolic routes. However, the overall success in improving metabolic stability was limited because of new metabolic pathways taking over. The ketone showed no or very little tendency to form an imine as measured in the methoxyl amine trapping reaction, but CYP-independent reduction to the corresponding inactive alcohol was seen to varying degrees for some compounds. The masked aniline structure in the R<sub>1</sub> amide was carefully considered by measurement of the corresponding aromatic amine in the genotoxicity Ames test. Any Ames active amines were avoided, even though amide cleavage was not observed for all compounds in question.</div><div class="NLM_p">During progression of the series, an early dose prediction based on in vitro data and an average steady-state concentration (eD2M average concn) targeting IC<sub>80</sub> (3× IC<sub>50</sub>) was used to rank the molecules and guide optimization. The compounds with the most promising in vitro profiles were pursued into rat PK studies. A refined early dose prediction utilized a one-compartment PK model to target the MEC (eD2M MEC) based on in vitro data in combination with the rat PK parameters. Compound <b>4i</b> showed good overall properties and was predicted to have the lowest dose using either of these early models for dose prediction.</div><div class="NLM_p">The series of compounds showed no rodent activity, and in vivo PK/PD investigations were undertaken in dogs using ex vivo measurement of the biomarker LTB<sub>4</sub> in blood. Target engagement was robustly demonstrated for <b>4i</b> with no time delay in the onset of the effect. The ex vivo potency in dogs suggests a good correlation with the in vitro data, 34 versus 28 nM, respectively. Several in vivo PK/PD studies in dogs were undertaken with both oral and IV dosing of <b>4i</b> to build a robust prediction of the required human dose. With a twice-daily dose of 280 mg, we predict compound <b>4i</b> to achieve an exposure level above the defined minimum inhibitory concentration with a maximum free concentration of 0.38 μM. This dose suggests wide margins to any in vitro safety screening data including secondary pharmacology panels. Thus, <b>4i</b> holds the promise to achieve a therapeutic window sufficient to be progressed as a clinical candidate.</div><div class="NLM_p last">Compound <b>4i</b> was identified from a novel series of FLAP inhibitors with the potential for b.i.d. dosing to be progressed into preclinical in vivo safety studies. We envision that this novel series of compounds with the front-runner compound <b>4i</b> will allow for testing the hypothesis that FLAP inhibition will reduce inflammation and micro- and macrovascular dysfunction in CAD patients.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Chemistry</h3><div class="NLM_p">All solvents and reagents were obtained from commercially available sources and used without further purification. The microwave syntheses were performed in a Biotage initiator with an external surface IR probe. Flash column chromatography was carried out on prepacked silica gel columns supplied by Biotage and using Biotage automated flash systems with UV detection. Analytical high-performance liquid chromatography/mass spectrometry (HPLC/MS) was conducted on a QTOF mass spectrometer using a UV detector monitoring either at (a) 210 nm with a BEH C18 column (2.1 × 100 mm, 1.7 μm, 0.7 mL/min flow rate), using a gradient of 2% v/v CH<sub>3</sub>CN in H<sub>2</sub>O (ammonium carbonate buffer pH 10) to 98% v/v CH<sub>3</sub>CN in H<sub>2</sub>O, or at (b) 230 nm with an HSS C18 column (2.1 × 100 mm, 1.8 μm, 0.7 mL/min flow rate), using a gradient of 2% v/v CH<sub>3</sub>CN in H<sub>2</sub>O (ammonium formate buffer pH 3) to 98% v/v CH<sub>3</sub>CN in H<sub>2</sub>O. All tested compounds were determined to be ≥95% pure using the analytical method (a) or (b) described above based on the peak area percentage. Preparative HPLC was performed by either a Waters FractionLynx with ZQ MS detector on either a Waters XBridge C18 OBD 5 μm column (19 × 150 mm, flow rate 30 mL/min, or 30 × 150 mm, flow rate 60 mL/min) using a varying gradient of CH<sub>3</sub>CN with 0.2% NH<sub>3</sub> at pH 10 or a Waters SunFire C18 OBD 5 μm column (19 × 150 mm, flow rate 30 mL/min, or 30 × 150 mm, flow rate 60 mL/min) using a varying gradient of CH<sub>3</sub>CN with 0.1 M HCO<sub>2</sub>H or on a Gilson preparative HPLC with a UV/vis detector 155 on a Kromasil C8 10 μm column (20 × 250 mm, flow rate 19 mL/min, or 50 × 250 mm, flow rate 100 mL/min) using a varying gradient of CH<sub>3</sub>CN with 0.1 M HCO<sub>2</sub>H or 0.1 M acetic acid. <sup>1</sup>H NMR and <sup>13</sup>C spectra were recorded on a Bruker Avance II or III spectrometer at a proton frequency of 400, 500, or 600 MHz at 25 °C. Chemical shifts (δ) are given in parts per million (ppm), with the residual solvent signal used as a reference. Coupling constants (<i>J</i>) are reported as Hz. NMR abbreviations are used as follows: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>trans</i>-<i>N</i>-(3,5-Dimethyl-1,2-oxazol-4-yl)-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4c</b> (<i>rac</i>))</h4><div class="NLM_p">Water (4 mL), K<sub>3</sub>PO<sub>4</sub> (1.02 g, 4.82 mmol) and Pd(dppf)Cl<sub>2</sub> (0.130 g, 0.16 mmol) were added to a solution of <i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carboxylic acid (<b>1</b> (rac), 0.500 g, 1.61 mmol) and 1<i>H</i>-pyrazol-3-ylboronic acid (0.270 g, 2.41 mmol) in dimethylformamide (DMF) (10 mL), and the resulting reaction mixture was heated in a microwave reactor at 100 °C for 30 min. The reaction mixture was then concentrated in vacuo, and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated NH<sub>4</sub>Cl(aq), with pH adjusted to ∼3 using HCl. The organic phase was dried (phase separator) and concentrated in vacuo, and the residue was purified by preparative HPLC (C8, 25 → 65% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN, HCO<sub>2</sub>H 95/5/0.2) to give <i>trans</i>-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxylic acid (<b>3a</b> (<i>rac</i>), 312 mg, 65%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.11 (br s, 1H), 12.18 (br s, 1H), 8.09 (d, <i>J</i> = 8.3 Hz, 2H), 8.02 (d, <i>J</i> = 8.1 Hz, 2H), 7.85 (br s, 1H), 6.91 (d, <i>J</i> = 2.1 Hz, 1H), 3.63–3.73 (m, 1H), 2.67–2.8 (m, 1H), 2.10–2.20 (m, 1H), 1.94–2.03 (m, 1H), 1.83–1.89 (m, 1H), 1.76–1.83 (m, 1H), 1.32–1.59 (m, 3H), 1.11–1.24 (m, 1H); MS <i>m</i>/<i>z</i>: 297.3 [M – H]<sup>−</sup>.</div><div class="NLM_p last"><i>O</i>-(Benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate (TBTU) (215 mg, 0.67 mmol) was added to a stirred solution of 3,5-dimethylisoxazol-4-amine (75 mg, 0.67 mmol), <b>3a</b> (<i>rac</i>) (100 mg, 0.34 mmol), and <i>N</i>-ethyl-<i>N</i>-(propan-2-yl)propan-2-amine (DIPEA) (0.175 mL, 1.01 mmol) in DMF (2 mL), and the resulting reaction mixture was stirred at room temperature (rt) for 16 h. The reaction mixture was partitioned between 1 M Na<sub>2</sub>CO<sub>3</sub>(aq) and CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was dried (phase separator) and concentrated in vacuo, and the residue was purified by preparative HPLC (XBridge, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2) to give <b>4c</b> (<i>rac</i>) (23 mg, 17%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.07 (br s, 1H), 9.35 (s, 1H), 8.01 (d, <i>J</i> = 8.4 Hz, 2H), 7.93 (d, <i>J</i> = 8.1 Hz, 2H), 7.78 (br s, 1H), 6.82 (d, <i>J</i> = 2.2 Hz, 1H), 3.65–3.77 (m, 1H), 2.77–2.88 (m, 1H), 2.03–2.15 (m, 4H), 1.90–2.02 (m, 4H), 1.83 (d, <i>J</i> = 12.8 Hz, 1H), 1.75 (d, <i>J</i> = 12.9 Hz, 1H), 1.44–1.56 (m, 2H), 1.26–1.39 (m, 1H), 1.13–1.24 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 393.1921; found, 393.1923.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4d</b> (<i>rac</i>))</h4><div class="NLM_p last">Compound <b>4d</b> (<i>rac</i>) was prepared from compound <b>1</b> (<i>rac</i>) in a manner analogous to compound <b>4c</b> (<i>rac</i>) described above using 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine (15 mg, 22%); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.09 (s, 1H), 9.36 (s, 1H), 8.02 (d, <i>J</i> = 8.2 Hz, 2H), 7.97 (d, <i>J</i> = 8.1 Hz, 2H), 7.85 (s, 1H), 7.69 (s, 1H), 6.85 (s, 1H), 3.69–3.8 (m, 1H), 3.62 (s, 3H), 2.87–2.96 (m, 1H), 2.01–2.13 (m, 4H), 1.96 (d, <i>J</i> = 12.7 Hz, 1H), 1.84 (d, <i>J</i> = 12.8 Hz, 1H), 1.77 (d, <i>J</i> = 12.8 Hz, 1H), 1.39–1.56 (m, 2H), 1.29–1.4 (m, 1H), 1.14–1.23 (m, 1H). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 392.2081; found, 392.2085.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4d</b>)</h4><div class="NLM_p last">Compound <b>4d</b> was prepared from (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)cyclohexane-1-carboxylic acid (<b>1</b>) in a manner analogous to compound <b>4c</b> (<i>rac</i>) described above using 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrochloride (41 mg, 48%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.06 (br s, 1H), 9.32 (s, 1H), 7.87–8.05 (m, 4H), 7.82 (br s, 1H), 7.65 (s, 1H), 6.82 (d, <i>J</i> = 2.1 Hz, 1H), 3.66–3.77 (m, 1H), 3.59 (s, 3H), 2.83–2.95 (m, 1H), 1.98–2.08 (m, 4H), 1.89–1.97 (m, 1H), 1.68–1.84 (m, 2H), 1.25–1.54 (m, 3H), 1.09–1.23 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 392.2081; found, 392.2080.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (1<i>S</i>,2<i>S</i>)-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4d</b> (<i>S</i>,<i>S</i>))</h4><div class="NLM_p last">Compound <b>4d</b> (<i>S</i>,<i>S</i>) was prepared from (1<i>S</i>,2<i>S</i>)-2-(4-bromobenzoyl)cyclohexane-1-carboxylic acid (<b>1</b> (<i>S</i>,<i>S</i>)) in a manner analogous to compound <b>4c</b> (<i>rac</i>) described above using 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine (46 mg, 55%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.06 (br s, 1H), 9.32 (s, 1H), 7.87–8.08 (m, 4H), 7.82 (br s, 1H), 7.65 (s, 1H), 6.82 (d, <i>J</i> = 2.1 Hz, 1H), 3.66–3.79 (m, 1H), 3.59 (s, 3H), 2.83–2.96 (m, 1H), 2–2.09 (m, 4H), 1.94 (d, <i>J</i> = 10.6 Hz, 1H), 1.69–1.86 (m, 2H), 1.26–1.56 (m, 3H), 1.1–1.23 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 392.2081; found, 392.2093.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(pyridin-2-yl)benzoyl]cyclohexane-1-carboxamide (<b>4e</b> (<i>rac</i>))</h4><div class="NLM_p">DIPEA (4.32 mL, 24.78 mmol) was added to a mixture of compound <b>1</b> (<i>rac</i>) (1.542 g, 4.96 mmol) and 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine dihydrochloride (1.095 g, 5.95 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (11 mL). When all material had dissolved, TBTU (2.068 g, 6.44 mmol) was added and the reaction mixture was stirred at rt overnight. The reaction mixture was then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub>(aq). The organic phase was washed with saturated NaHCO<sub>3</sub>(aq) (×2). The aqueous phases were combined and extracted with CH<sub>2</sub>Cl<sub>2</sub> (×5). The organic phases were combined and dried (phase separator) and concentrated in vacuo. The residue was purified by flash chromatography (20 → 100% EtOAc in heptane) to give <i>trans</i>-2-(4-bromobenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexanecarboxamide (<b>2a</b> (<i>rac</i>), 1.876 g, 94%) as a white solid: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.79–7.85 (m, 2H), 7.64 (s, 1H), 7.55–7.61 (m, 2H), 6.95 (s, 1H), 3.72 (s, 3H), 3.62–3.71 (m, 1H), 2.80–2.87 (m, 1H), 2.15 (s, 3H), 1.98–2.10 (m, 2H), 1.82–1.95 (m, 2H), 1.68–1.81 (m, 1H), 1.30–1.50 (m, 3H); MS <i>m</i>/<i>z</i>: 406.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Compound <b>2a</b> (<i>rac</i>) (0.15 g, 0.37 mmol), KOAc (0.182 g, 1.86 mmol), Pd(dppf)Cl<sub>2</sub> (0.019 g, 0.03 mmol), and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.122 g, 0.48 mmol) were added to a microwave vessel. Dioxane (3 mL) was then added, and the reaction was heated to 120 °C under N<sub>2</sub> for 1 h using microwave irradiation. LCMS indicated the formation of the corresponding boronic acid, (4-{<i>trans</i>-2-[(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)carbamoyl]cyclohexane-1-carbonyl}phenyl)boronic acid; <i>m</i>/<i>z</i>: 368.4 [M – H]<sup>−</sup>. The reaction mixture was diluted with H<sub>2</sub>O (2 mL) and dioxane (1 mL) and filtered (syringe filter). The filtrated solution was taken to the next step without purification.</div><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (155 mg, 1.12 mmol), Pd(dppf)Cl<sub>2</sub> (22 mg, 0.03 mmol), and 2-chloropyridine (0.046 mL, 0.49 mmol) were added to a microwave vial, followed by addition of the solution containing crude (4-{<i>trans</i>-2-[(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)carbamoyl]cyclohexane-1-carbonyl}phenyl)boronic acid (∼0.37 mmol) in dioxane/H<sub>2</sub>O (6 mL). The resulting reaction mixture was heated at 140 °C for 10 min using microwave irradiation. The reaction mixture was then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub>(aq). The organic phase was dried (phase separator) and concentrated in vacuo. The residue was purified by preparative HPLC (XBridge, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2 buffer), flash column chromatography (0 → 25% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>), and then preparative HPLC (C8, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/HCO<sub>2</sub>H 95/5/0.2) to give <b>4e</b> (<i>rac</i>) (8 mg, 5%): <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.33 (s, 1H), 8.67–8.71 (m, 1H), 8.17–8.23 (m, 2H), 8.05–8.09 (m, 2H), 8.02–8.05 (m, 1H), 7.91 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.64 (s, 1H), 7.40 (ddd, <i>J</i> = 7.5, 4.8, 1.0 Hz, 1H), 3.71–3.78 (m, 1H), 3.58 (s, 3H), 2.86–2.93 (m, 1H), 2.01–2.07 (m, 4H), 1.91–1.97 (m, 1H), 1.77–1.84 (m, 1H), 1.71–1.77 (m, 1H), 1.38–1.54 (m, 2H), 1.26–1.37 (m, 1H), 1.1–1.21 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 403.2129; found, 403.2136.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(1<i>H</i>-pyrrol-2-yl)benzoyl]cyclohexane-1-carboxamide (<b>4f</b> (<i>rac</i>))</h4><div class="NLM_p">EtOH (4 mL), H<sub>2</sub>O (4 mL), K<sub>3</sub>PO<sub>4</sub> (2.05 g, 9.64 mmol), and Pd(dppf)Cl<sub>2</sub> (0.208 g, 0.26 mmol) were added to a solution of compound <b>1</b> (<i>rac</i>) (1 g, 3.21 mmol) and 1-(<i>tert</i>-butoxycarbonyl)-1<i>H</i>-pyrrol-2-ylboronic acid (0.814 g, 3.86 mmol) in DME (8 mL). The resulting reaction mixture was heated in a microwave reactor at 135 °C for 25 min, and the mixture was then acidified with 3.8 M HCl and stirred at 70 °C for 1 h. The reaction mixture was filtered (celite) and concentrated in vacuo. The residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated NaCl(aq). The organic phase was dried (phase separator) and concentrated in vacuo. The crude product, <i>trans</i>-2-[4-(1<i>H</i>-pyrrol-2-yl)benzoyl]cyclohexane-1-carboxylic acid (<b>3b</b> (<i>rac</i>)), was used in the next step without further purification; MS <i>m</i>/<i>z</i>: 296.2 [M – H]<sup>−</sup>.</div><div class="NLM_p last">TBTU (97 mg, 0.30 mmol) was added to a stirred solution of crude <b>3b</b> (<i>rac</i>) (60 mg, 0.20 mmol), 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrochloride (0.120 g, 0.81 mmol), and DIPEA (0.105 mL, 0.61 mmol) in DMF (1 mL), and the reaction mixture was stirred at rt for 19 h. The reaction mixture was then concentrated in vacuo, and the residue was purified by preparative HPLC (XBridge, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2) to give <b>4f</b> (<i>rac</i>) (6.3 mg, 7%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.81 (br s, 1H), 7.94 (d, <i>J</i> = 8.4 Hz, 2H), 7.64 (s, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.07 (s, 1H), 6.91 (s, 1H), 6.65 (s, 1H), 6.32 (q, <i>J</i> = 2.6 Hz, 1H), 3.63–3.75 (m, 4H), 2.81–2.92 (m, 1H), 2.15 (s, 3H), 2.00–2.12 (m, 2H), 1.70–1.96 (m, 3H), 1.24–1.56 (m, 3H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 391.2129; found, 391.2128.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(1-methyl-1<i>H</i>-pyrazol-5-yl)benzoyl]cyclohexane-1-carboxamide (<b>4g</b> (<i>rac</i>))</h4><div class="NLM_p">Compound <b>4g</b> (<i>rac</i>) was prepared from compound <b>1</b> (<i>rac</i>) in a manner analogous to compound <b>4c</b> (<i>rac</i>). The use of 5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1-methyl-1<i>H</i>-pyrazole in step 1 gave <i>trans</i>-2-[4-(1-methyl-1<i>H</i>-pyrazol-5-yl)benzoyl]cyclohexane-1-carboxylic acid (<b>3c</b> (<i>rac</i>), 0.541 g, 57%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.05 (d, <i>J</i> = 8.1 Hz, 2H), 7.54 (s, 1H), 7.52 (d, <i>J</i> = 8.2 Hz, 2H), 6.37 (s, 1H), 3.93 (s, 3H), 3.50–3.61 (m, 1H), 2.92–3.02 (m, 1H), 2.17–2.32 (m, 1H), 2.01–2.12 (m, 1H), 1.83–1.94 (m, 2H), 1.26–1.57 (m, 4H); MS <i>m</i>/<i>z</i>: 311.4 [M – H]<sup>−</sup>.</div><div class="NLM_p last">Subsequent use of 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine in step 2 provided the title compound (50 mg, 55%); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.34 (s, 1H), 8.02–8.10 (m, 2H), 7.65–7.68 (m, 2H), 7.64 (s, 1H), 7.48 (d, <i>J</i> = 1.9 Hz, 1H), 6.50 (d, <i>J</i> = 1.9 Hz, 1H), 3.87 (s, 3H), 3.69–3.76 (m, 1H), 3.59 (s, 3H), 2.85–2.93 (m, 1H), 2.03 (s, 4H), 1.89–1.97 (m, 1H), 1.77–1.84 (m, 1H), 1.70–1.77 (m, 1H), 1.37–1.52 (m, 2H), 1.26–1.36 (m, 1H), 1.11–1.21 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 406.2238; found, 406.2212.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(4-methyl-1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4h</b> (<i>rac</i>))</h4><div class="NLM_p">K<sub>2</sub>CO<sub>3</sub> (0.315 g, 3.21 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.326 g, 1.29 mmol) and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (0.026 g, 0.03 mmol) were added to a solution of compound <b>1</b> (<i>rac</i>) (0.200 g, 0.64 mmol) in degassed dimethyl sulfoxide (DMSO) (2.5 mL). The reaction mixture was heated at 100 °C for 30 min using microwave irradiation and was then partitioned between EtOAc and H<sub>2</sub>O. The aqueous phase was extracted with EtOAc, and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue was purified by flash column chromatography (40 → 100% EtOAc in heptane) to give <i>trans</i>-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)cyclohexanecarboxylic acid (0.233 g, quantitative): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.97 (d, <i>J</i> = 8.2 Hz, 2H), 7.93 (d, <i>J</i> = 8.2 Hz, 2H), 3.55–3.67 (m, 1H), 2.94–3.03 (m, 1H), 2.22–2.32 (m, 1H), 2.02–2.1 (m, 1H), 1.83–1.95 (m, 2H), 1.41–1.6 (m, 4H), 1.29 (s, 12H); MS <i>m</i>/<i>z</i>: 357.4 [M – H]<sup>−</sup>.</div><div class="NLM_p">1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrochloride (0.090 g, 0.61 mmol) and TBTU (0.072 g, 0.22 mmol) were added to a solution of <i>trans</i>-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)cyclohexanecarboxylic acid (0.073 g, 0.20 mmol) and DIPEA (0.177 mL, 1.02 mmol) in DMF (2 mL). The reaction mixture was stirred at rt for 3.5 h and was then partitioned between EtOAc and H<sub>2</sub>O. The organic phase was washed with saturated NaHCO<sub>3</sub>(aq) and H<sub>2</sub>O, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The residue, crude <i>trans</i>-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]cyclohexane-1-carboxamide, was taken to the next step without further purifications; MS <i>m</i>/<i>z</i>: 452.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Pd(dtbpf)Cl<sub>2</sub> (0.020 g, 0.03 mmol) and a solution of K<sub>2</sub>CO<sub>3</sub> (98 mg, 0.71 mmol) in H<sub>2</sub>O (2 mL) were added to a solution of crude <i>trans</i>-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]cyclohexane-1-carboxamide (160 mg, 0.35 mmol) and 3-bromo-4-methyl-1<i>H</i>-pyrazole (57 mg, 0.35 mmol) in dioxane (2 mL). The reaction mixture was stirred at 80 °C for 2.5 h and at 100 °C for 0.5 h. More 3-bromo-4-methyl-1<i>H</i>-pyrazole (57 mg, 0.35 mmol) in dioxane (1 mL) and a solution of K<sub>2</sub>CO<sub>3</sub> (98 mg, 0.71 mmol) in H<sub>2</sub>O (0.5 mL) were added, and the resulting reaction mixture was heated at 80 °C for 0.5 h. The reaction mixture was then partitioned between EtOAc and H<sub>2</sub>O and the aqueous phase was extracted with EtOAc (×3). The combined organic phases were washed with saturated NaCl(aq), saturated NH<sub>4</sub>Cl(aq), and saturated NaCl(aq), dried (phase separator), and concentrated in vacuo. The residue was purified by preparative HPLC (XBridge, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2 buffer) to give <b>4h</b> (<i>rac</i>) (46 mg, 32%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.71 (d, <i>J</i> = 8.1 Hz, 2H), 7.65 (s, 1H), 7.44 (br s, 1H), 7.37 (br s, 1H), 3.74–3.81 (m, 1H), 3.69 (s, 3H), 2.87–2.94 (m, 1H), 2.26 (s, 3H), 2.13 (s, 3H), 2.03–2.11 (m, 2H), 1.84–1.94 (m, 2H), 1.72–1.83 (m, 1H), 1.44–1.54 (m, 1H), 1.27–1.43 (m, 2H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 406.2238; found, 406.2254.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(5-methyl-1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4i</b>)</h4><div class="NLM_p">A solution of T3P (50% in EtOAc, 24 mL, 40.3 mmol) was slowly added to a suspension of compound <b>1</b> (10.0 g, 32.1 mmol) and 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine dihydrochloride (6.1 g, 33.1 mmol) and Et<sub>3</sub>N (24 mL, 173 mmol) in EtOAc (110 mL) at 45–50 °C, and the reaction mixture was stirred overnight at 50 °C. More 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine dihydrochloride (2.0 g, 6.4 mmol), EtOAc (25 mL), DIPEA (10 mL, 57.4 mmol), and a solution of T3P (50% in EtOAc, 10 mL, 16.8 mmol) were then added at 50 °C, and the reaction mixture was stirred at 60 °C for 2 h. The reaction mixture was cooled to rt and diluted with EtOAc, and the organic phase was washed with 8% NaHCO<sub>3</sub>(aq), saturated NaCl(aq), 1 M HCl(aq), and saturated NaCl(aq). The organic phase was filtered through a phase separator containing Na<sub>2</sub>SO<sub>4</sub> to give (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (<b>2a</b>, 11.7 g, 90%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.8–7.87 (m, 2H), 7.65 (s, 1H), 7.56–7.61 (m, 2H), 7.13 (s, 1H), 3.72 (s, 3H), 3.66–3.71 (m, 1H), 2.83–2.91 (m, 1H), 2.13 (s, 3H), 1.99–2.11 (m, 2H), 1.83–1.95 (m, 2H), 1.67–1.8 (m, 1H), 1.28–1.52 (m, 3H); MS <i>m</i>/<i>z</i>: 402.1 [M – H]<sup>−</sup>.</div><div class="NLM_p">A solution of K<sub>2</sub>CO<sub>3</sub> (13.0 g, 93.9 mmol) in degassed water (50 mL) was added to a mixture of <b>2a</b> (10.55 g, 23.48 mmol), crude 3-methyl-1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (11.15 g, 30.53 mmol), and Pd(dtbpf)Cl<sub>2</sub> (0.454 g, 0.70 mmol) in degassed dioxane (50 mL). The reaction mixture was heated at 60 °C for 1 h and was then partitioned between EtOAc and saturated NaCl(aq). The aqueous phase was extracted with EtOAc (×2), and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue was purified by flash column chromatography (0 → 10% EtOH in EtOAc) to give (1<i>R</i>,2<i>R</i>)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-2-{4-[3-methyl-1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexane-1-carboxamide (10.57 g, 92%) as a yellow-white foam; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.06 (dd, <i>J</i> = 8.5, 3.3 Hz, 2H), 7.68 (s, 1H), 7.58 (dd, <i>J</i> = 8.5, 3.2 Hz, 2H), 7.07 (d, <i>J</i> = 4.3 Hz, 1H), 6.17 (d, <i>J</i> = 1.3 Hz, 1H), 5.06–5.14 (m, 1H), 3.74–3.82 (m, 1H), 3.72 (d, <i>J</i> = 1.2 Hz, 3H), 3.55–3.64 (m, 1H), 2.86–2.95 (m, 1H), 2.5–2.64 (m, 1H), 2.33 (s, 3H), 2.18 (d, <i>J</i> = 1.6 Hz, 3H), 2.00–2.16 (m, 4H), 1.86–1.97 (m, 2H), 1.71–1.84 (m, 3H), 1.31–1.61 (m, 5H); MS <i>m</i>/<i>z</i>: 490.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">HCl(aq) (3.8 M, 6.24 mL, 23.7 mmol) was added to a solution of (1<i>R</i>,2<i>R</i>)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-2-{4-[3-methyl-1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexane-1-carboxamide (10.56 g, 21.57 mmol) in dioxane (100 mL) and water (25 mL), and the reaction mixture was stirred at rt for 1 h 40 min. The reaction mixture was then quenched by the addition of saturated NaHCO<sub>3</sub>(aq). The mixture was then transferred to a separatory funnel with the aid of EtOAc and washed with saturated NaHCO<sub>3</sub>(aq). The aqueous phase was extracted with EtOAc (×2), and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue was purified by flash column chromatography (0 → 10% EtOH in EtOAc) to give <b>4i</b> (7.92 g, 91%) as a white powder after freeze-drying from CH<sub>3</sub>CN/H<sub>2</sub>O; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.00 (d, <i>J</i> = 8.5 Hz, 2H), 7.82 (d, <i>J</i> = 8.4 Hz, 2H), 7.66 (s, 1H), 7.22 (br s, 1H), 6.43 (s, 1H), 3.73–3.81 (m, 1H), 3.70 (s, 3H), 2.86–2.93 (m, 1H), 2.37 (s, 3H), 2.14 (s, 3H), 2.03–2.12 (m, 2H), 1.83–1.95 (m, 2H), 1.74–1.84 (m, 1H), 1.46–1.55 (m, 1H), 1.27–1.44 (m, 2H); HRMS (ESI): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>, 406.2238 [M + H]<sup>+</sup>; found, 406.2240.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (1<i>R</i>,2<i>R</i>)-2-[4-(1<i>H</i>-Pyrazol-3-yl)benzoyl]-<i>N</i>-[2-(pyridin-2-yl)ethyl]cyclohexane-1-carboxamide (<b>4j</b>)</h4><div class="NLM_p last">Compound <b>4j</b> was prepared from compound <b>1</b> in a manner analogous to compound <b>4c</b> (<i>rac</i>) described above using 2-(pyridin-2-yl)ethanamine (44 mg, 33%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.09 (br s, 1H), 8.46 (d, <i>J</i> = 4.2 Hz, 1H), 7.99 (d, <i>J</i> = 8.5 Hz, 2H), 7.89–7.96 (m, 3H), 7.77 (br s, 1H), 7.65–7.71 (m, 1H), 7.16–7.22 (m, 2H), 6.82 (d, <i>J</i> = 2.2 Hz, 1H), 3.58–3.68 (m, 1H), 3.18–3.38 (m, 2H), 2.76 (t, <i>J</i> = 7.1 Hz, 2H), 2.55–2.63 (m, 1H), 1.81–1.90 (m, 2H), 1.65–1.77 (m, 2H), 1.17–1.47 (m, 3H), 1.05–1.16 (m, 1H); HRMS (ESI): calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup>, 403.2129 [M + H]<sup>+</sup>; found, 403.2110.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-[2-(Methanesulfonyl)-2-methylpropyl]-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4k</b>)</h4><div class="NLM_p">K<sub>2</sub>CO<sub>3</sub> (3.57 g, 25.84 mmol) and Pd(dtbpf)Cl<sub>2</sub> (0.210 g, 0.32 mmol) were added to a solution of compound <b>1</b> (2.01 g, 6.46 mmol) and 1-(tetrahydro-2<i>H</i>-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (2.70 g, 9.69 mmol) dissolved in dioxane (40 mL) and water (20 mL). The reaction mixture was degassed and backfilled with nitrogen (×3) and was then heated at 80 °C for 30 min. The mixture was allowed to cool to rt and was then diluted with EtOAc. The mixture was washed with 1 M KHSO<sub>4</sub>(aq). The phases were separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were dried (phase separator), and the solvent was removed under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and concentrated again. The crude product, (1<i>R</i>,2<i>R</i>)-2-{4-[1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexane-1-carboxylic acid, was collected as a brown gum and was used without further purifications; MS <i>m</i>/<i>z</i>: 381.3 [M – H]<sup>−</sup>.</div><div class="NLM_p">DIPEA (0.40 mL, 2.29 mmol) was added to a solution of (1<i>R</i>,2<i>R</i>)-2-{4-[1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexane-1-carboxylic acid (203 mg, 0.53 mmol), 2-methyl-2-(methylsulfonyl)propan-1-amine (233 mg, 1.54 mmol), and TBTU (187 mg, 0.58 mmol) in DMF (2 mL), and the resulting reaction mixture was stirred at rt for 40 min. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO<sub>3</sub>(aq) (×2) and saturated NaCl(aq). The organic phase was dried (phase separator), and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (60 → 100% EtOAc in heptane) to give (1<i>R</i>,2<i>R</i>)-<i>N</i>-[2-(methanesulfonyl)-2-methylpropyl]-2-{4-[1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexane-1-carboxamide (249 mg, 91%); MS <i>m</i>/<i>z</i>: 516.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">HCl (in CH<sub>3</sub>OH) (1.2 M, 0.80 mL, 0.96 mmol) was added to a solution of (1<i>R</i>,2<i>R</i>)-<i>N</i>-[2-(methanesulfonyl)-2-methylpropyl]-2-{4-[1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexane-1-carboxamide (242 mg, 0.47 mmol) in CH<sub>3</sub>OH (100 mL), and the resulting reaction mixture was concentrated in vacuo at 16 °C. The residue was dissolved in 100 mL CH<sub>3</sub>OH and concentrated again at 16–18 °C. The crude material was purified by reversed-phase HPLC (XBridge C18, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2) to give <b>4k</b> (110 mg, 54%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.07 (br s, 1H), 7.89–8.08 (m, 5H), 7.83 (br s, 1H), 6.83 (d, <i>J</i> = 2.2 Hz, 1H), 3.64–3.74 (m, 1H), 3.27–3.42 (m, 2H), 2.89 (s, 3H), 2.68–2.79 (m, 1H), 1.89–2.03 (m, 2H), 1.7–1.83 (m, 2H), 1.36–1.54 (m, 2H), 1.24–1.36 (m, 1H), 1.16 (s, 4H), 1.10 (s, 3H); HRMS (ESI): calcd for C<sub>22</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub>S<sup>+</sup>, 432.1952 [M + H]<sup>+</sup>; found, 432.1967.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-methyl-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4l</b>)</h4><div class="NLM_p">A solution of compound <b>1</b> (<i>rac</i>) (200 mg, 0.64 mmol), TBTU (371 mg, 1.16 mmol), <i>N</i>,1,3-trimethyl-1<i>H</i>-pyrazol-4-amine (161 mg, 1.29 mmol), and DIPEA (0.337 mL, 1.93 mmol) in NMP (4 mL) was stirred at 50 °C for 2 h. The reaction was quenched by addition of saturated NaHCO<sub>3</sub>(aq), and the mixture was diluted with EtOAc. The phases were separated, and the organic phase was washed with saturated NaCl(aq), saturated NH<sub>4</sub>Cl(aq), and saturated NaCl(aq). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. The crude product, <i>trans</i>-2-(4-bromobenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-methylcyclohexane-1-carboxamide (<b>2b</b> (<i>rac</i>)), was used in the next step without further purification; MS <i>m</i>/<i>z</i>: 418.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">Crude <b>2b</b> (<i>rac</i>) (268 mg, 0.64 mmol), 1<i>H</i>-pyrazol-3-ylboronic acid (129 mg, 1.15 mmol), Pd(dppf)Cl<sub>2</sub> (46.3 mg, 0.06 mmol), and K<sub>2</sub>CO<sub>3</sub> (265 mg, 1.92 mmol) were dissolved in dioxane (3 mL) and H<sub>2</sub>O (3 mL). The mixture was heated at reflux for 5 h, and the mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated NaCl(aq). The phases were separated and the organic phase was dried (phase-separator) and evaporated, leaving a black solid. The residue was filtered through a flash column (0 → 10% EtOH in EtOAc), and the orange residue was purified by preparative HPLC (XBridge, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2 buffer) to give <i>trans</i>-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-methyl-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4l</b> (<i>rac</i>), 86 mg, 33%); <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.10 (s, 1H), 7.91–8.1 (m, 4H), 7.86 (br s, 1H), 7.84 (s, 1H), 6.86 (d, <i>J</i> = 2.2 Hz, 1H), 3.81 (s, 3H), 3.72–3.78 (m, 1H), 2.92 (s, 3H), 2.68–2.76 (m, 1H), 2.21 (s, 3H), 1.79–1.92 (m, 2H), 1.63–1.72 (m, 2H), 1.41–1.52 (m, 1H), 1.28–1.38 (m, 1H), 0.94–1.08 (m, 2H); MS <i>m</i>/<i>z</i>: 406.2 [M + H]<sup>+</sup>.</div><div class="NLM_p">The enantiomers of <b>4l</b> (<i>rac</i>) (65 mg, 0.16 mmol) were separated by chiral chromatography on a Chiralpak IA 250 × 20 mm, 5 μm HPLC column; 13 mg (65 mg/mL in EtOH) was injected and eluted with EtOH at a flow rate of 15 mL/min and detected at 245 nm.</div><div class="NLM_p last">The second eluted compound was collected and evaporated to yield <b>4l</b> (27 mg, 97% ee); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 406.2238; found, 406.2238.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-(6-Methoxypyrimidin-4-yl)-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4m</b>)</h4><div class="NLM_p last">Compound <b>4m</b> was prepared from compound <b>1</b> in a manner analogous to compound <b>4i</b> described above. Use of 6-methoxypyrimidin-4-amine gave (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)-<i>N</i>-(6-methoxypyrimidin-4-yl)cyclohexane-1-carboxamide (<b>2c</b>); MS <i>m</i>/<i>z</i>: 418.2 [M + H]<sup>+</sup>. Subsequent use of 1<i>H</i>-pyrazol-3-ylboronic acid provided the title compound (320 mg, 49%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.49 (s, 1H), 8.46 (s, 1H), 8.25 (s, 1H), 8.04 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 (d, <i>J</i> = 8.1 Hz, 2H), 7.66 (d, <i>J</i> = 2.3 Hz, 1H), 7.44 (s, 1H), 6.71 (d, <i>J</i> = 2.3 Hz, 1H), 3.91 (s, 3H), 3.68–3.80 (m, 1H), 2.84–2.97 (m, 1H), 2.08–2.19 (m, 2H), 1.82–1.97 (m, 2H), 1.64–1.74 (m, 1H), 1.44–1.55 (m, 1H), 1.27–1.42 (m, 2H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>24</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 406.1874; found, 406.1910.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(2-Hydroxy-2-methylpropyl)-5-({<i>trans</i>-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carbonyl}amino)pyrazine-2-carboxamide (<b>4n</b> (<i>rac</i>))</h4><div class="NLM_p">DIPEA (4.54 mL, 26.1 mmol), methyl 5-aminopyrazine-2-carboxylate (1.00 g, 6.53 mmol), and T3P (7.79 mL, 13.1 mmol, 50% in EtOAc) were added to a solution of compound <b>1</b> (<i>rac</i>) (2.23 g, 7.17 mmol) in EtOAc (10 mL), and the resulting reaction mixture was heated at 150 °C using micro-wave irradiation. The resulting mixture was concentrated in vacuo, and the residue was purified by flash column chromatography (1 → 5% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 1.20 g (41%) of methyl 5-{[<i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}pyrazine-2-carboxylate as a yellow solid (1.20 g, 41%); MS <i>m</i>/<i>z</i>: 446 [M + H]<sup>+</sup>.</div><div class="NLM_p">A solution of LiOH (259 mg, 10.8 mmol) in water (5 mL) was added dropwise to a solution of methyl 5-[[<i>trans</i>-2-[(4-bromophenyl)carbonyl]cyclohexane]amido]pyrazine-2-carboxylate (1.2 g, 2.69 mmol) in methanol (10 mL), and the resulting reaction mixture was stirred for 5 h at rt. The reaction mixture was then concentrated in vacuo and diluted with H<sub>2</sub>O. The reaction mixture was cooled to 0 °C, and the pH value of the solution was adjusted to 2 with 1 M HCl(aq). The resulting solution was extracted with of EtOAc (×3), and the combined organic phases was washed with saturated NaCl(aq), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. This resulted in 660 mg of 5-{[<i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}pyrazine-2-carboxylic acid as a white solid. The product was used directly in the next step without further purification; MS <i>m</i>/<i>z</i>: 430 [M – H]<sup>−</sup>.</div><div class="NLM_p">1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (441 mg, 2.30 mmol) and HOBt (310 mg, 2.29 mmol) were added to a solution of 5-{[<i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}pyrazine-2-carboxylic acid (330 mg, 0.76 mmol) in DMF (8 mL) under N<sub>2</sub>. The resulting solution was stirred for 10 min at rt and then 1-amino-2-methylpropan-2-ol (68 mg, 0.76 mmol) was added, and the resulting reaction mixture was stirred for 12 h at rt. The reaction mixture was then diluted with H<sub>2</sub>O and extracted with EtOAc (×3). The combined organic phases were concentrated in vacuo. The residue was purified by flash column chromatography (1 → 5% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 380 mg of 5-{[<i>trans</i>-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}-<i>N</i>-(2-hydroxy-2-methylpropyl)pyrazine-2-carboxamide (<b>2d</b> (<i>rac</i>)) as a white solid; MS <i>m</i>/<i>z</i>: 503 [M + H]<sup>+</sup>.</div><div class="NLM_p last">1<i>H</i>-Pyrazol-3-ylboronic acid (167 mg, 1.50 mmol), a solution of K<sub>2</sub>CO<sub>3</sub> (275 mg, 1.99 mmol) in H<sub>2</sub>O (2 mL), and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (162.5 mg, 0.20 mmol) were added to a solution of <b>2d</b> (<i>rac</i>) (500 mg, 0.99 mmol) in dioxane (10 mL) in a sealed tub under N<sub>2</sub>. The resulting reaction mixture was stirred for 5 h at 80 °C, and the mixture was then diluted with H<sub>2</sub>O and extracted with EtOAc (×3). The organic phases were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under vacuum. The residue was purified by flash column chromatography (1 → 5% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) and preparative HPLC (C8, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN, HCO<sub>2</sub>H 95/5/0.2) to give <b>4n</b> (<i>rac</i>) (55 mg, 11%) as an off-white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 9.31 (d, <i>J</i> = 1.2 Hz, 1H), 8.95 (d, <i>J</i> = 1.4 Hz, 1H), 8.08 (d, <i>J</i> = 8.3 Hz, 2H), 7.94 (br s, 2H), 7.59–7.80 (m, 2H), 6.80 (d, <i>J</i> = 2.2 Hz, 1H), 3.80–3.91 (m, 1H), 3.41 (d, <i>J</i> = 2.5 Hz, 2H), 3.05–3.15 (m, 1H), 2.2–2.27 (m, 1H), 2.12–2.18 (m, 1H), 1.86–1.99 (m, 2H), 1.45–1.68 (m, 3H), 1.28–1.37 (m, 1H), 1.23 (s, 6H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>31</sub>N<sub>6</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 491.2401; found, 491.2437.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-(Pyrazolo[1,5-<i>a</i>]pyrimidin-3-yl)-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4o</b>)</h4><div class="NLM_p last">Compound <b>4o</b> was prepared from compound <b>1</b> in a manner analogous to compound <b>4i</b> described above. Use of pyrazolo[1,5-<i>a</i>]pyrimidin-3-amine gave (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)-<i>N</i>-(pyrazolo[1,5-<i>a</i>]pyrimidin-3-yl)cyclohexane-1-carboxamide (<b>2e</b>); MS <i>m</i>/<i>z</i>: 425.2 [M – H]<sup>−</sup>. Subsequent use of 1<i>H</i>-pyrazol-3-ylboronic acid provided the title compound (56 mg, 58%): <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.08 (s, 1H), 10.24 (s, 1H), 8.98 (dd, <i>J</i> = 7.0, 1.6 Hz, 1H), 8.50 (dd, <i>J</i> = 4.0, 1.6 Hz, 1H), 8.40 (s, 1H), 8.02–8.10 (m, 2H), 7.88–8.00 (m, 2H), 7.85 (s, 1H), 6.99 (dd, <i>J</i> = 7.0, 4.0 Hz, 1H), 6.85 (d, <i>J</i> = 2.0 Hz, 1H), 3.70–3.85 (m, 1H), 3.04–3.15 (m, 1H), 2.11–2.21 (m, 1H), 1.93–2.03 (m, 1H), 1.75–1.88 (m, 2H), 1.44–1.60 (m, 2H), 1.30–1.42 (m, 1H), 1.13–1.26 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 415.1877; found, 415.1895.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-[1-Methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4p</b>)</h4><div class="NLM_p">Compound <b>4p</b> was prepared from compound <b>1</b> in a manner analogous to compound <b>4i</b> described above. Use of 1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine gave (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)-<i>N</i>-[1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]cyclohexane-1-carboxamide (<b>2f</b>, 4.72 g, 79%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.02 (s, 1H), 7.84 (d, <i>J</i> = 8.6 Hz, 2H), 7.60 (d, <i>J</i> = 8.6 Hz, 2H), 7.41 (br s, 1H), 3.84 (s, 3H), 3.61–3.68 (m, 1H), 2.83–2.92 (m, 1H), 2.02–2.1 (m, 2H), 1.84–1.96 (m, 2H), 1.64–1.75 (m, 1H), 1.35–1.52 (m, 2H), 1.26–1.34 (m, 1H); MS <i>m</i>/<i>z</i>: 455.7 [M – H]<sup>−</sup>.</div><div class="NLM_p last">Subsequent use of 1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole provided the title compound <b>4p</b> (405 mg, 58%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.32 (br s, 1H), 8.01–8.06 (m, 3H), 7.88 (d, <i>J</i> = 8.3 Hz, 2H), 7.65 (d, <i>J</i> = 2.4 Hz, 1H), 7.48 (br s, 1H), 6.71 (d, <i>J</i> = 2.4 Hz, 1H), 3.82 (s, 3H), 3.70–3.77 (m, 1H), 2.84–2.95 (m, 1H), 2.05–2.16 (m, 2H), 1.85–1.98 (m, 2H), 1.68–1.80 (m, 1H), 1.29–1.55 (m, 3H); <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>): δ −60.13; HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 446.1798; found, 446.1793.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-[1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4q</b>)</h4><div class="NLM_p last">Compound <b>4q</b> was prepared from compound <b>1</b> in a manner analogous to compound <b>4i</b> described above. Use of 1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine gave (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)-<i>N</i>-[1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]cyclohexane-1-carboxamide (<b>2g</b>); MS <i>m</i>/<i>z</i>: 458.1 [M + H]<sup>+</sup>. Subsequent use of 1<i>H</i>-pyrazol-3-ylboronic acid provided the title compound <b>4q</b> (120 mg, 59%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.63 (br s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.99 (s, 1H), 7.87 (d, <i>J</i> = 8.2 Hz, 2H), 7.65 (br s, 1H), 7.49 (br s, 1H), 6.71 (br s, 1H), 3.90 (s, 3H), 3.70–3.80 (m, 1H), 2.84–2.94 (m, 1H), 2.03–2.15 (m, 2H), 1.84–1.96 (m, 2H), 1.71–1.83 (m, 1H), 1.25–1.56 (m, 3H); <sup>19</sup>F NMR (470 MHz, CDCl<sub>3</sub>): δ −58.2; HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 446.1798; found, 446.1805.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-[3-(Difluoromethoxy)-1-methyl-1<i>H</i>-pyrazol-4-yl]-2-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4r</b>)</h4><div class="NLM_p last">Compound <b>4r</b> was prepared from compound <b>1</b> in a manner analogous to compound <b>4n</b> described above. Use of 3-(difluoromethoxy)-1-methyl-1<i>H</i>-pyrazol-4-amine hydrochloride<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> gave (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)-<i>N</i>-[3-(difluoromethoxy)-1-methyl-1<i>H</i>-pyrazol-4-yl]cyclohexane-1-carboxamide (<b>2h</b>, 360 mg, 52%); MS <i>m</i>/<i>z</i>: 456 [M + H]<sup>+</sup>. Subsequent use of 1<i>H</i>-pyrazol-3-ylboronic acid provided the title compound <b>4r</b> (125 mg, 64%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.04 (d, <i>J</i> = 8.5 Hz, 2H), 7.87 (d, <i>J</i> = 8.5 Hz, 2H), 7.76 (s, 1H), 7.66 (d, <i>J</i> = 2.2 Hz, 1H), 7.50 (s, 1H), 6.79 (t, <i>J</i> = 73.7 Hz, 1H), 6.71 (d, <i>J</i> = 2.1 Hz, 1H), 3.75–3.85 (m, 1H), 3.67 (s, 3H), 2.86–2.97 (m, 1H), 2.05–2.18 (m, 2H), 1.85–1.98 (m, 2H), 1.67–1.80 (m, 1H), 1.25–1.58 (m, 3H); <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>): δ −82.82 (ABd, <i>J</i> = 166.6 Hz), −83.35 (ABd, <i>J</i> = 166.3 Hz); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>24</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 444.1842; found, 444.1824.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-[3-(Difluoromethyl)-1-methyl-1<i>H</i>-pyrazol-4-yl]-2-[4-(5-methyl-1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4s</b>)</h4><div class="NLM_p last">Compound <b>4s</b> was prepared from compound <b>1</b> in a manner analogous to compound <b>4i</b> described above. Use of 3-(difluoromethyl)-1-methyl-1<i>H</i>-pyrazol-4-amine gave (1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)-<i>N</i>-[3-(difluoromethyl)-1-methyl-1<i>H</i>-pyrazol-4-yl]cyclohexane-1-carboxamide (<b>2i</b>, 370 mg, 44%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.97 (s, 1H), 7.82–7.88 (m, 2H), 7.59 (d, <i>J</i> = 8.4 Hz, 2H), 7.56 (br s, 1H), 6.71 (t, <i>J</i> = 54.7 Hz, 1H), 3.79 (s, 3H), 3.60–3.71 (m, 1H), 2.82–2.91 (m, 1H), 1.99–2.11 (m, 2H), 1.83–1.96 (m, 2H), 1.66–1.73 (m, 1H), 1.28–1.52 (m, 3H); <sup>19</sup>F NMR (470 MHz, CDCl<sub>3</sub>): δ −111.22 (d, <i>J</i> = 308.6 Hz), −112.00 (d, <i>J</i> = 309.6 Hz); MS <i>m</i>/<i>z</i>: 440.0 [M + H]<sup>+</sup>. Subsequent use of crude 3-methyl-1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole provided the title compound <b>4s</b> (84 mg, 47% over two steps): <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.75 (s, 1H), 9.72 (s, 1H), 7.97–8.07 (m, 2H), 7.93 (s, 1H), 7.81–7.92 (m, 2H), 6.98 (t, <i>J</i> = 53.8 Hz, 1H), 6.53–6.62 (m, 1H), 3.76 (s, 3H), 3.70–3.75 (m, 1H), 2.89–2.95 (m, 1H), 2.20–2.32 (m, 3H), 2.02–2.09 (m, 1H), 1.96 (d, <i>J</i> = 10.4 Hz, 1H), 1.83 (d, <i>J</i> = 12.7 Hz, 1H), 1.76 (d, <i>J</i> = 13.0 Hz, 1H), 1.39–1.56 (m, 2H), 1.28–1.38 (m, 1H), 1.11–1.22 (m, 1H); <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.02 (ABd, <i>J</i> = 305.1 Hz), −112.71 (ABd, <i>J</i> = 305.1 Hz); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 442.2049; found, 442.2079.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (1<i>R</i>,2<i>R</i>)-<i>N</i>-(3-Cyano-1-methyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(5-methyl-1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4t</b>)</h4><div class="NLM_p">The mixture of compound <b>1</b> (<i>rac</i>) (1.3 g, 4.1 mmol), 4-amino-1-methyl-1<i>H</i>-pyrazole-3-carbonitrile (0.5 g, 4.1 mmol), T3P (50% in EtOAc, 1.5 mL, 4.9 mmol), and DMAP (1.0 g, 8.2 mol) in DCE (10 mL) was stirred under microwave irradiation and heated at 100 °C for 1 h. The mixture was cooled to rt, diluted with CH<sub>2</sub>Cl<sub>2</sub>, and washed with saturated NaCl(aq). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue was purified by flash column chromatography (petroleum ether/EtOAc, 3:1) to afford <i>trans</i>-2-(4-bromobenzoyl)-<i>N</i>-(3-cyano-1-methyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (<b>2j</b> (<i>rac</i>), 0.4 g, 24%) as a white solid; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.99 (s, 2H), 7.83 (d, <i>J</i> = 8.4 Hz, 2H), 7.64 (s, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 2H), 3.85 (s, 3H), 3.69–3.62 (m, 1H), 2.91–2.84 (m, 1H), 2.12–2.03 (m, 2H), 1.95–1.86 (m, 2H), 1.76–1.69 (m, 1H), 1.49–1.39 (m, 3H); MS <i>m</i>/<i>z</i>: 415.0 [M + H]<sup>+</sup>.</div><div class="NLM_p">Subsequent use of crude 3-methyl-1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole in a manner analogous to compound <b>4i</b> described above provided <i>trans</i>-<i>N</i>-(3-cyano-1-methyl-1<i>H</i>-pyrazol-4-yl)-2-[4-(5-methyl-1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>4t</b> (<i>rac</i>), 102 mg, 68% over two steps).</div><div class="NLM_p">The enantiomers of <b>4t</b> (<i>rac</i>) (77 mg, 0.18 mmol) were separated by chiral chromatography on a Chiralpak AD 250 × 20 mm, 5 μm HPLC column; 52 mg (26 mg/mL in EtOH/CH<sub>2</sub>Cl<sub>2</sub> 2:1) was injected and eluted with heptane/EtOH 7:3 at a flow rate of 18 mL/min and detected at 260 nm.</div><div class="NLM_p last">The second eluted compound was collected and evaporated to yield <b>4t</b> (30 mg, 99% ee); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.97–8.04 (m, 3H), 7.83 (d, <i>J</i> = 8.4 Hz, 2H), 7.79 (s, 1H), 6.44 (s, 1H), 3.84 (s, 3H), 3.67–3.79 (m, 1H), 2.87–2.96 (m, 1H), 2.39 (s, 3H), 2.06–2.17 (m, 2H), 1.85–1.97 (m, 2H), 1.64–1.76 (m, 1H), 1.26–1.57 (m, 3H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 417.2034; found, 417.2056.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-Methyl-4-({(1<i>R</i>,2<i>R</i>)-2-[4-(5-methyl-1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carbonyl}amino)-1<i>H</i>-pyrazole-3-carboxamide (<b>4u</b>)</h4><div class="NLM_p">A solution of T3P (50% in EtOAc, 1.93 mL, 3.25 mmol) was added to a solution of compound <b>1</b> (674 mg, 2.17 mmol) and methyl 4-amino-1-methyl-1<i>H</i>-pyrazole-3-carboxylate hydrochloride (457 mg, 2.38 mmol) and Et<sub>3</sub>N (24 mL, 173 mmol) in EtOAc (9 mL), and the reaction mixture was stirred for 2 h at 80 °C. The reaction mixture was cooled to rt and diluted with EtOAc, and the organic phase was washed with saturated NaHCO<sub>3</sub>(aq) (×2), saturated NH<sub>4</sub>Cl(aq), and saturated NaCl(aq). The organic phase was dried (phase separator) and concentrated in vacuo. The residue was purified by flash chromatography (50% EtOAc in heptane) to give methyl 4-{[(1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}-1-methyl-1<i>H</i>-pyrazole-3-carboxylate (0.64 g, 66%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.09 (s, 1H), 8.04 (s, 1H), 7.84 (d, <i>J</i> = 8.5 Hz, 2H), 7.57 (d, <i>J</i> = 8.5 Hz, 2H), 3.96 (s, 3H), 3.85 (s, 3H), 3.6–3.68 (m, 1H), 2.84–3 (m, 1H), 2.09–2.17 (m, 1H), 1.97–2.05 (m, 1H), 1.82–1.94 (m, 2H), 1.58–1.7 (m, 1H), 1.35–1.48 (m, 2H), 1.25–1.33 (m, 1H); MS <i>m</i>/<i>z</i>: 448.0 [M + H]<sup>+</sup>.</div><div class="NLM_p">A solution of methyl 4-{[(1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}-1-methyl-1<i>H</i>-pyrazole-3-carboxylate (0.64 g, 1.43 mmol) in tetrahydrofuran (THF) (3 mL), CH<sub>3</sub>OH (3 mL), and aqueous LiOH (1 M, 3 mL, 3.0 mmol) was stirred at rt. After 2 h, the reaction mixture was concentrated in vacuo, and 3.8 M HCl(aq) (1 mL) and H<sub>2</sub>O (20 mL) were added to the residue. The resulting mixture was extracted with EtOAc, and the organic phase was dried (phase separator) and concentrated in vacuo to give crude 4-{[(1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}-1-methyl-1<i>H</i>-pyrazole-3-carboxylic acid (603 mg, quantitative); MS <i>m</i>/<i>z</i>: 432.1 [M – H]<sup>−</sup>.</div><div class="NLM_p">A mixture of crude 4-{[(1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}-1-methyl-1<i>H</i>-pyrazole-3-carboxylic acid (563 mg, 1.30 mmol), ammonium chloride (139 mg, 2.59 mmol), DIPEA (0.679 mL, 3.89 mmol), and TBTU (749 mg, 2.33 mmol) in DMF (5 mL) was stirred at rt overnight. Then, 5 mL DMSO was added and the mixture was filtrated. The filtrate was purified by preparative HPLC (5 → 75% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2 buffer). Products containing fractions were partially concentrated and extracted with EtOAc. The organic phase was dried (phase separator) and concentrated in vacuo to give 4-{[(1<i>R</i>,2<i>R</i>)-2-(4-bromobenzoyl)cyclohexane-1-carbonyl]amino}-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (<b>2k</b>, 355 mg, 63%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.75 (s, 1H), 8.04 (s, 1H), 7.93 (d, <i>J</i> = 8.4 Hz, 2H), 7.73 (d, <i>J</i> = 8.4 Hz, 2H), 7.64 (br s, 1H), 7.46 (br s, 1H), 3.79 (s, 3H), 3.62–3.72 (m, 1H), 2.82–2.93 (m, 1H), 1.98–2.06 (m, 1H), 1.86–1.94 (m, 1H), 1.78–1.84 (m, 1H), 1.71–1.75 (m, 1H), 1.35–1.55 (m, 3H), 1.10–1.22 (m, 1H).</div><div class="NLM_p last">Compound <b>4u</b> was prepared from <b>2k</b> and 3-methyl-1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole in a manner analogous to compound <b>4i</b> described above (46 mg, 47% over two steps); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.75 (br s, 1H), 9.75 (s, 1H), 8.05 (s, 1H), 8.00 (d, <i>J</i> = 7.6 Hz, 2H), 7.89 (d, <i>J</i> = 7.1 Hz, 2H), 7.64 (br s, 1H), 7.47 (br s, 1H), 6.56 (br s, 1H), 3.78 (s, 3H), 3.67–3.76 (m, 1H), 2.81–2.92 (m, 1H), 2.28 (br s, 3H), 1.91–2.05 (m, 2H), 1.7–1.85 (m, 2H), 1.36–1.59 (m, 3H), 1.13–1.26 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 435.2139; found, 435.2131.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>trans</i>-2-(4-Bromo-2-methylbenzoyl)cyclohexane-1-carboxylic Acid (<b>6</b> (<i>rac</i>))</h4><div class="NLM_p last"><i>n</i>-Butyllithium (2.5 M, 13.5 mL, 33.68 mmol) was added dropwise over 45 min to a solution of 4-bromo-1-iodo-2-methylbenzene (10.0 g, 33.68 mmol) in THF (100 mL) under nitrogen at −78 °C, and the reaction mixture was stirred at −78 °C for 45 min. <i>trans</i>-Hexahydro-2-benzofuran-1,3-dione (5.0 g, 32.4 mmol) in diethyl ether (20 mL) was added dropwise over 15 min, and the reaction mixture was stirred at −78 °C for 2 h. Saturated NH<sub>4</sub>Cl(aq) was added, and the reaction mixture was allowed to attain rt and concentrated in vacuo. EtOAc was added to the crude product, and the organic phase was washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated in vacuo. The crude product was purified by preparative HPLC (C8, 45 → 85% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/CH<sub>3</sub>CO<sub>2</sub>H, 95/5/0.2) and lyophilized to give <b>6</b> (<i>rac</i>) (2.16 g, 20%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.44 (d, <i>J</i> = 8.8 Hz, 1H), 7.24–7.30 (m, 2H), 3.17 (td, <i>J</i> = 12.0, 3.4 Hz, 1H), 2.66–2.79 (m, 1H), 2.24 (s, 3H), 2.09 (d, <i>J</i> = 13.3 Hz, 1H), 1.60–1.82 (m, 3H), 0.97–1.40 (m, 4H); MS <i>m</i>/<i>z</i>: 323.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[6-(1<i>H</i>-pyrazol-3-yl)pyridine-3-carbonyl]cyclohexane-1-carboxamide (<b>7</b> (<i>rac</i>))</h4><div class="NLM_p"><i>n</i>-Butyllithium (2.5 M, 13.0 mL, 32.4 mmol) was added at a rate of 10 mL/h to a solution of 2,5-dibromopyridine (7.92 g, 32.4 mmol) in diethyl ether (100 mL) under N<sub>2</sub> at −78 °C, and the reaction mixture was stirred at −78 °C for 1 h. <i>trans</i>-Hexahydro-2-benzofuran-1,3-dione (5.0 g, 32.4 mmol) in diethyl ether (20 mL) was added dropwise over 15 min, and the reaction mixture was stirred at −78 °C for 2 h. Saturated NH<sub>4</sub>Cl(aq) was added, and the reaction mixture was stirred at −78 °C for 30 min and then at rt for 15 min. The reaction mixture was diluted with diethyl ether and the phases were separated. The aqueous layer was extracted with EtOAc, acidified, and extracted again with EtOAc. The combined EtOAc layers were washed with brine, dried (phase-separator), and concentrated in vacuo to give crude <b>5</b> (<i>rac</i>) (6.68 g), which was used without further purification; MS <i>m</i>/<i>z</i>: 314.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">K<sub>3</sub>PO<sub>4</sub> (0.182 g, 0.86 mmol) in water (0.3 mL) was added to a mixture of <b>5</b> (<i>rac</i>) (0.090 g, 0.29 mmol), 1<i>H</i>-pyrazol-3-ylboronic acid (0.035 g, 0.32 mmol), and Pd(dppf)Cl<sub>2</sub> (0.023 g, 0.030 mmol) in a mixture of DME (0.60 mL) and EtOH (0.30 mL), and the reaction mixture was heated in a microwave reactor at 130 °C for 20 min. 1<i>H</i>-Pyrazol-3-ylboronic acid (0.032 g, 0.29 mmol) and Pd(dppf)Cl<sub>2</sub> (0.023 g, 0.030 mmol) were added to the reaction mixture, and it was heated in a microwave reactor at 130 °C for 30 min. The reaction mixture was concentrated in vacuo, and the crude product was suspended in water. The aqueous phase was acidified and extracted with EtOAc, and the organic phase was concentrated in vacuo. The crude product was purified by preparative HPLC (C8, 0 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/HCO<sub>2</sub>H 95/5/0.2) to give <i>trans</i>-2-[6-(1<i>H</i>-pyrazol-3-yl)pyridine-3-carbonyl]cyclohexane-1-carboxylic acid (0.024 g, 28%); MS <i>m</i>/<i>z</i>: 300.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">1,3-Dimethyl-1<i>H</i>-pyrazol-4-amine (0.074 g, 0.67 mmol), TBTU (0.129 g, 0.40 mmol), and 4-methylmorpholine (0.073 mL, 0.67 mmol) were added to a solution of <i>trans</i>-2-[6-(1<i>H</i>-pyrazol-3-yl)pyridine-3-carbonyl]cyclohexane-1-carboxylic acid (0.100 g, 0.33 mmol) in DMF (5 mL), and the reaction mixture was stirred under N<sub>2</sub> at rt overnight. The reaction mixture was diluted with DMSO and purified by preparative HPLC (C8, 0 → 75% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/HCO<sub>2</sub>H 95/5/0.2) and then by preparative HPLC (C18, 5 → 95% CH<sub>3</sub>CN in 0.1 M HCO<sub>2</sub>H, pH 3) to give <b>7</b> (<i>rac</i>) (8 mg, 6%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.22 (s, 1H), 8.28 (d, <i>J</i> = 8.1 Hz, 1H), 7.83 (d, <i>J</i> = 8.0 Hz, 1H), 7.66 (s, Hz, 1H), 7.24 (s, 1H), 6.91 (s, 1H), 5.30 (s, 2H), 3.66–3.78 (m, 4H), 2.90 (t, <i>J</i> = 9.7 Hz, 1H), 2.15 (s, 3H), 2.08 (d, <i>J</i> = 12.9 Hz, 2H), 1.84–1.97 (m, 2H), 1.70–1.82 (m, 1H), 1.28–1.57 (m, 3H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 393.2034; found, 393.2038.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[2-methyl-4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>8</b> (<i>rac</i>))</h4><div class="NLM_p">TBTU (2.35 g, 7.31 mmol) was added to a solution of <b>6</b> (<i>rac</i>) (2.16 g, 6.64 mmol), 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride (1.18 g, 7.97 mmol), and DIPEA (5.78 mL, 33.21 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL), and the reaction mixture was stirred at rt for 20 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic phase was washed with saturated NaHCO<sub>3</sub>(aq), dried (phase-separator), and concentrated in vacuo. The crude product was purified by silica gel flash chromatography (30 → 80%, EtOAc/CH<sub>3</sub>OH/Et<sub>3</sub>N 100/10/1 in heptane) to give <i>trans</i>-2-(4-bromo-2-methylbenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (2.15 g, 77%); MS <i>m</i>/<i>z</i>: 418.0 [M – H]<sup>−</sup>.</div><div class="NLM_p last"><i>trans</i>-2-(4-Bromo-2-methylbenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (0.20 g, 0.48 mmol), 1<i>H</i>-pyrazol-3-ylboronic acid (0.080 g, 0.72 mmol), Pd(dppf)Cl<sub>2</sub> (0.035 g, 0.05 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.198 g, 1.43 mmol) were suspended in 1,4-dioxane (2 mL) and water (2 mL), and the reaction mixture was heated at reflux for 18 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic phase was washed with water, filtered through celite, dried (phase-separator), and concentrated in vacuo. Another batch of crude products was prepared from <i>trans</i>-2-(4-bromo-2-methylbenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (0.10 g, 0.24 mmol) and 1<i>H</i>-pyrazol-3-ylboronic acid (0.035 g, 0.31 mmol) as described above. The two batches were pooled and purified using preparative HPLC (C18, 25 → 65% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2) and then by preparative HPLC (C18, 5 → 95% CH<sub>3</sub>CN in H<sub>2</sub>O/NH<sub>3</sub> 99.8/0.2) to give <b>8</b> (<i>rac</i>) (0.10 g, 34%): <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.02 (s, 1H), 9.38 (s, 1H), 7.91 (d, <i>J</i> = 7.3 Hz, 1H), 7.66–7.86 (m, 4H), 6.80 (d, <i>J</i> = 2.1 Hz, 1H), 3.66 (s, 3H), 3.47–3.56 (m, 1H), 2.87 (td, <i>J</i> = 12.1, 3.6 Hz, 1H), 2.36 (s, 3H), 2.09 (s, 3H), 2.02–2.06 (m, 1H), 1.84–1.90 (m, 1H), 1.81 (d, <i>J</i> = 11.7 Hz, 1H), 1.73–1.78 (m, 1H), 1.28–1.46 (m, 3H), 1.13–1.23 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 406.2238; found, 406.2232.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>trans</i>-2-[4-(Benzyloxy)-2-fluorobenzoyl]cyclohexane-1-carboxylic Acid (<b>10</b> (<i>rac</i>))</h4><div class="NLM_p last"><i>n</i>-Butyl lithium (14.5 mL, 33.05 mmol, 2.5 M in hexane) was added dropwise at −78 °C under nitrogen to a solution of <b>9</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (9.29 g, 33.05 mmol) in diethyl ether (140 mL), and the reaction mixture was stirred at −78 °C for 30 min. A cooled solution of <i>trans</i>-hexahydro-2-benzofuran-1,3-dione (6.11 g, 39.66 mmol) in THF (100 mL) was added at −78 °C, and the reaction mixture was stirred at −78 °C for 1 h. Saturated NH<sub>4</sub>Cl(aq) (220 mL) was added, and the reaction was allowed to attain rt. pH was adjusted to pH ≈ 4 with 2 M HCl(aq), the layers were separated, and the aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (C8, 40 → 85% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/HCO<sub>2</sub>H, 95/5/0.2) to give <b>10</b> (<i>rac</i>) (3.77 g, 32%): <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.83 (t, <i>J</i> = 8.7 Hz, 1H), 7.39 (ddd, <i>J</i> = 28.2, 22.5, 7.2 Hz, 5H), 6.90 (d, <i>J</i> = 8.7 Hz, 1H), 6.84 (d, <i>J</i> = 13.6 Hz, 1H), 5.16 (s, 2H), 3.43 (t, <i>J</i> = 10.0 Hz, 1H), 2.76 (s, 1H), 2.16 (d, <i>J</i> = 10.4 Hz, 1H), 2.05 (d, <i>J</i> = 13.0 Hz, 1H), 1.85 (t, <i>J</i> = 11.5 Hz, 2H), 1.40 (dt, <i>J</i> = 26.3, 12.9 Hz, 3H), 1.15 (t, <i>J</i> = 12.4 Hz, 1H); MS <i>m</i>/<i>z</i>: 355.5 [M – H]<sup>−</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-(2-fluoro-4-hydroxybenzoyl)cyclohexane-1-carboxamide (<b>11</b> (<i>rac</i>))</h4><div class="NLM_p">DIPEA (5.99 mL, 34.37 mmol), 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride (1.42 g, 9.62 mmol), and TBTU (3.31 g, 10.31 mmol) were added to a solution of <b>10</b> (<i>rac</i>) (2.45 g, 6.87 mmol) in DMF (20 mL) under nitrogen, and the reaction mixture was stirred at rt for 6 h. The reaction mixture was partitioned between saturated NaHCO<sub>3</sub>(aq) and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine, dried (phase-separator), and concentrated in vacuo. The crude product was purified by preparative HPLC (C8, 40 → 85% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/HCO<sub>2</sub>H, 95/5/0.2) to give <i>trans</i>-2-[4-(benzyloxy)-2-fluorobenzoyl]-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (1.92 g, 62%); MS <i>m</i>/<i>z</i>: 450.5 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Ammonium formate (0.81 g, 12.8 mmol) and Pd(OH)<sub>2</sub> (0.60 g, 0.85 mmol) was added to a solution of <i>trans</i>-2-[4-(benzyloxy)-2-fluorobenzoyl]-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (1.92 g, 4.27 mmol) in CH<sub>3</sub>OH (30 mL), and the reaction mixture was heated in a microwave reactor at 100 °C for 15 min. The reaction mixture was filtered through a pad of celite, the celite was washed with EtOAc and CH<sub>3</sub>OH, and the filtrate was concentrated in vacuo to give <b>11</b> (<i>rac</i>) (1.53 g, quantitative): <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.74 (t, <i>J</i> = 8.8 Hz, 1H), 7.59 (s, 1H), 6.64 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 6.54 (dd, <i>J</i> = 13.6, 2.1 Hz, 1H), 3.72 (s, 3H), 3.52–3.61 (m, 1H), 2.90 (t, <i>J</i> = 11.3 Hz, 1H), 2.13 (s, 5H), 1.87 (d, <i>J</i> = 12.6 Hz, 2H), 1.49 (dq, <i>J</i> = 57.7, 12.9 Hz, 3H), 1.21 (q, <i>J</i> = 11.2, 9.7 Hz, 1H); MS <i>m</i>/<i>z</i>: 360.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[2-fluoro-4-(1<i>H</i>-pyrazol-5-yl)benzoyl]cyclohexane-1-carboxamide (<b>12</b> (<i>rac</i>))</h4><div class="NLM_p">K<sub>2</sub>CO<sub>3</sub> (0.88 g, 6.38 mmol) was added to a suspension of <b>11</b> (<i>rac</i>) (1.53 g, 4.25 mmol) and 1,1,1-trifluoro-<i>N</i>-phenyl-<i>N</i>-(trifluoromethanesulfonyl)methanesulfonamide (2.73 g, 7.65 mmol) in DMF (18 mL) under nitrogen, and the reaction mixture was stirred at rt for 6 h. The reaction mixture was diluted with water, and the aqueous phase was extracted with EtOAc. The organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (C8, 35 → 75% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/HCO<sub>2</sub>H, 95/5/0.2) to give 4-{<i>trans</i>-2-[(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)carbamoyl]cyclohexane-1-carbonyl}-3-fluorophenyl trifluoromethanesulfonate (1.45 g, 69%); MS <i>m</i>/<i>z</i>: 492.5 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Pd(dppf)<sub>2</sub>Cl<sub>2</sub> (0.30 g, 0.36 mmol) and 2 M K<sub>2</sub>CO<sub>3</sub>(aq) (2.78 mL, 5.55 mmol) were added to a suspension of 4-{<i>trans</i>-2-[(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)carbamoyl]cyclohexane-1-carbonyl}-3-fluorophenyl trifluoromethanesulfonate (0.68 g, 1.39 mmol) and 1<i>H</i>-pyrazol-5-ylboronic acid (0.31 g, 2.76 mmol) in 1,4-dioxane (9.5 mL), and the reaction mixture was heated in a microwave reactor at 100 °C for 20 min. The reaction mixture was concentrated in vacuo, and the crude product was purified by preparative HPLC (C18, 15 → 75% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub>, 95/5/0.2) to give <b>12</b> (<i>rac</i>) (0.29 g, 51%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.85 (t, <i>J</i> = 7.8 Hz, 1H), 7.71 (d, <i>J</i> = 7.9 Hz, 2H), 7.47–7.61 (m, 3H), 6.61 (s, 1H), 3.61–3.75 (m, 4H), 2.89 (t, <i>J</i> = 10.8 Hz, 1H), 2.10–2.19 (m, 4H), 1.99–2.09 (m, 1H), 1.80–1.93 (m, 2H), 1.72 (q, <i>J</i> = 12.2 Hz, 1H), 1.46 (d, <i>J</i> = 12.9 Hz, 1H), 1.32 (d, <i>J</i> = 13.0 Hz, 1H), 1.13–1.26 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 410.1992; found, 410.1992.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (−)-<i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[2-fluoro-4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>12</b> (<i>S</i>,<i>S</i>))</h4><div id="sec4_1_28_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (+)-<i>trans</i>-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[2-fluoro-4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>12</b>)</h5><div class="NLM_p last">The enantiomers of <b>12</b> (<i>rac</i>) (1.15 g, 2.81 mmol) were separated by chiral chromatography on a ReproSil column (8 μm, 250 × 50 mm); 192 mg (64 mg/mL in <i>i</i>-propanol/CH<sub>2</sub>Cl<sub>2</sub>, 1:1) was injected and eluted with heptane/<i>i</i>-propanol (30:70) at a flow rate of 120 mL/min and detected at 332 nm. The first eluted compound was collected and evaporated to give <b>12</b> (<i>S</i>,<i>S</i>) (0.546 g, 47%, >99.9% ee): [α]<sub class="stack">D</sub><sup class="stack">20</sup> −80.3 (<i>c</i> 1.0, CH<sub>3</sub>CN); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 410.1992; found, 410.1977. The second eluted compound was collected and evaporated to give <b>12</b> (0.561 g, 49%, 97.9% ee). [α]<sub class="stack">D</sub><sup class="stack">20</sup> +72.0 (<i>c</i> 1.0, CH<sub>3</sub>CN); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.86 (t, <i>J</i> = 7.9 Hz, 1H), 7.72 (s, 1H), 7.51–7.63 (m, 3H), 7.16 (s, 1H), 6.66 (d, <i>J</i> = 2.4 Hz, 1H), 3.72 (s, 3H), 3.63–3.71 (m, 1H), 2.79–2.89 (m, 1H), 2.13–2.22 (m, 4H), 2.00–2.08 (m, 1H), 1.89 (t, <i>J</i> = 12.4 Hz, 2H), 1.68–1.81 (m, 1H), 1.30–1.56 (m, 3H), 1.24 (qd, <i>J</i> = 12.8, 3.2 Hz, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 410.1992; found, 410.1991.</div></div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (1<i>S</i>,2<i>S</i>)-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2-[2-fluoro-4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohexane-1-carboxamide (<b>12</b> (<i>S</i>,<i>S</i>))</h4><div class="NLM_p">T3P (50% in EtOAc, 0.55 mL, 0.92 mmol) was added to a solution of (1<i>S</i>,6<i>S</i>)-6-(4-bromo-2-fluorobenzoyl)cyclohex-3-ene-1-carboxylic acid (<b>14</b> (<i>S</i>,<i>S</i>), 0.20 g, 0.61 mmol), 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride (0.18 g, 1.22 mmol), and Et<sub>3</sub>N (0.51 mL, 3.67 mmol) in EtOAc (3.0 mL), and the reaction mixture was stirred at rt for 3 days and then heated in a microwave reactor at 80 °C for 1 h. The reaction mixture was partitioned between EtOAc and saturated NaHCO<sub>3</sub>(aq). The organic phase was dried (phase-separator) and concentrated in vacuo. The crude product was purified by preparative HPLC (C18, 15 → 65% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2) to give (1<i>S</i>,6<i>S</i>)-6-(4-bromo-2-fluorobenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohex-3-ene-1-carboxamide (0.18 g, 70%); MS <i>m</i>/<i>z</i>: 422.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">1<i>H</i>-Pyrazol-3-ylboronic acid (0.064 g, 0.57 mmol) and a degassed solution of K<sub>2</sub>CO<sub>3</sub> (0.21 g, 1.52 mmol) in water (2 mL) were added to a solution of (1<i>S</i>,6<i>S</i>)-2-(4-bromo-2-fluorobenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)cyclohexane-1-carboxamide (0.16 g, 0.38 mmol) in dioxane (2 mL), and the reaction mixture was heated in a microwave reactor at 85 °C for 1 h. The reaction mixture was diluted with EtOAc, and the organic phase was washed with saturated NaCl(aq). The aqueous phase was extracted twice with EtOAc, and the combined organic phase was dried (phase-separator) and concentrated in vacuo. The crude product was purified by preparative HPLC (C18, 15 → 65% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2) to give (1<i>S</i>,6<i>S</i>)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-6-[2-fluoro-4-(1<i>H</i>-pyrazol-3-yl)benzoyl]cyclohex-3-ene-1-carboxamide (<b>15</b> (<i>S</i>,<i>S</i>), 0.080 g, 52%); MS <i>m</i>/<i>z</i>: 408.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">A palladium catalyst (Pd/C, 10%, 0.050 g, 0.050 mmol) was added to a solution of compound <b>15</b> (<i>S</i>,<i>S</i>) (0.080 g, 0.20 mmol) in CH<sub>3</sub>OH (5 mL), and the reaction mixture was stirred at rt under hydrogen (1 atm) for 3 days. The reaction mixture was filtrated and concentrated in vacuo, and the crude compound was purified by preparative HPLC (C18, 5 → 70% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/HCO<sub>2</sub>H 95/5/0.2) to give <b>12</b> (<i>S</i>,<i>S</i>) (0.045 g, 56%): <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.16 (s, 1H), 9.36 (s, 1H), 7.66–7.89 (m, 5H), 6.90 (d, <i>J</i> = 1.7 Hz, 1H), 3.62 (s, 3H), 3.45–3.55 (m, 1H), 2.86 (t, <i>J</i> = 11.1 Hz, 1H), 2.00 (m, 5H), 1.80 (d, <i>J</i> = 10.4 Hz, 2H), 1.23–1.45 (m, 3H), 1.15 (q, <i>J</i> = 12.6 Hz, 1H); <sup>19</sup>F NMR (470 MHz, DMSO): δ −111.86 (s); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 410.1992; found, 410.1977; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −76.3 (<i>c</i> 1.0, CH<sub>3</sub>CN).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (2<i>E</i>)-4-(4-Bromo-2-fluorophenyl)-4-oxobut-2-enoic Acid (<b>13</b>)</h4><div class="NLM_p last">A mixture of 1-(4-bromo-2-fluorophenyl)ethan-1-one (100 g, 460.8 mmol), oxoacetic acid (55.1 g, 599 mmol) and methane sulfonic acid (2.99 mL, 46.1 mmol) in CH<sub>3</sub>CO<sub>2</sub>H (500 mL) under N<sub>2</sub> was heated at 130 °C for 20 h. The reaction mixture was allowed to cool to 80 °C and water (750 mL) was slowly added. The reaction mixture was cooled to 20 °C during 2 h and then stirred at rt for 1 h. The suspension was filtered and the solid cake was washed with 25% CH<sub>3</sub>CO<sub>2</sub>H(aq) (200 mL) and then water (3 × 150 mL). The solids were dried under reduced pressure at 45 °C for 3 days to give <b>13</b> (92 g, 73%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.26 (br s, 1H), 7.53–7.73 (m, 2H), 7.17–7.37 (m, 2H), 6.70 (dd, <i>J</i> = 15.5, 1.4 Hz, 1H); MS <i>m</i>/<i>z</i>: 270.8 [M – H]<sup>−</sup>.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>trans</i>-6-(4-Bromo-2-fluorobenzoyl)cyclohex-3-ene-1-carboxylic Acid (<b>14</b> (<i>rac</i>))</h4><div class="NLM_p last">A suspension of buta-1,3-diene (20% in toluene, 227 mL, 671.7 mmol) was added to a mixture of <b>13</b> (91.7 g, 335.8 mmol) in toluene (500 mL) in a steel cylinder, and the reaction mixture was heated at 60 °C and 1 bar overnight. EtOAc (2 × 200 mL) was added to the reaction mixture, and the mixture was concentrated in vacuo. EtOAc (100 mL) was added to the crude product, followed by heptane (300 mL), and the suspension was heated to 80 °C. The suspension was slowly allowed to attain rt and then stirred at rt for 1 h. The solids were collected by filtration and washed with EtOAc (20% in heptane, 50 mL) and then with heptane (150 mL) to give <b>14</b> (<i>rac</i>) (98.9 g, 90%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.59 (t, <i>J</i> = 8.1 Hz, 1H), 7.18–7.34 (m, 2H), 5.54–5.69 (m, 2H), 3.52 (td, <i>J</i> = 10.9, 5.3 Hz, 1H), 2.95 (dddd, <i>J</i> = 11.0, 7.4, 5.6, 2.7 Hz, 1H), 2.27–2.5 (m, 2H), 2.06–2.21 (m, 1H), 1.88 (ddd, <i>J</i> = 16.9, 14.2, 2.8 Hz, 1H); MS <i>m</i>/<i>z</i>: 326 [M – H]<sup>−</sup>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (−)-<i>trans</i>-6-(4-Bromo-2-fluorobenzoyl)cyclohex-3-ene-1-carboxylic Acid (<b>14</b>) and (+)-<i>trans</i>-6-(4-Bromo-2-fluorobenzoyl)cyclohex-3-ene-1-carboxylic Acid (<b>14</b> (<i>S</i>,<i>S</i>))</h4><div class="NLM_p last">The enantiomers of <b>14</b> (<i>rac</i>) were separated by chiral supercritical-fluid chromatography (SFC) on a Lux C2 column (5 μm, 250 × 30 mm); 800 mg (200 mg/mL in CH<sub>3</sub>OH) was injected and eluted with 20% CH<sub>3</sub>OH in CO<sub>2</sub> (g) (175 bar) at a flow rate of 130 mL/min and detected at 280 nm. The first eluted compound was collected and evaporated, dissolved in EtOAc (30 mL) and then treated with heptane (250 mL). The suspension formed was cooled on an ice bath and filtered to give <b>14</b> (42.3 g, 43%, 99.9% ee): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.59 (t, <i>J</i> = 8.1 Hz, 1H), 7.16–7.30 (m, 2H), 5.60 (qdt, <i>J</i> = 7.0, 4.8, 2.3 Hz, 2H), 3.51 (td, <i>J</i> = 10.9, 5.3 Hz, 1H), 2.94 (tdd, <i>J</i> = 10.9, 5.6, 2.0 Hz, 1H), 2.24–2.49 (m, 2H), 2.12 (ddtd, <i>J</i> = 16.0, 11.1, 4.4, 2.4 Hz, 1H), 1.88 (dddt, <i>J</i> = 17.3, 11.1, 4.2, 2.3 Hz, 1H); [α]<sub class="stack">D</sub><sup class="stack">20</sup> −16.8 (<i>c</i> 1.0, CH<sub>3</sub>CN). The second eluted compound was collected and evaporated, dissolved in EtOAc (30 mL), and then treated with heptane (250 mL). The suspension formed was cooled on an ice bath and filtered to give <b>14</b> (<i>S</i>,<i>S</i>) (45 g, 45%, 99.6% ee): <sup>19</sup>F NMR (470 MHz, CDCl<sub>3</sub>): δ −108.82 (s); [α]<sub class="stack">D</sub><sup class="stack">20</sup> 18.6 (<i>c</i> 1.0, CH<sub>3</sub>CN).</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (1<i>R</i>,2<i>R</i>)-2-(4-Bromo-2-fluorobenzoyl)cyclohexane-carboxylic Acid (<b>16</b>)</h4><div class="NLM_p last">A rhodium catalyst (5% Rh/C, 0.63 g, 0.31 mmol) was added to a solution of <b>14</b> in THF (100 mL). The reaction mixture was stirred at rt under hydrogen (2 bar) for 16 h. The crude product was filtered through celite, the filtrate was evaporated, and the crude product was re-crystallized from methyl <i>tert</i>-butylether and heptane. The solid formed was dried in vacuo to give <b>16</b> (9.16 g, 91%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.60 (t, <i>J</i> = 8.1 Hz, 1H), 7.18–7.29 (m, 2H), 3.19–3.30 (m, 1H), 2.73 (t, <i>J</i> = 11.3 Hz, 1H), 2.03–2.13 (m, 1H), 1.94 (d, <i>J</i> = 13.3 Hz, 1H), 1.66–1.79 (m, 2H), 1.15–1.4 (m, 3H), 0.97–1.07 (m, 1H); MS <i>m</i>/<i>z</i>: 308.8 [M – H]<sup>−</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-({(1<i>R</i>,2<i>R</i>)-2-[2-Fluoro-4-(3-methyl-1<i>H</i>-pyrazol-5-yl)benzoyl]cyclohexane-1-carbonyl}amino)-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (<b>17</b>)</h4><div class="NLM_p">4-Amino-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (0.33 g, 2.38 mmol) was added to a solution of <b>16</b> (0.52 g, 1.59 mmol), <i>N</i>-[(dimethylamino)-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridin-1-ylmethylene]-<i>N</i>-methylmethanaminium hexafluorophosphate <i>N</i>-oxide (HATU) (0.60 g, 1.59 mmol), and DIPEA (0.55 mL, 3.18 mmol) in DMF (3 mL), and the reaction mixture was stirred at rt for 3 h. The reaction mixture was diluted with EtOAc, and the organic phase was washed twice with saturated NaHCO<sub>3</sub>(aq). The water phase was extracted once more with EtOAc, and the combined organic phase was dried (phase-separator) and evaporated, and the crude product was dried in vacuo overnight to give 4-({[(1<i>R</i>,2<i>R</i>)-2-(4-bromo-2-fluorobenzoyl)cyclohexyl]-carbonyl}amino)-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (1.29 g); MS <i>m</i>/<i>z</i>: 453.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">K<sub>2</sub>CO<sub>3</sub> (0.88 g, 6.36 mmol) and Pd(dtbpf)Cl<sub>2</sub> (0.092 g, 0.14 mmol) were added to a solution of 4-({[(1<i>R</i>,2<i>R</i>)-2-(4-bromo-2-fluorobenzoyl)cyclohexyl]carbonyl}-amino)-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (1.29 g) and 1-(tetrahydro-2<i>H</i>-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (0.70 g, 2.39 mmol) in dioxane (6 mL) and water (6 mL). The reaction mixture was evacuated and purged with N<sub>2</sub> three times, and then heated in a preheated oil-bath at 80 °C for 1 h. The reaction mixture was diluted with EtOAc, and the organic phase was washed with saturated NaCl(aq). The aqueous phase was extracted with EtOAc, and the combined organic phase was dried (phase-separator) and evaporated in vacuo. The crude product was purified by silica gel flash chromatography (75% → 100% EtOAc in heptane) to give 4-{[(1<i>R</i>,2<i>R</i>)-2-{2-fluoro-4-[3-methyl-1-(oxan-4-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexane-1-carbonyl]amino}-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (0.49 g, 58%); MS <i>m</i>/<i>z</i>: 521.4 [M – H]<sup>−</sup>.</div><div class="NLM_p last">HCl (1.25 M in CH<sub>3</sub>OH, 0.5 mL, 0.63 mmol) was added to a solution of 4-({[(1<i>R</i>,2<i>R</i>)-2-{2-fluoro-4-[3-methyl-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1<i>H</i>-pyrazol-5-yl]benzoyl}cyclohexyl]carbonyl}amino)-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (0.22 g, 0.40 mmol) in CH<sub>3</sub>OH (10 mL), and the reaction mixture was concentrated in vacuo at 16 °C. The residue was dissolved in CH<sub>3</sub>OH (10 mL) and concentrated in vacuo at 16 °C. The crude product was purified by preparative HPLC (C18, 5 → 80% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2) to give <b>17</b> (0.13 g, 69%): <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.99 (s, 1H), 7.83 (t, <i>J</i> = 8.0 Hz, 1H), 7.54–7.65 (m, 2H), 6.53 (s, 1H), 3.84 (s, 3H), 3.56–3.64 (m, 1H), 2.86 (t, <i>J</i> = 10.6 Hz, 1H), 2.35 (s, 3H), 2.12 (dd, <i>J</i> = 18.0, 14.0 Hz, 2H), 1.90 (d, <i>J</i> = 10.4 Hz, 2H), 1.59 (q, <i>J</i> = 12.4 Hz, 1H), 1.41–1.52 (m, 2H), 1.33–1.22 (m, 1H); <sup>19</sup>F NMR (470 MHz, CD<sub>3</sub>OD): δ −112.78 (s); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>25</sub>FN<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 905.4023; found, 905.4113.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>rac</i>)-<i>N</i>-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-3-(2-fluoro-4-(1<i>H</i>-pyrazol-3-yl)benzoyl)bicyclo[2.2.2]octane-2-carboxamide (<b>21</b> (<i>rac</i>))</h4><div class="NLM_p">DIPEA (1.960 mL, 11.22 mmol) was added to a suspension of bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic anhydride (1.00 g, 5.61 mmol) and 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine dihydrochloride (1.033 g, 5.61 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). The mixture was stirred at rt for 30 min, at which time 1,1′-carbonyl-diimidazole (1.876 g, 11.22 mmol) was added, and the mixture was stirred at rt for 60 min. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with saturated NH<sub>4</sub>Cl(aq) (×2), saturated NaHCO<sub>3</sub>(aq), and saturated NaCl(aq). The organic phase was dried, and the solvent was removed under reduced pressure to give 2-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-3a,4,7,7a-tetrahydro-1<i>H</i>-4,7-ethanoisoindole-1,3(2<i>H</i>)-dione <b>18</b> (1.382 g, 91%) as a solid which was used in the next step without further purification.</div><div class="NLM_p">Pd/C (0.524 g, 0.25 mmol) was added to a solution of <b>18</b> (1.336 g, 4.92 mmol) in THF (70 mL). The mixture was hydrogenated at rt, at 1 atm for 1.5 h. The reaction mixture was filtered, and the solvent was removed under reduced pressure to give 2-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)hexahydro-1<i>H</i>-4,7-ethanoisoindole-1,3(2<i>H</i>)-dione <b>19</b> (1.331 g, 99%) as a solid which was used in the next step without purification.</div><div class="NLM_p">Compound <b>19</b> (0.600 g, 2.20 mmol) and 1,4-dibromo-2-fluorobenzene (0.557 g, 2.20 mmol) were dissolved in THF (20 mL) and cooled to −78 °C and <i>n</i>-butyllithium (1.32 mL, 3.29 mmol) was added. The mixture was stirred at −78 °C for 60 min and was then allowed to reach rt before being quenched with saturated NH<sub>4</sub>Cl(aq). The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and saturated NaHCO<sub>3</sub>(aq). The organic phase was washed with saturated NH<sub>4</sub>Cl(aq) and saturated NaCl(aq) and then dried, before the solvent was removed under reduced pressure. The residue was purified by flash column chromatography (50% → 100% of CH<sub>3</sub>OH/EtOAc 1:9 in heptane) and preparative HPLC (XBridge, 40 → 80% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2 buffer). Organic solvents from the combined fractions were removed under reduced pressure, and the aqueous residue was extracted with EtOAc and CH<sub>2</sub>Cl<sub>2</sub>. The organic phases were dried (phase separator), and the solvent was removed under reduced pressure. To facilitate precipitation, the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>/pentane and then the solvent was removed under reduced pressure. (<i>rac</i>)-3-(4-Bromo-2-fluorobenzoyl)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)bicyclo[2.2.2]octane-2-carboxamide <b>20</b> (<i>rac</i>) (0.106 g, 10.77%) was collected as a solid; MS <i>m</i>/<i>z</i>: 448.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (98 mg, 0.71 mmol) and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (19 mg, 0.02 mmol) were added to a solution of <b>20</b> (<i>rac</i>) (106 mg, 0.24 mmol) and 1<i>H</i>-pyrazol-3-ylboronic acid (40 mg, 0.35 mmol) in dioxane (2 mL) and water (2 mL). The mixture was degassed and backfilled with N<sub>2</sub> and then heated at reflux for 60 min. More 1<i>H</i>-pyrazol-3-ylboronic acid (13 mg, 0.12 mmol) was added together with Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (19 mg, 0.02 mmol), and the mixture was heated at reflux for another 30 min. The mixture was allowed to reach rt and was then diluted with EtOAc and water. The aqueous phase was extracted once with EtOAc. The combined organic phase was washed with saturated NaHCO<sub>3</sub>(aq), saturated NaCl(aq), saturated NH<sub>4</sub>Cl(aq), and saturated NaCl(aq), before the organic phase was dried (phase separator), and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography (50% → 100% CH<sub>3</sub>OH/EtOAc 1:9 in heptane) to give (<i>rac</i>)-<i>N</i>-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-3-(2-fluoro-4-(1<i>H</i>-pyrazol-3-yl)benzoyl)bicyclo[2.2.2]octane-2-carboxamide (<b>21</b> (<i>rac</i>), 14 mg, 14%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.17 (s, 1H), 9.41 (s, 1H), 7.85–7.88 (m, 1H), 7.78–7.84 (m, 3H), 7.75 (d, <i>J</i> = 12.9 Hz, 1H), 6.79–7.00 (m, 1H), 4.09 (d, <i>J</i> = 6.5 Hz, 1H), 3.69 (s, 3H), 3.44 (d, <i>J</i> = 6.9 Hz, 1H), 2.09 (s, 3H), 1.98 (s, 1H), 1.94 (s, 1H), 1.72–1.81 (m, 1H), 1.63–1.71 (m, 1H), 1.46–1.61 (m, 3H), 1.32–1.43 (m, 2H), 1.22–1.3 (m, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>27</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 436.2143; found, 436.2158.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (1<i>R</i>,6<i>R</i>)-6-(4-Bromobenzoyl)cyclohex-3-ene-1-carboxylate (<b>25</b>)</h4><div class="NLM_p">A suspension of (<i>E</i>)-ethyl 4-(4-bromophenyl)-4-oxobut-2-enoate (<b>24</b>, 5.3 g, 18.7 mmol) in toluene (16 mL) was transferred to a steel bomb with a Teflon insert. Hydroquinone (0.021 g, 0.19 mmol) and excess of cooled −78 °C buta-1,3-diene (7.9 mL, 94 mmol) were added, and the reaction mixture was stirred at rt for 1 h, then at 160 °C overnight, and 200 °C for 2 h before being cooled to rt. The reaction mixture was then concentrated in vacuo, and the residue was purified by flash column chromatography (5 → 10% EtOAc in heptane) to give ethyl <i>trans</i>-6-(4-bromobenzoyl)cyclohex-3-ene-1-carboxylate (<b>25</b> (<i>rac</i>), 6.0 g, 95%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.85–7.90 (m, 2H), 7.60–7.66 (m, 2H), 5.68–5.83 (m, 2H), 3.98–4.15 (m, 2H), 3.73–3.85 (m, 1H), 3.05–3.17 (m, 1H), 2.51–2.63 (m, 1H), 2.32–2.43 (m, 1H), 2.18–2.32 (m, 1H), 2.02–2.16 (m, 1H), 1.17 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p">The isomers of <b>25</b> (<i>rac</i>) (4.6 g, 13.6 mmol) were separated by chiral SFC on a Lux C2 250 × 30 mm, 5 μm column; 575 mg (115 mg/mL in CH<sub>3</sub>OH) was injected and eluted at 40 °C with 10% CH<sub>3</sub>OH in CO<sub>2</sub>, 120 bar at a flow rate of 130 mL/min and detected at 254 nm.</div><div class="NLM_p last">The first eluted compound was collected and evaporated to yield <b>25</b> (2.23 g, 99.9% ee); [α]<sub class="stack">D</sub><sup class="stack">25</sup> −31.4 (<i>c</i> 1.0, CH<sub>3</sub>CN).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (1<i>S</i>,3<i>R</i>,4<i>R</i>,6<i>R</i>)-<i>N</i>-[1-Methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]-4-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]bicyclo[4.1.0]heptane-3-carboxamide (<b>27</b>)</h4><div class="NLM_p"><i>trans</i>-Ethyl 6-(4-bromobenzoyl)cyclohex-3-enecarboxylate (<b>25</b> (<i>rac</i>), 510 mg, 1.51 mmol) was dissolved in DCE (3.8 mL) and cooled to 0 °C before the mixture was degassed and backfilled with N<sub>2</sub> (×2). Diethylzinc (1 M in heptane, 3.02 mL, 3.02 mmol) was added to the solution followed by dropwise addition of chloroiodomethane (0.441 mL, 6.05 mmol). The mixture was stirred at 0 °C for 30 min and was then stirred at rt overnight. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated Na<sub>2</sub>EDTA(aq) and the mixture was stirred for a couple of min, then a small portion of saturated NaHCO<sub>3</sub>(aq) was added, and the mixture was stirred until two clear phases were formed. The mixture was washed with saturated NaHCO<sub>3</sub>(aq). The aqueous phase was extracted once with CH<sub>2</sub>Cl<sub>2</sub> and the organic phases were combined and dried (phase separator), before the solvent was removed under reduced pressure: <sup>1</sup>H NMR showed product/starting material ∼5:1.</div><div class="NLM_p">The crude mixture was dissolved in DCE (3.8 mL) and cooled to 0 °C before the mixture was degassed and backfilled with N<sub>2</sub> (×2). Diethylzinc (1 M in heptane, 3.02 mL, 3.02 mmol) was added to the solution followed by dropwise addition of chloroiodomethane (0.441 mL, 6.05 mmol). The mixture was stirred at 0 °C for 30 min and was then stirred at rt overnight. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated Na<sub>2</sub>EDTA(aq), and the mixture was stirred for a couple of min, then a small portion of saturated NaHCO<sub>3</sub>(aq) was added, and the mixture was stirred until two clear phases were formed. The mixture was washed with saturated NaHCO<sub>3</sub>(aq). The aqueous phase was extracted once with CH<sub>2</sub>Cl<sub>2</sub> and the organic phases were combined and dried (phase separator) before the solvent was removed under reduced pressure. Ethyl (<i>trans</i>-4-(4-bromobenzoyl)bicyclo[4.1.0]heptane-3-carboxylate (<b>26</b> (<i>rac</i>), 524 mg, 99%) was collected as a colorless oil and used without further purification; MS <i>m</i>/<i>z</i>: 351.0 [M + H]<sup>+</sup>.</div><div class="NLM_p">Lithium hydroxide (0.5 M in water) (11 mL, 5.5 mmol) was added to a solution of <b>26</b> (<i>rac</i>) (521 mg, 1.48 mmol) in THF (2 mL) and CH<sub>3</sub>OH (2 mL). The mixture was heated at 60 °C for 6 h and then stirred at rt overnight. The mixture was concentrated under reduced pressure. The residue was dissolved in water, and 3.8 M HCl(aq) was added until a white precipitate formed and pH was ∼2. The mixture was extracted with EtOAc (×3). The organic phases were combined and dried (phase separator), and the solvent was removed under reduced pressure. <i>trans</i>-4-(4-Bromobenzoyl)bicyclo[4.1.0]heptane-3-carboxylic acid (478 mg, 100%) was collected as a white foam; MS <i>m</i>/<i>z</i>: 321.1 [M – H]<sup>−</sup>.</div><div class="NLM_p">Et<sub>3</sub>N (0.603 mL, 4.33 mmol) and then a solution of T3P (50% in EtOAc, 1.03 mL, 1.73 mmol) were added to a mixture of <i>trans</i>-4-(4-bromobenzoyl)bicyclo[4.1.0]heptane-3-carboxylic acid (466 mg, 1.44 mmol) and 1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine (313 mg, 1.90 mmol) in EtOAc (13 mL). The reaction mixture was stirred at rt overnight. More 1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine (119 mg, 0.72 mmol), Et<sub>3</sub>N (0.300 mL, 2.16 mmol), and a solution of T3P (0.515 mL, 0.87 mmol) were added, and the mixture was stirred at rt overnight. The mixture was diluted with EtOAc and washed with saturated NaHCO<sub>3</sub>(aq) (×2), saturated NH<sub>4</sub>Cl(aq), and saturated NaCl(aq). The organic phase was dried (phase separator), and the solvent was removed under reduced pressure. The residue was purified by preparative HPLC (35 → 80% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2 buffer). Products containing fractions were partially concentrated and extracted with CH<sub>2</sub>Cl<sub>2</sub> (×2). The organic phase was dried (phase separator) and concentrated in vacuo to give <i>trans</i>-4-(4-bromobenzoyl)-<i>N</i>-(1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl)bicyclo[4.1.0]heptane-3-carboxamide (431 mg, 64%) as an off-white solid; MS <i>m</i>/<i>z</i>: 470.0 [M + H]<sup>+</sup>.</div><div class="NLM_p">K<sub>2</sub>CO<sub>3</sub> (505 mg, 3.66 mmol) and Pd(dtbpf)Cl<sub>2</sub> (59 mg, 0.09 mmol) were added to a solution of <i>trans</i>-4-(4-bromobenzoyl)-<i>N</i>-(1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl)bicyclo[4.1.0]heptane-3-carboxamide (430 mg, 0.91 mmol) and 1<i>H</i>-pyrazol-3-ylboronic acid (153 mg, 1.37 mmol) in dioxane (4.5 mL) and water (4.5 mL). The mixture was degassed and backfilled with N<sub>2</sub> (×3) and then heated at 80 °C for 45 min in a microwave reactor. The mixture was diluted with EtOAc and washed with H<sub>2</sub>O. The aqueous phase was extracted once with EtOAc. The combined organic phases were washed with saturated NH<sub>4</sub>Cl(aq) and saturated NaCl(aq). The EtOAc layer was dried (phase separator) and the solvent was removed under reduced pressure. The residue was dissolved in EtOAc and filtered (SiO<sub>2</sub>). The compound was eluted with EtOAc and the solvent was then removed under reduced pressure. The crude compound was purified by preparative HPLC (15 → 75% CH<sub>3</sub>CN in H<sub>2</sub>O/CH<sub>3</sub>CN/NH<sub>3</sub> 95/5/0.2 buffer). Products containing fractions were partially concentrated and extracted with CH<sub>2</sub>Cl<sub>2</sub> (×3). The organic phase was dried (phase separator) and concentrated in vacuo to give <i>trans</i>-4-(4-(1<i>H</i>-pyrazol-3-yl)benzoyl)-<i>N</i>-(1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl)bicyclo[4.1.0]heptane-3-carboxamide (335 mg, 80%) as a white solid; MS <i>m</i>/<i>z</i>: 458.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">The isomers of <i>trans</i>-4-(4-(1<i>H</i>-pyrazol-3-yl)benzoyl)-<i>N</i>-(1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl)bicyclo[4.1.0]heptane-3-carboxamide (317 mg, 0.69 mmol) were separated by chiral SFC on a ReproSil 250 × 30 mm, 8 μm column; 20 mg (65 mg/mL in EtOH) was injected and eluted at 40 °C with 20% EtOH/Et<sub>3</sub>N 100/0.5 in CO<sub>2</sub>, 120 bar at a flow rate of 70 mL/min and detected at 260 nm.</div><div class="NLM_p last">The third eluted compound was collected and evaporated to yield <b>27</b> (48 mg, 98% ee); [α]<sub class="stack">D</sub><sup class="stack">25</sup> +86.4 (<i>c</i> 0.50, CH<sub>3</sub>CN); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.02 (s, 1H), 7.99 (d, <i>J</i> = 8.4 Hz, 2H), 7.88 (d, <i>J</i> = 8.3 Hz, 2H), 7.66 (br s, 1H), 7.43 (br s, 1H), 6.72 (br s, 1H), 3.82 (s, 3H), 3.47–3.58 (m, 1H), 2.68–2.79 (m, 1H), 2.39–2.53 (m, 1H), 2.31 (dd, <i>J</i> = 13.6, 4.2 Hz, 1H), 1.77–1.88 (m, 2H), 1.04–1.17 (m, 2H), 0.75–0.86 (m, 1H), 0.31 (q, <i>J</i> = 5.1 Hz, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>23</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 458.1798; found, 458.1840.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (1<i>S</i>,3<i>R</i>,4<i>R</i>,6<i>R</i>)-<i>N</i>-[1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]-4-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]bicyclo[4.1.0]heptane-3-carboxamide (<b>28</b>)</h4><div class="NLM_p">Compound <b>28</b> was prepared from <b>25</b> in a manner analogous to compound <b>27</b> described above. Use of 1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine gave (3<i>R</i>,4<i>R</i>)-4-(4-bromobenzoyl)-<i>N</i>-[1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]bicyclo[4.1.0]heptane-3-carboxamide (274 mg, 47%); MS <i>m</i>/<i>z</i>: 470.0 [M + H]<sup>+</sup>.</div><div class="NLM_p">Subsequent use of 1<i>H</i>-pyrazol-3-ylboronic acid provided (3<i>R</i>,4<i>R</i>)-<i>N</i>-[1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]-4-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]bicyclo[4.1.0]heptane-3-carboxamide (122 mg, 63%); MS <i>m</i>/<i>z</i>: 458.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">The isomers of (3<i>R</i>,4<i>R</i>)-<i>N</i>-[1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl]-4-[4-(1<i>H</i>-pyrazol-3-yl)benzoyl]bicyclo[4.1.0]heptane-3-carboxamide (120 mg, 0.26 mmol) were separated by chiral SFC on a ReproSil 250 × 30 mm, 8 μm column; 80 mg (40 mg/mL in EtOH) was injected and eluted at 40 °C with 30% EtOH in CO<sub>2</sub>, 150 bar at a flow rate of 80 mL/min and detected at 270 nm.</div><div class="NLM_p last">The first eluted compound was collected and evaporated to yield <b>28</b> (43 mg, 99.6% de); [α]<sub class="stack">D</sub><sup class="stack">25</sup> +90.7 (<i>c</i> 1.0, CH<sub>3</sub>CN); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.01 (s, 1H), 7.98 (d, <i>J</i> = 5.4 Hz, 2H), 7.88 (d, <i>J</i> = 8.4 Hz, 2H), 7.67 (d, <i>J</i> = 2.3 Hz, 1H), 7.38 (s, 1H), 6.72 (d, <i>J</i> = 2.1 Hz, 1H), 3.92 (s, 3H), 3.48–3.60 (m, 1H), 2.66–2.78 (m, 1H), 2.40–2.52 (m, 1H), 2.30 (dd, <i>J</i> = 13.7, 4.4 Hz, 1H), 1.76–1.90 (m, 2H), 1.02–1.16 (m, 2H), 0.74–0.88 (m, 1H), 0.31 (q, <i>J</i> = 5.2 Hz, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>23</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 458.1798; found, 458.1814.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1-Methyl-4-({(1<i>R</i>,2<i>R</i>)-2-[6-(5-methyl-1<i>H</i>-pyrazol-3-yl)-1,2-benzoxazol-3-yl]cyclohexane-1-carbonyl}amino)-1<i>H</i>-pyrazole-3-carboxamide (<b>32</b>)</h4><div class="NLM_p">Hydroxylamine hydrochloride (0.633 g, 9.11 mmol) was added to a solution of <b>16</b> (1.00 g, 3.04 mmol) in pyridine (10 mL). The reaction mixture was stirred at 100 °C overnight (16 h). The reaction mixture was then concentrated in vacuo, and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and 1 M KHSO<sub>4</sub>(aq). The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic phases were dried (phase separator) and concentrated in vacuo to give crude (1<i>R</i>,6<i>R</i>)-6-[(4-bromo-2-fluorophenyl)(hydroxyimino)methyl]cyclohex-3-ene-1-carboxylic acid (<b>29</b>). The crude material was taken to the next step without further purifications; MS <i>m</i>/<i>z</i>: 342.2 [M – H]<sup>−</sup>.</div><div class="NLM_p">Sodium hydride (0.608 g, 15.2 mmol) (60% in mineral oil) was added to a solution of crude <b>29</b> (1.046 g, 3.04 mmol) in DMF (15 mL). The reaction mixture was stirred at rt overnight (15 h). The mixture was then partitioned between EtOAc and 1 M KHSO<sub>4</sub>(aq), the aqueous phase was extracted with EtOAc, and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue was purified by reversed-phase HPLC (30 → 95% CH<sub>3</sub>CN in 0.2% HO<sub>2</sub>H(aq)) to give (1<i>R</i>,6<i>R</i>)-6-(6-bromo-1,2-benzoxazol-3-yl)cyclohex-3-ene-1-carboxylic acid (<b>30</b>, 0.581 g, 59%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.73–7.75 (m, 1H), 7.54–7.58 (m, 1H), 7.42 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 3.28–3.38 (m, 1H), 2.97–3.07 (m, 1H), 2.19–2.28 (m, 1H), 2.09–2.17 (m, 1H), 1.86–1.96 (m, 2H), 1.55–1.66 (m, 2H), 1.4–1.54 (m, 2H); MS <i>m</i>/<i>z</i>: 322.1 [M – H]<sup>−</sup>.</div><div class="NLM_p">A solution of K<sub>2</sub>CO<sub>3</sub> (0.989 g, 7.16 mmol) in degassed water (10 mL) was added to mixture of <b>30</b> (0.580 g, 1.79 mmol), crude 3-methyl-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1.202 g, 4.12 mmol) and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.188 g, 0.27 mmol) in degassed dioxane (20 mL), and the reaction mixture was heated at 90 °C for 15 min. The reaction mixture was cooled to rt and then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated NH<sub>4</sub>Cl(aq). The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the combined organic phases were dried (phase separator) and concentrated in vacuo. The residue was purified by reversed-phase HPLC (C8, 30 → 100% CH<sub>3</sub>CN in 0.2% CH<sub>3</sub>CO<sub>2</sub>H(aq)) to give (1<i>R</i>,6<i>R</i>)-6-{6-[3-methyl-1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]-1,2-benzoxazol-3-yl}cyclohex-3-ene-1-carboxylic acid (<b>31</b>, 0.704 g, 96%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.77 (dd, <i>J</i> = 8.1, 2.5 Hz, 1H), 7.69 (d, <i>J</i> = 7.8 Hz, 1H), 7.42–7.47 (m, 1H), 6.20 (s, 1H), 5.15 (d, <i>J</i> = 9.7 Hz, 1H), 4.16 (d, <i>J</i> = 11.7 Hz, 1H), 3.54–3.67 (m, 1H), 3.35–3.47 (m, 1H), 3.05–3.18 (m, 1H), 2.53–2.65 (m, 1H), 2.35 (s, 3H), 2.17–2.31 (m, 2H), 2.01–2.06 (m, 1H), 1.90–1.98 (m, 2H), 1.72–1.86 (m, 2H), 1.60–1.70 (m, 2H), 1.46–1.58 (m, 4H); MS <i>m</i>/<i>z</i>: 408.4 [M – H]<sup>−</sup>.</div><div class="NLM_p">DIPEA (0.698 mL, 4.01 mmol) and HATU (0.559 g, 1.47 mmol) were added to a solution of <b>31</b> (0.547 g, 1.34 mmol) and 4-amino-1-methyl-1<i>H</i>-pyrazole-3-carboxamide (0.281 g, 2.00 mmol) in DMF (8 mL), and the reaction mixture was stirred at rt overnight (18 h). The reaction mixture was then partitioned between EtOAc and saturated NaHCO<sub>3</sub>(aq). The aqueous phase was extracted with EtOAc, and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude product, 1-methyl-4-{[(1<i>R</i>,2<i>R</i>)-2-{6-[3-methyl-1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]-1,2-benzoxazol-3-yl}cyclohexane-1-carbonyl]amino}-1<i>H</i>-pyrazole-3-carboxamide, was taken to the next step without further purifications; MS <i>m</i>/<i>z</i>: 532.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">HCl(aq) (3.8 M, 0.388 mL, 1.47 mmol) was added to a solution of crude 1-methyl-4-{[(1<i>R</i>,2<i>R</i>)-2-{6-[3-methyl-1-(oxan-2-yl)-1<i>H</i>-pyrazol-5-yl]-1,2-benzoxazol-3-yl}cyclohexane-1-carbonyl]amino}-1<i>H</i>-pyrazole-3-carboxamide (0.712 g, 1.34 mmol) in dioxane (40 mL) and water (10 mL), and the reaction mixture was stirred at rt for 4.5 h. The reaction mixture was then quenched by addition of saturated NaHCO<sub>3</sub>(aq). The mixture was transferred to a separatory funnel with the aid of EtOAc and was washed with saturated NaHCO<sub>3</sub>(aq). The aqueous phase was extracted with EtOAc (×2) and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue was purified by reversed-phase HPLC (XBridge C18, 15 → 70% CH<sub>3</sub>CN in 0.2% NH<sub>3</sub>(aq)) to give <b>32</b> (0.444 g, 74%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.93 (s, 1H), 7.84 (br s, 2H), 7.74 (br s, 1H), 6.52 (s, 1H), 3.79 (s, 3H), 3.43–3.52 (m, 1H), 2.97–3.07 (m, 1H), 2.34 (s, 3H), 2.10–2.24 (m, 2H), 1.91–2.00 (m, 2H), 1.69–1.80 (m, 2H), 1.51–1.66 (m, 2H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>26</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 448.2092; found, 448.2105.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-Methyl-4-({(1<i>S</i>,3<i>R</i>,4<i>R</i>,6<i>R</i>)-4-[6-(5-methyl-1<i>H</i>-pyrazol-3-yl)-1,2-benzoxazol-3-yl]bicyclo[4.1.0]heptane-3-carbonyl}amino)-1<i>H</i>-pyrazole-3-carboxamide (<b>35</b>)</h4><div class="NLM_p">Sulfuric acid (0.034 mL, 0.61 mmol) was added to a solution of <b>14</b> (2.00 g, 6.11 mmol) in EtOH (15 mL), and the mixture was heated at reflux for 2 days. The mixture was allowed to cool to rt and was concentrated under reduced pressure. The residue was partitioned between saturated NaHCO<sub>3</sub>(aq) and EtOAc. The aqueous phase was extracted once with EtOAc and the combined organic phases were dried (phase separator) and the solvent removed under reduced pressure. Ethyl (1<i>R</i>,6<i>R</i>)-6-(4-bromo-2-fluorobenzoyl)cyclohex-3-ene-1-carboxylate (2.171 g, 100%) was collected as a pale yellow oil; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.73 (t, <i>J</i> = 8.1 Hz, 1H), 7.40 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.36 (dd, <i>J</i> = 10.4, 1.7 Hz, 1H), 5.67–5.82 (m, 2H), 4.04–4.14 (m, 2H), 3.63–3.74 (m, 1H), 3.01–3.13 (m, 1H), 2.41–2.59 (m, 2H), 2.14–2.30 (m, 1H), 1.98–2.11 (m, 1H), 1.20 (t, <i>J</i> = 7.1, 7.1 Hz, 3H).</div><div class="NLM_p">Cyclopropanation of ethyl (1<i>R</i>,6<i>R</i>)-6-(4-bromo-2-fluorobenzoyl)cyclohex-3-ene-1-carboxylate was performed in a manner analogous to compound <b>26</b> described above and ethyl (3<i>R</i>,4<i>R</i>)-4-(4-bromo-2-fluorobenzoyl)bicyclo[4.1.0]heptane-3-carboxylate was taken to the next step without further purifications; MS <i>m</i>/<i>z</i>: 369.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">Lithium hydroxide (0.275 g, 11.48 mmol) was dissolved in water (10 mL) and added to a solution of crude ethyl (3<i>R</i>,4<i>R</i>)-4-(4-bromo-2-fluorobenzoyl)bicyclo[4.1.0]heptane-3-carboxylate (1.06 g, 2.87 mmol) in THF (10 mL) and CH<sub>3</sub>OH (10 mL). The reaction mixture was heated at 50 °C for 80 min, was allowed to cool to rt, and was then concentrated under reduced pressure. The residue was partitioned between water and EtOAc. 3.8 M HCl(aq) was added until pH was ∼3. The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were dried (phase separator) and the solvent was removed under reduced pressure. (3<i>R</i>,4<i>R</i>)-4-(4-Bromo-2-fluorobenzoyl)bicyclo[4.1.0]heptane-3-carboxylic acid (<b>33</b>, 0.996 g, quantitative) was collected as an off-white foam and used without purifications.</div><div class="NLM_p">Compound <b>34</b> was prepared from (3<i>R</i>,4<i>R</i>)-4-(4-bromo-2-fluorobenzoyl)bicyclo[4.1.0]heptane-3-carboxylic acid (<b>33</b>) in a manner analogous to compound <b>30</b> described above (0.353 g, 37%); MS <i>m</i>/<i>z</i>: 334.1 [M + H]<sup>+</sup>.</div><div class="NLM_p">1-Methyl-4-({(3<i>R</i>,4<i>R</i>)-4-[6-(5-methyl-1<i>H</i>-pyrazol-3-yl)-1,2-benzoxazol-3-yl]bicyclo[4.1.0]heptane-3-carbonyl}amino)-1<i>H</i>-pyrazole-3-carboxamide was prepared from <b>34</b> in a manner analogous to compound <b>32</b> described above (0.255 mg, 57% overall yield); MS <i>m</i>/<i>z</i>: 460.3 [M + H]<sup>+</sup>.</div><div class="NLM_p">The isomers of 1-methyl-4-({(3<i>R</i>,4<i>R</i>)-4-[6-(5-methyl-1<i>H</i>-pyrazol-3-yl)-1,2-benzoxazol-3-yl]bicyclo[4.1.0]heptane-3-carbonyl}amino)-1<i>H</i>-pyrazole-3-carboxamide (237 mg, 0.52 mmol) were separated by chiral SFC on a Whelk-O1 250 × 30 mm, 5 μm column. The sample (20 mg/mL in EtOH) was injected and eluted at 40 °C with 35% CH<sub>3</sub>OH in CO<sub>2</sub>, 150 bar at a flow rate of 120 mL/min and detected at 250 nm.</div><div class="NLM_p last">The first eluted compound was collected and evaporated to yield <b>35</b> (91 mg, 98.9% de); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.72 (s, 1H), 9.70 (s, 1H), 7.93–7.98 (m, 2H), 7.91 (s, 1H), 7.80 (d, <i>J</i> = 8.4 Hz, 1H), 7.57 (s, 1H), 7.41 (s, 1H), 6.60 (s, 1H), 3.32 (s, 3H), 3.16–3.25 (m, 1H), 2.91–3.02 (m, 1H), 2.43–2.49 (m, 1H), 2.28 (s, 3H), 2.19–2.26 (m, 1H), 2.02–2.13 (m, 1H), 1.61–1.74 (m, 1H), 1.03–1.17 (m, 2H), 0.65–0.76 (m, 1H), 0.41 (q, <i>J</i> = 4.9 Hz, 1H); HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>26</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 460.2092; found, 460.2136.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65"><a href="/doi/suppl/10.1021/acs.jmedchem.8b02012" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b02012" class="ext-link">10.1021/acs.jmedchem.8b02012</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula string (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">General experimental setup for analysis and characterization, FLAP binding assay, whole blood LTB<sub>4</sub> assay, assays related to ADME and safety profiling (log <i>D</i>, solubility, CYP inhibition, hepatocyte CL<sub>int</sub> (human, rat, dog), Caco-2 <i>P</i><sub>app</sub> assay, RM trapping (GSH and CH<sub>3</sub>ONH<sub>2</sub>), CYP reaction profiling (CYP3A4 contribution and fraction metabolised), plasma protein binding (human, rat, dog), fraction unbound in the incubation, blood/plasma ratio, hERG inhibition, inhibition of other cardiac ion channels, liver panel, phospholipidosis, hAhR activation, Ames test, in vitro micronucleus assay, whole blood COX-1 and COX-2 assays), MetID experimental details, in vivo PK and PK/PD experimental details, and dose prediction equations (<a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_001.csv">jm8b02012_si_001.csv (2.46 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf">jm8b02012_si_002.pdf (974.0 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b02012" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Malin Lemurell</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8718-9421" title="Orcid link">http://orcid.org/0000-0001-8718-9421</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8ee3efe2e7e0a0e2ebe3fbfcebe2e2ceeffdfafceff4ebe0ebedefa0ede1e3"><span class="__cf_email__" data-cfemail="355854595c5b1b59505840475059597554464147544f505b5056541b565a58">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Ulander</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans Emtenäs</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Science
IMED Biotech Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susanne Winiwarter</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9808-1683" title="Orcid link">http://orcid.org/0000-0002-9808-1683</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Broddefalk</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marianne Swanson</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin A. Hayes</span> - <span class="hlFld-Affiliation affiliation">Discovery Science IMED Biotech Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2640-8464" title="Orcid link">http://orcid.org/0000-0002-2640-8464</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luna Prieto Garcia</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annika Westin Eriksson</span> - <span class="hlFld-Affiliation affiliation">Drug Safety & Metabolism IMED
Biotech Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Meuller</span> - <span class="hlFld-Affiliation affiliation">Discovery Science IMED Biotech Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Cassel</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span>Present Address:
                        Contribution to this work was performed as employee of the Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabrielle Saarinen</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span>Present Address:
                        Contribution to this work was performed as employee of the Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhong-Qing Yuan</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Löfberg</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span>Present Address:
                        Contribution to this work was performed as employee of the Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 43183, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Staffan Karlsson</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Science
IMED Biotech Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5302-7157" title="Orcid link">http://orcid.org/0000-0002-5302-7157</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monica Sundqvist</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span>; 
    <span>Present Address:
                        Contribution to this work was performed as employee of the Cardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 43183, Sweden</span>; 
    <span>Present Address:
                        Department of DMPK, Research, LEO Pharma A/S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl Whatling</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular, Renal and Metabolism IMED Biotech
Unit, , , and , AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal 43183, Sweden</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions from M.L., J.U., H.E., S.W., J.B., M.S., M.A.H., L.P.G., A.W.E. and C.W. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Magnus Johansson, Jan Lindberg for synthetic chemistry support; the Separation Science Laboratory and Structure Analysis Support at AstraZeneca Gothenburg for help with compound purification and analysis; for development of biological assays and generation of screening results the authors acknowledge J.M., Anita Dellsén, Anna Rönnborg and Angela Menschik-Lunden; Ulf Bredberg for input on ADME and PK; Anna Carlsson for biotransformation and MetID determinations; Patrik Johansson for help with graphical abstract FLAP; Margareta Herslöf for project lead during early hit finding and lead generation; Jörgen Jensen for project lead during lead optimisation.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ACS</td><td class="NLM_def"><p class="first last">acute coronary syndrome</p></td></tr><tr><td class="NLM_term">Bpin</td><td class="NLM_def"><p class="first last">4,4,5,5-tetramethyl-1,3,2-dioxaborolane</p></td></tr><tr><td class="NLM_term">CAD</td><td class="NLM_def"><p class="first last">coronary artery disease</p></td></tr><tr><td class="NLM_term">Cav3.2</td><td class="NLM_def"><p class="first last">human cardiac ion channel ICaT</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimadazole</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenas</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>-ethyl-<i>N</i>-(propan-2-yl)propan-2-amine</p></td></tr><tr><td class="NLM_term">Dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">Dtbpf</td><td class="NLM_def"><p class="first last">1,1′-bis(di-<i>t</i>-butylphosphino(ferrocene)</p></td></tr><tr><td class="NLM_term">eD2M</td><td class="NLM_def"><p class="first last">early dose to man</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">FLAP</td><td class="NLM_def"><p class="first last">5-lipoxygenase activating protein</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">hAhR</td><td class="NLM_def"><p class="first last">human aromatic hydrocarbon receptor</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>N</i>-[(dimethylamino)-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridin-1-ylmethylene]-<i>N</i>-methylmethanaminium hexafluorophosphate <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">hBSEP</td><td class="NLM_def"><p class="first last">human bile salt export pump (ABCB11)</p></td></tr><tr><td class="NLM_term">HCN4</td><td class="NLM_def"><p class="first last">human cardiac ion channel IF</p></td></tr><tr><td class="NLM_term">hMrp2</td><td class="NLM_def"><p class="first last">human multi-drug resistance protein 2</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">hWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">IKs</td><td class="NLM_def"><p class="first last">human cardiac ion channel hKv7.1/hKCNE1</p></td></tr><tr><td class="NLM_term">Ito</td><td class="NLM_def"><p class="first last">human cardiac ion channel hKv4.3/hKChIP2.2</p></td></tr><tr><td class="NLM_term">Kv1.5</td><td class="NLM_def"><p class="first last">human cardiac ion channel IKUR</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">LTA<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene A<sub>4</sub></p></td></tr><tr><td class="NLM_term">LTB<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene B<sub>4</sub></p></td></tr><tr><td class="NLM_term">LTC<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene C<sub>4</sub></p></td></tr><tr><td class="NLM_term">LTD<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene D<sub>4</sub></p></td></tr><tr><td class="NLM_term">LTE<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene E<sub>4</sub></p></td></tr><tr><td class="NLM_term">5-LO</td><td class="NLM_def"><p class="first last">5-lipoxygenase</p></td></tr><tr><td class="NLM_term">LVEF</td><td class="NLM_def"><p class="first last">left ventricular ejection fraction</p></td></tr><tr><td class="NLM_term">MEC</td><td class="NLM_def"><p class="first last">minimum effective concentration</p></td></tr><tr><td class="NLM_term">MOE</td><td class="NLM_def"><p class="first last">Molecular Operating Environment</p></td></tr><tr><td class="NLM_term">Nav1.5</td><td class="NLM_def"><p class="first last">human cardiac channel INa</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl morpholine</p></td></tr><tr><td class="NLM_term">PGE<sub>2</sub></td><td class="NLM_def"><p class="first last">prostaglandin E<sub>2</sub></p></td></tr><tr><td class="NLM_term">PhN(Tf)2</td><td class="NLM_def"><p class="first last">1,1,1-trifluoro-<i>N</i>-phenyl-<i>N</i>-(trifluoromethanesulfonyl)-methanesulfonamide</p></td></tr><tr><td class="NLM_term">QTOF</td><td class="NLM_def"><p class="first last">quadrupole time of flight</p></td></tr><tr><td class="NLM_term">Rac</td><td class="NLM_def"><p class="first last">racemic</p></td></tr><tr><td class="NLM_term">RM</td><td class="NLM_def"><p class="first last">reactive metabolites</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last"><i>n</i>-propanephosphonic acid anhydride</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">TXB<sub>2</sub></td><td class="NLM_def"><p class="first last">thromboxane B<sub>2</sub></p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56568" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56568" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters-Golden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, W. R.</span></span> <span> </span><span class="NLM_article-title">Leukotrienes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1056/nejmra071371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1056%2Fnejmra071371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=17978293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=1841-1854&author=M.+Peters-Goldenauthor=W.+R.+Henderson&title=Leukotrienes&doi=10.1056%2Fnejmra071371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotrienes</span></div><div class="casAuthors">Peters-Golden, Marc; Henderson, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1841-1854</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Leukotrienes comprise a family of products of the 5-lipoxygenase pathway of arachidonic acid metab.  The cysteinyl leukotrienes C4, D4, and E4 account for the biol. activity that was previously termed "slow-reacting substance of anaphylaxis", and the efficacy of antagonists to type 1 cysteinyl leukotriene receptor (CysLT1) in asthma validates the importance of cysteinyl leukotrienes and CysLT1 in this disease.  Here, the authors discuss: synthesis of leukotrienes; leukotriene receptors; blockade of leukotriene synthesis and leukotriene receptors; leukotrienes in disease; and leukotrienes in antimicrobial defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjehKHMPz2p7Vg90H21EOLACvtfcHk0lj67weCpc7l_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM&md5=4e617e65cf4b1f55f595bc03344fdb55</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2Fnejmra071371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmra071371%26sid%3Dliteratum%253Aachs%26aulast%3DPeters-Golden%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DW.%2BR.%26atitle%3DLeukotrienes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D1841%26epage%3D1854%26doi%3D10.1056%2Fnejmra071371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPheat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herslöf, M.</span></span> <span> </span><span class="NLM_article-title">The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1879</span>– <span class="NLM_lpage">1893</span>, <span class="refDoi"> DOI: 10.1517/13543784.16.12.1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1517%2F13543784.16.12.1879" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1879-1893&author=C.+Whatlingauthor=W.+McPheatauthor=M.+Hersl%C3%B6f&title=The+potential+link+between+atherosclerosis+and+the+5-lipoxygenase+pathway%3A+investigational+agents+with+new+implications+for+the+cardiovascular+field&doi=10.1517%2F13543784.16.12.1879"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.12.1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.12.1879%26sid%3Dliteratum%253Aachs%26aulast%3DWhatling%26aufirst%3DC.%26aulast%3DMcPheat%26aufirst%3DW.%26aulast%3DHersl%25C3%25B6f%26aufirst%3DM.%26atitle%3DThe%2520potential%2520link%2520between%2520atherosclerosis%2520and%2520the%25205-lipoxygenase%2520pathway%253A%2520investigational%2520agents%2520with%2520new%2520implications%2520for%2520the%2520cardiovascular%2520field%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1879%26epage%3D1893%26doi%3D10.1517%2F13543784.16.12.1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J.</span></span> <span> </span><span class="NLM_article-title">What’s all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.tips.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=18187210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=72-78&author=J.+Evansauthor=A.+Fergusonauthor=R.+Mosleyauthor=J.+Hutchinson&title=What%E2%80%99s+all+the+FLAP+about%3F%3A+5-lipoxygenase-activating+protein+inhibitors+for+inflammatory+diseases&doi=10.1016%2Fj.tips.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases</span></div><div class="casAuthors">Evans, Jilly F.; Ferguson, Andrew D.; Mosley, Ralph T.; Hutchinson, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">72-78</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Leukotrienes have physiol. roles in innate immune responses and pathol. roles in inflammatory diseases, such as asthma, allergic rhinitis and atherosclerosis.  Anti-leukotriene therapy has proven benefits in the treatment of respiratory disease, either through the inhibition of leukotriene synthesis or the selective antagonism of leukotriene receptors.  The first committed step in the synthesis of leukotrienes is the oxidn. of arachidonic acid (AA) by 5-lipoxygenase (5-LO), and the integral membrane protein 5-lipoxygenase-activating protein (FLAP) is an essential partner of 5-LO for this process.  FLAP was molecularly identified via a photoaffinity probe and an affinity gel based on MK-886, a selective leukotriene inhibitor that has no activity against broken-cell prepns. of 5-LO.  Several FLAP inhibitors showed efficacy in early clin. trials in asthma but were not developed com. for unpublished reasons.  Recently, the FLAP (ALOX5AP) gene has been linked to risk for myocardial infarction, stroke and restenosis, reigniting pharmaceutical interest in this target.  In addn., the recent detn. of the crystal structure of inhibitor-bound FLAP offers exciting potential for novel FLAP inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQmgWVV5NuILVg90H21EOLACvtfcHk0li0UC9t1NHzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLg%253D&md5=332a3d2569c28baeff5dcda2a79377da</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DA.%26aulast%3DMosley%26aufirst%3DR.%26aulast%3DHutchinson%26aufirst%3DJ.%26atitle%3DWhat%25E2%2580%2599s%2520all%2520the%2520FLAP%2520about%253F%253A%25205-lipoxygenase-activating%2520protein%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D72%26epage%3D78%26doi%3D10.1016%2Fj.tips.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaab, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewolinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Wetering de Rooij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04386.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1111%2Fj.1365-2125.2012.04386.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=22803688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Squ70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=779-790&author=G.+Bainauthor=C.+D.+Kingauthor=K.+Schaabauthor=M.+Rewolinskiauthor=V.+Norrisauthor=C.+Amberyauthor=J.+Bentleyauthor=M.+Yamadaauthor=A.+M.+Santiniauthor=J.+van+de+Wetering+de+Rooijauthor=N.+Stockauthor=J.+Zunicauthor=J.+H.+Hutchinsonauthor=J.+F.+Evans&title=Pharmacodynamics%2C+pharmacokinetics+and+safety+of+GSK2190915%2C+a+novel+oral+anti-inflammatory+5-lipoxygenase-activating+protein+inhibitor&doi=10.1111%2Fj.1365-2125.2012.04386.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor</span></div><div class="casAuthors">Bain, Gretchen; King, Christopher D.; Schaab, Kevin; Rewolinski, Melissa; Norris, Virginia; Ambery, Claire; Bentley, Jane; Yamada, Masanori; Santini, Angelina M.; van de Wetering de Rooij, Jeroen; Stock, Nicholas; Zunic, Jasmine; Hutchinson, John H.; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">779-790</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations.  Method : Western European subjects received single (50-1000 mg) or multiple (10-450 mg) oral doses of GSK2190915 or placebo in a dose-escalating manner.  Japanese subjects received three of four GSK2190915 doses (10-200 mg) plus placebo once in a four period crossover design.  Blood samples were collected for GSK2190915 concns. and blood and urine were collected to measure leukotriene B4 and leukotriene E4, resp., as pharmacodynamic markers of drug activity.  Results : There was no clear difference in adverse events between placebo and active drug-treated subjects in either study.  Maximum plasma concns. of GSK2190915 and area under the curve increased in a dose-related manner and mean half-life values ranged from 16-34 h.  Dose-dependent inhibition of blood leukotriene B4 prodn. was obsd. and near complete inhibition of urinary leukotriene E4 excretion was shown at all doses except the lowest dose.  The EC50 values for inhibition of LTB4 were 85 nm and 89 nm in the Western European and Japanese studies, resp.  Conclusion : GSK2190915 is well-tolerated with pharmacokinetics and pharmacodynamics in Western European and Japanese subjects that support once daily dosing for 24 h inhibition of leukotrienes.  Doses of ≥50 mg show near complete inhibition of urinary leukotriene E4 at 24 h post-dose, whereas doses of ≥150 mg are required for 24 h inhibition of blood LTB4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnkQtxs-NZfbVg90H21EOLACvtfcHk0li0UC9t1NHzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Squ70%253D&md5=c0b4858ea6d2f13b5b3245b92e38aaee</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04386.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04386.x%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DSchaab%26aufirst%3DK.%26aulast%3DRewolinski%26aufirst%3DM.%26aulast%3DNorris%26aufirst%3DV.%26aulast%3DAmbery%26aufirst%3DC.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bde%2BWetering%2Bde%2BRooij%26aufirst%3DJ.%26aulast%3DStock%26aufirst%3DN.%26aulast%3DZunic%26aufirst%3DJ.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%2520and%2520safety%2520of%2520GSK2190915%252C%2520a%2520novel%2520oral%2520anti-inflammatory%25205-lipoxygenase-activating%2520protein%2520inhibitor%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D779%26epage%3D790%26doi%3D10.1111%2Fj.1365-2125.2012.04386.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drajesk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awni, W. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/s0009-9236(98)90164-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fs0009-9236%2898%2990164-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=9542476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADyaK1cXisVWnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=324-331&author=S.+L.+Wongauthor=J.+Drajeskauthor=M.+Changauthor=C.+Lanniauthor=G.+Wittauthor=R.+Hansenauthor=W.+M.+Awni&title=Pharmacokinetics+and+pharmacodynamics+of+single+and+multiple+oral+doses+of+a+novel+5-lipoxygenase+inhibitor+%28ABT-761%29+in+healthy+volunteers&doi=10.1016%2Fs0009-9236%2898%2990164-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers</span></div><div class="casAuthors">Wong, Shekman L.; Drajesk, Jeffrey; Chang, Min; Lanni, Carmine; Witt, Galen; Hansen, Robert; Awni, Walid M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology and Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-331</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">This study evaluated the safety, pharmacokinetics and pharmacodynamics of ABT-761 [R(+)-N-[3-[5-(4-fluorophenylmethyl)-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea], a new N-hydroxyurea analog.  This was a randomized, double-blind, placebo-controlled, single- and multiple-dose (15-day) study of ABT-761 (50 to 200 mg/day) in healthy, nonsmoking adult male volunteers.  The pharmacokinetics were evaluated by investigation of the time- and dose-dependent effects of ABT-761, and the pharmacol. selectivity of ABT-761 was evaluated based on calcium ionophore-stimulated leukotriene B4 (LTB4) and thromboxane B2 (TXB2) biosynthesis ex vivo in whole blood.  After single and multiple doses, mean obsd. time to reach max. concn. values of ABT-761 ranged from 4.0 to 7.5 h.  Mean values for max. concn. and area under the plasma concn.-time curve from 0 to 24 h increased approx. linearly with dose.  Mean terminal half-life and apparent vol. of distribution during the terminal elimination phase of ABT-761 ranged from 15.4 to 17.8 h and 69.5 to 78.9 L, resp., and was dose independent.  Steady state was reached on day 11 after multiple dosing.  Less than 0.05% of unchanged ABT-761 was recovered in urine within the 24-h period after day 15 dosing.  Population ABT-761 plasma concn. at which 50% of the max. possible inhibition was obsd. for LTB4 inhibition was 0.24 μg/mL.  No differences in mean TXB2 inhibition were obsd. between the subjects receiving ABT-761 and placebo.  These results indicate that ABT-761 is a potent and selective inhibitor of 5-lipoxygenase and the pharmacokinetics of ABT-761 are time and dose independent between 50 and 200 mg/day after single and multiple dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTZfiiiAa-7Vg90H21EOLACvtfcHk0lgJKkj2KiPqFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVWnu70%253D&md5=2d561a945ff6360736789690f8e02a5c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fs0009-9236%2898%2990164-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0009-9236%252898%252990164-3%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BL.%26aulast%3DDrajesk%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DLanni%26aufirst%3DC.%26aulast%3DWitt%26aufirst%3DG.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DAwni%26aufirst%3DW.%2BM.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520single%2520and%2520multiple%2520oral%2520doses%2520of%2520a%2520novel%25205-lipoxygenase%2520inhibitor%2520%2528ABT-761%2529%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1998%26volume%3D63%26spage%3D324%26epage%3D331%26doi%3D10.1016%2Fs0009-9236%2898%2990164-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tardif, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">L’Allier, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grégoire, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotz, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pressacco, J.</span></span> <span> </span><span class="NLM_article-title">Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with recent acute coronary syndrome</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1161/circimaging.110.937169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1161%2Fcircimaging.110.937169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=20190281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A280%3ADC%252BC3czksVarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=298-307&author=J.-C.+Tardifauthor=P.+L.+L%E2%80%99Allierauthor=R.+Ibrahimauthor=J.+C.+Gr%C3%A9goireauthor=A.+Nozzaauthor=M.+Cossetteauthor=S.+Kouzauthor=M.-A.+Lavoieauthor=J.+Paquinauthor=T.+M.+Brotzauthor=R.+Taubauthor=J.+Pressacco&title=Treatment+with+5-lipoxygenase+inhibitor+VIA-2291+%28atreleuton%29+in+patients+with+recent+acute+coronary+syndrome&doi=10.1161%2Fcircimaging.110.937169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome</span></div><div class="casAuthors">Tardif Jean-Claude; L'allier Philippe L; Ibrahim Reda; Gregoire Jean C; Nozza Anna; Cossette Marieve; Kouz Simon; Lavoie Marc-Andre; Paquin Janie; Brotz Tilmann M; Taub Rebecca; Pressacco Josephine</div><div class="citationInfo"><span class="NLM_cas:title">Circulation. Cardiovascular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">298-307</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Production of leukotrienes by 5-lipoxygenase (5-LO) has been linked to unstable atherosclerotic plaques and cardiovascular events.  VIA-2291 is a potent 5-LO inhibitor.  METHODS AND RESULTS:  In a double-blinded study, 191 patients were randomly assigned 3 weeks after an acute coronary syndrome to receive 25, 50, or 100 mg VIA-2291 or placebo daily for 12 weeks.  The primary study end point, whole blood stimulated leukotriene LTB4 at trough drug level, was reduced in all VIA-2291 groups (P<0.0001) in a dose-dependent fashion, with approximately 80% inhibition in >90% of patients in the 100-mg group.  A significant reduction of urine leukotriene LTE4 was obtained in all dose groups.  No serious adverse events were considered related to study drug.  A subset of 93 patients who had undergone a 64-slice coronary CT examination at baseline continued on study medication for a total of 24 weeks and underwent a repeat scan.  Five of these patients withdrew or were noncompliant and 28 had nonevaluable scans.  Among the 60 remaining patients, new coronary plaques were observed in 5 of 18 (27.8%) placebo-treated patients and in 2 of 42 (4.8%) VIA-2291-treated patients (P=0.01).  A reduction in noncalcified plaque volume at 24 weeks versus placebo was observed in VIA-2291-treated groups in the 34 of these 60 patients in whom this end point was analyzable (P<0.01).  CONCLUSIONS:  VIA-2291 reduces leukotriene production at 12 weeks after an acute coronary syndrome.  Preliminary data from the CT substudy suggest that such a reduction in leukotriene production may influence atherosclerosis; however, this requires confirmation in a larger study.  Clinical Trial Registration- URL: http://www.clinicaltrials.gov.  Unique identifier: NCT00358826.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrLYXMby2XrySm0e6ZOaemfW6udTcc2eYd5681I8OLTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czksVarsw%253D%253D&md5=2b668946b510c248724b4df82176deb3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1161%2Fcircimaging.110.937169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fcircimaging.110.937169%26sid%3Dliteratum%253Aachs%26aulast%3DTardif%26aufirst%3DJ.-C.%26aulast%3DL%25E2%2580%2599Allier%26aufirst%3DP.%2BL.%26aulast%3DIbrahim%26aufirst%3DR.%26aulast%3DGr%25C3%25A9goire%26aufirst%3DJ.%2BC.%26aulast%3DNozza%26aufirst%3DA.%26aulast%3DCossette%26aufirst%3DM.%26aulast%3DKouz%26aufirst%3DS.%26aulast%3DLavoie%26aufirst%3DM.-A.%26aulast%3DPaquin%26aufirst%3DJ.%26aulast%3DBrotz%26aufirst%3DT.%2BM.%26aulast%3DTaub%26aufirst%3DR.%26aulast%3DPressacco%26aufirst%3DJ.%26atitle%3DTreatment%2520with%25205-lipoxygenase%2520inhibitor%2520VIA-2291%2520%2528atreleuton%2529%2520in%2520patients%2520with%2520recent%2520acute%2520coronary%2520syndrome%26jtitle%3DCirculation%26date%3D2010%26volume%3D3%26spage%3D298%26epage%3D307%26doi%3D10.1161%2Fcircimaging.110.937169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsson, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span> <span> </span><span class="NLM_article-title">Recent advances for FLAP inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2607</span>– <span class="NLM_lpage">2612</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.bmcl.2015.04.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=26004579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFWgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2607-2612&author=D.+Pettersenauthor=%C3%96.+Davidssonauthor=C.+Whatling&title=Recent+advances+for+FLAP+inhibitors&doi=10.1016%2Fj.bmcl.2015.04.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances for FLAP inhibitors</span></div><div class="casAuthors">Pettersen, Daniel; Davidsson, Oejvind; Whatling, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2607-2612</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. A no. of FLAP inhibitors have been progressed to clin. trials for respiratory and other inflammatory indications but so far no drug has reached the market.  With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease.  We also show how recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP inhibitors paving the way for new compd. classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_be1PSARIkLVg90H21EOLACvtfcHk0lj0Lu0vbT3a9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFWgtrs%253D&md5=f6eab0befa0ce24c17ff5e153a3b4907</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.090%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DD.%26aulast%3DDavidsson%26aufirst%3D%25C3%2596.%26aulast%3DWhatling%26aufirst%3DC.%26atitle%3DRecent%2520advances%2520for%2520FLAP%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2607%26epage%3D2612%26doi%3D10.1016%2Fj.bmcl.2015.04.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roppe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span> <span> </span><span class="NLM_article-title">5-lipoxygenase-activating protein (FLAP) inhibitors. part 4: development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8013</span>– <span class="NLM_lpage">8029</span>, <span class="refDoi"> DOI: 10.1021/jm2008369</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2008369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVaisLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8013-8029&author=N.+S.+Stockauthor=G.+Bainauthor=J.+Zunicauthor=Y.+Liauthor=J.+Ziffauthor=J.+Roppeauthor=A.+Santiniauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=C.+D.+Kingauthor=C.+Bacceiauthor=C.+Leeauthor=H.+Rongauthor=C.+Chapmanauthor=A.+Broadheadauthor=D.+Lorrainauthor=L.+Correaauthor=J.+H.+Hutchinsonauthor=J.+F.+Evansauthor=P.+Prasit&title=5-lipoxygenase-activating+protein+%28FLAP%29+inhibitors.+part+4%3A+development+of+3-%5B3-tert-Butylsulfanyl-1-%5B4-%286-ethoxypyridin-3-yl%29benzyl%5D-5-%285-methylpyridin-2-ylmethoxy%29-1H-indol-2-yl%5D-2%2C2-dimethylpropionic+acid+%28AM803%29%2C+a+potent%2C+oral%2C+once+daily+FLAP+inhibitor&doi=10.1021%2Fjm2008369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor</span></div><div class="casAuthors">Stock, Nicholas S.; Bain, Gretchen; Zunic, Jasmine; Li, Yiwei; Ziff, Jeannie; Roppe, Jeffrey; Santini, Angelina; Darlington, Janice; Prodanovich, Pat; King, Christopher D.; Baccei, Christopher; Lee, Catherine; Rong, Haojing; Chapman, Charles; Broadhead, Alex; Lorrain, Dan; Correa, Lucia; Hutchinson, John H.; Evans, Jilly F.; Prasit, Peppi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8013-8029</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc (I) is described (AM803, now GSK2190915).  Building upon AM103, SAR studies centering around the pyridine moiety led to the discovery of compds. that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h).  Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclin. toxicol. and pharmacokinetics in rat and dog.  11Cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model.  This compd. has successfully completed phase 1 clin. studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph6QQEmUcpHbVg90H21EOLACvtfcHk0lj0Lu0vbT3a9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVaisLrP&md5=603c7ee09513152640d3e2b91177db0b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm2008369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008369%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DN.%2BS.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DZunic%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZiff%26aufirst%3DJ.%26aulast%3DRoppe%26aufirst%3DJ.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DBaccei%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DBroadhead%26aufirst%3DA.%26aulast%3DLorrain%26aufirst%3DD.%26aulast%3DCorrea%26aufirst%3DL.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DPrasit%26aufirst%3DP.%26atitle%3D5-lipoxygenase-activating%2520protein%2520%2528FLAP%2529%2520inhibitors.%2520part%25204%253A%2520development%2520of%25203-%255B3-tert-Butylsulfanyl-1-%255B4-%25286-ethoxypyridin-3-yl%2529benzyl%255D-5-%25285-methylpyridin-2-ylmethoxy%2529-1H-indol-2-yl%255D-2%252C2-dimethylpropionic%2520acid%2520%2528AM803%2529%252C%2520a%2520potent%252C%2520oral%252C%2520once%2520daily%2520FLAP%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8013%26epage%3D8029%26doi%3D10.1021%2Fjm2008369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span>; <span class="NLM_string-name">Bartolozzi, A.</span>; <span class="NLM_string-name">Simpson, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the novel oxadiazole-containing 5-lipoxygenase activating protein (FLAP) inhibitor BI 665915</span>.  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_publisher-name">American Chemical Society</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1239</span>, pp  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">119</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=101-119&author=H.+Takahashi&author=A.+Bartolozzi&author=T.+Simpson&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch004%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520the%2520novel%2520oxadiazole-containing%25205-lipoxygenase%2520activating%2520protein%2520%2528FLAP%2529%2520inhibitor%2520BI%2520665915%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2016%26volume%3D1239%26spage%3D101%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gür, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Çalışkan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banoglu, E.</span></span> <span> </span><span class="NLM_article-title">Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.ejmech.2017.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=28784429" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2018&pages=34-48&author=Z.+T.+G%C3%BCrauthor=B.+%C3%87al%C4%B1%C5%9Fkanauthor=E.+Banoglu&title=Drug+discovery+approaches+targeting+5-lipoxygenase-activating+protein+%28FLAP%29+for+inhibition+of+cellular+leukotriene+biosynthesis&doi=10.1016%2Fj.ejmech.2017.07.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCr%26aufirst%3DZ.%2BT.%26aulast%3D%25C3%2587al%25C4%25B1%25C5%259Fkan%26aufirst%3DB.%26aulast%3DBanoglu%26aufirst%3DE.%26atitle%3DDrug%2520discovery%2520approaches%2520targeting%25205-lipoxygenase-activating%2520protein%2520%2528FLAP%2529%2520for%2520inhibition%2520of%2520cellular%2520leukotriene%2520biosynthesis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D153%26spage%3D34%26epage%3D48%26doi%3D10.1016%2Fj.ejmech.2017.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemurell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winiwarter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsson, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtenäs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hovdal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydén-Landergren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlind, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herslöf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drmota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigfridsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1021/jm501531v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501531v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=897-911&author=M.+Lemurellauthor=J.+Ulanderauthor=S.+Winiwarterauthor=A.+Dahl%C3%A9nauthor=%C3%96.+Davidssonauthor=H.+Emten%C3%A4sauthor=J.+Broddefalkauthor=M.+Swansonauthor=D.+Hovdalauthor=A.+T.+Plowrightauthor=A.+Pettersenauthor=M.+Ryd%C3%A9n-Landergrenauthor=J.+Barlindauthor=A.+Llinasauthor=M.+Hersl%C3%B6fauthor=T.+Drmotaauthor=K.+Sigfridssonauthor=S.+Mosesauthor=C.+Whatling&title=Discovery+of+AZD6642%2C+an+inhibitor+of+5-lipoxygenase+activating+protein+%28FLAP%29+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Fjm501531v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm501531v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501531v%26sid%3Dliteratum%253Aachs%26aulast%3DLemurell%26aufirst%3DM.%26aulast%3DUlander%26aufirst%3DJ.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DDahl%25C3%25A9n%26aufirst%3DA.%26aulast%3DDavidsson%26aufirst%3D%25C3%2596.%26aulast%3DEmten%25C3%25A4s%26aufirst%3DH.%26aulast%3DBroddefalk%26aufirst%3DJ.%26aulast%3DSwanson%26aufirst%3DM.%26aulast%3DHovdal%26aufirst%3DD.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26aulast%3DPettersen%26aufirst%3DA.%26aulast%3DRyd%25C3%25A9n-Landergren%26aufirst%3DM.%26aulast%3DBarlind%26aufirst%3DJ.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DHersl%25C3%25B6f%26aufirst%3DM.%26aulast%3DDrmota%26aufirst%3DT.%26aulast%3DSigfridsson%26aufirst%3DK.%26aulast%3DMoses%26aufirst%3DS.%26aulast%3DWhatling%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520AZD6642%252C%2520an%2520inhibitor%2520of%25205-lipoxygenase%2520activating%2520protein%2520%2528FLAP%2529%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D897%26epage%3D911%26doi%3D10.1021%2Fjm501531v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spade, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altemus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boekelheide, K.</span></span> <span> </span><span class="NLM_article-title">Identification of sperm mRNA biomarkers associated with testis injury during preclinical testing of pharmaceutical compounds</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2017.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.taap.2017.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=28167222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFSntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2017&pages=1-7&author=E.+Dereauthor=D.+J.+Spadeauthor=S.+J.+Hallauthor=A.+Altemusauthor=J.+D.+Smithauthor=J.+A.+Phillipsauthor=J.+S.+Moffitauthor=K.+T.+Blanchardauthor=K.+Boekelheide&title=Identification+of+sperm+mRNA+biomarkers+associated+with+testis+injury+during+preclinical+testing+of+pharmaceutical+compounds&doi=10.1016%2Fj.taap.2017.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of sperm mRNA biomarkers associated with testis injury during preclinical testing of pharmaceutical compounds</span></div><div class="casAuthors">Dere, Edward; Spade, Daniel J.; Hall, Susan J.; Altemus, Aimee; Smith, James D.; Phillips, Jonathan A.; Moffit, Jeffrey S.; Blanchard, Kerry T.; Boekelheide, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The human testis is sensitive to toxicant-induced injury but current methods for detecting adverse effects are limited, insensitive and unreliable.  Animal studies use sensitive histopathol. endpoints to assess toxicity, but require testicular tissue that is not available during human clin. trials.  More sensitive and reliable mol. biomarkers of testicular injury are needed to better monitor testicular toxicity in both clin. and preclin.  Adult male Wistar Han rats were exposed for 4 wk to compds. previously assocd. with testicular injury, including cisplatin (0, 0.2, 0.3, or 0.4 mg/kg/day), BI665915 (0, 20, 70, 100 mg/kg/d), BI665636 (0, 20, 100 mg/kg/d) or BI163538 (0, 70, 150, 300 mg/kg/d) to evaluate reproductive toxicity and assess changes in sperm mRNA levels.  None of the compds. resulted in any significant changes in body, testis or epididymis wts., nor were there decreases in testicular homogenization resistant spermatid head counts.  Histopathol. evaluation found that only BI665915 treatment caused any testicular effects, including minor germ cell loss and disorganization of the seminiferous tubule epithelium, and an increase in the no. of retained spermatid heads.  A custom PCR-array panel was used to assess induced changes in sperm mRNA.  BI665915 treatment resulted in a significant increase in clusterin (Clu) levels and decreases in GTPase, IMAP family member 4 (Gimap4), prostaglandin D2 synthase (Ptgds) and transmembrane protein with EGF like and two follistatin like domains 1 (Tmeff1) levels.  Correlation anal. between transcript levels and quant. histopathol. endpoints found a modest assocn. between Clu with retained spermatid heads.  These results demonstrate that sperm mRNA levels are sensitive mol. indicators of testicular injury that can potentially be translated into a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo2LNsJ2tYnbVg90H21EOLACvtfcHk0likCDT5YdF6pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFSntbw%253D&md5=4fa08092dda1ef77af1f05e33b00ee5e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2017.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2017.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DDere%26aufirst%3DE.%26aulast%3DSpade%26aufirst%3DD.%2BJ.%26aulast%3DHall%26aufirst%3DS.%2BJ.%26aulast%3DAltemus%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DJ.%2BD.%26aulast%3DPhillips%26aufirst%3DJ.%2BA.%26aulast%3DMoffit%26aufirst%3DJ.%2BS.%26aulast%3DBlanchard%26aufirst%3DK.%2BT.%26aulast%3DBoekelheide%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520sperm%2520mRNA%2520biomarkers%2520associated%2520with%2520testis%2520injury%2520during%2520preclinical%2520testing%2520of%2520pharmaceutical%2520compounds%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2017%26volume%3D320%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.taap.2017.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. C.</span></span> <span> </span><span class="NLM_article-title">Eicosanoid transcellular biosynthesis: from cell-cell Interactions to in vivo tissue responses</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">375</span>, <span class="refDoi"> DOI: 10.1124/pr.58.3.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1124%2Fpr.58.3.8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=375&author=G.+Folcoauthor=R.+C.+Murphy&title=Eicosanoid+transcellular+biosynthesis%3A+from+cell-cell+Interactions+to+in+vivo+tissue+responses&doi=10.1124%2Fpr.58.3.8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.8%26sid%3Dliteratum%253Aachs%26aulast%3DFolco%26aufirst%3DG.%26aulast%3DMurphy%26aufirst%3DR.%2BC.%26atitle%3DEicosanoid%2520transcellular%2520biosynthesis%253A%2520from%2520cell-cell%2520Interactions%2520to%2520in%2520vivo%2520tissue%2520responses%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D375%26doi%3D10.1124%2Fpr.58.3.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamin, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujjainwalla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1126/science.1144346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1126%2Fscience.1144346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=17600184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFylur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2007&pages=510-512&author=A.+D.+Fergusonauthor=B.+M.+McKeeverauthor=S.+Xuauthor=D.+Wisniewskiauthor=D.+K.+Millerauthor=T.-T.+Yaminauthor=R.+H.+Spencerauthor=L.+Chuauthor=F.+Ujjainwallaauthor=B.+R.+Cunninghamauthor=J.+F.+Evansauthor=J.+W.+Becker&title=Crystal+structure+of+inhibitor-bound+human+5-lipoxygenase-activating+protein&doi=10.1126%2Fscience.1144346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein</span></div><div class="casAuthors">Ferguson, Andrew D.; McKeever, Brian M.; Xu, Shihua; Wisniewski, Douglas; Miller, Douglas K.; Yamin, Ting-Ting; Spencer, Robert H.; Chu, Lin; Ujjainwalla, Feroze; Cunningham, Barry R.; Evans, Jilly F.; Becker, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">5837</span>),
    <span class="NLM_cas:pages">510-512</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Leukotrienes are proinflammatory products of arachidonic acid oxidn. by 5-lipoxygenase that have been shown to be involved in respiratory and cardiovascular diseases.  The integral membrane protein 5-lipoxygenase-activating protein (FLAP) is essential for leukotriene biosynthesis.  We describe the x-ray crystal structures of human FLAP in complex with two leukotriene biosynthesis inhibitors at 4.0 and 4.2 angstrom resoln., resp.  The structures show that inhibitors bind in membrane-embedded pockets of FLAP, which suggests how these inhibitors prevent arachidonic acid (AA) from binding to FLAP and subsequently being transferred to 5-lipoxygenase (5-LO), thereby preventing leukotriene biosynthesis.  This structural information provides a platform for the development of therapeutics for respiratory and cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SUG1wwYenLVg90H21EOLACvtfcHk0likCDT5YdF6pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFylur4%253D&md5=63a64a92c9c07b4543a4ec93a239031f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1144346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1144346%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DMcKeever%26aufirst%3DB.%2BM.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWisniewski%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DYamin%26aufirst%3DT.-T.%26aulast%3DSpencer%26aufirst%3DR.%2BH.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DUjjainwalla%26aufirst%3DF.%26aulast%3DCunningham%26aufirst%3DB.%2BR.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DBecker%26aufirst%3DJ.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520inhibitor-bound%2520human%25205-lipoxygenase-activating%2520protein%26jtitle%3DScience%26date%3D2007%26volume%3D317%26spage%3D510%26epage%3D512%26doi%3D10.1126%2Fscience.1144346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span> </span><span class="NLM_article-title">Pipeline Pilot</span>.  <i>Basic Chemistry User Guide</i>; <span class="NLM_publisher-name">Scitegic Inc.</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pipeline+Pilot.+Basic+Chemistry+User+Guide%3B+Scitegic+Inc.%3A+San+Diego%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DPipeline%2520Pilot%26btitle%3DBasic%2520Chemistry%2520User%2520Guide%26pub%3DScitegic%2520Inc%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickup, B. T.</span></span> <span> </span><span class="NLM_article-title">A gaussian description of molecular shape</span>. <i>J. Phys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">3503</span>– <span class="NLM_lpage">3510</span>, <span class="refDoi"> DOI: 10.1021/j100011a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/j100011a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1995&pages=3503-3510&author=J.+A.+Grantauthor=B.+T.+Pickup&title=A+gaussian+description+of+molecular+shape&doi=10.1021%2Fj100011a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fj100011a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100011a016%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DJ.%2BA.%26aulast%3DPickup%26aufirst%3DB.%2BT.%26atitle%3DA%2520gaussian%2520description%2520of%2520molecular%2520shape%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1995%26volume%3D99%26spage%3D3503%26epage%3D3510%26doi%3D10.1021%2Fj100011a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krejsa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogalski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penzotti, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migeon, J. C.</span></span> <span> </span><span class="NLM_article-title">Predicting ADME properties and side effects: the BioPrint approach</span>. <i>Curr. Opin. Drug Discov. Devel.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=12951810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=470-480&author=C.+M.+Krejsaauthor=D.+Horvathauthor=S.+L.+Rogalskiauthor=J.+E.+Penzottiauthor=B.+Maoauthor=F.+Barbosaauthor=J.+C.+Migeon&title=Predicting+ADME+properties+and+side+effects%3A+the+BioPrint+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting ADME properties and side effects: The BioPrint approach</span></div><div class="casAuthors">Krejsa, Cecile M.; Horvath, Dragos; Rogalski, Sherri L.; Penzotti, Julie E.; Mao, Boryeu; Barbosa, Frederique; Migeon, Jacques C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">A review.  Computational methods are increasingly used to streamline and enhance the lead discovery and optimization process.  However, accurate prediction of absorption, distribution, metab. and excretion (ADME) and adverse drug reactions (ADR) is often difficult, due to the complexity of underlying physiol. mechanisms.  Modeling approaches have been hampered by the lack of large, robust and standardized training datasets.  In an extensive effort to build such a dataset, the BioPrint database was constructed by systematic profiling of nearly all drugs available on the market, as well as numerous ref. compds.  The database is composed of several large datasets: compd. structures and mol. descriptors, in vitro ADME and pharmacol. profiles, and complementary clin. data including therapeutic use information, pharmacokinetics profiles and ADR profiles.  These data have allowed the development of computational tools designed to integrate a program of computational chem. into library design and lead development.  Models based on chem. structure are strengthened by in vitro results that can be used as addnl. compd. descriptors to predict complex in vivo endpoints.  The BioPrint pharmacoinformatics platform represents a systematic effort to accelerate the process of drug discovery, improve quant. structure-activity relationships and develop in vitro/in vivo assocns.  In this review, we will discuss the importance of training set size and diversity in model development, the implementation of linear and neighborhood modeling approaches, and the use of in silico methods to predict potential clin. liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQ71juUoErrVg90H21EOLACvtfcHk0lgFV606hM80FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D&md5=f8db4e37cc895d67bf4a82efe021c5c2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRogalski%26aufirst%3DS.%2BL.%26aulast%3DPenzotti%26aufirst%3DJ.%2BE.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%2BC.%26atitle%3DPredicting%2520ADME%2520properties%2520and%2520side%2520effects%253A%2520the%2520BioPrint%2520approach%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discov.%2520Devel.%26date%3D2003%26volume%3D6%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span> <i>MOE
Molecular
Operating Environment</i>; <span class="NLM_publisher-name">Chemical Computing
Group, Inc.</span>: <span class="NLM_publisher-loc">Montreal,
Canada</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MOE%0AMolecular%0AOperating+Environment%3B+Chemical+Computing%0AGroup%2C+Inc.%3A+Montreal%2C%0ACanada%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMOE%250AMolecular%250AOperating%2520Environment%26pub%3DChemical%2520Computing%250AGroup%252C%2520Inc%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">OpenEye</span>.  <i>ROCS</i>; <span class="NLM_publisher-name">OpenEye</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=OpenEye&title=ROCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DROCS%26pub%3DOpenEye%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löfberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtenäs, H.</span></span> <span> </span><span class="NLM_article-title">A practical telescoped three-step sequence for the preparation of (1R,2R)-2-(4-Bromobenzoyl)cyclohexanecarboxylic acid: a key building block used in one of our drug development projects</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlyiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=618-624&author=S.+Karlssonauthor=R.+Bergmanauthor=J.+Broddefalkauthor=C.+L%C3%B6fbergauthor=P.+R.+Mooreauthor=A.+Starkauthor=H.+Emten%C3%A4s&title=A+practical+telescoped+three-step+sequence+for+the+preparation+of+%281R%2C2R%29-2-%284-Bromobenzoyl%29cyclohexanecarboxylic+acid%3A+a+key+building+block+used+in+one+of+our+drug+development+projects&doi=10.1021%2Facs.oprd.8b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical Telescoped Three-Step Sequence for the Preparation of (1R,2R)-2-(4-Bromobenzoyl)cyclohexanecarboxylic Acid: A Key Building Block Used in One of Our Drug Development Projects</span></div><div class="casAuthors">Karlsson, Staffan; Bergman, Rolf; Broddefalk, Johan; Loefberg, Christian; Moore, Peter R.; Stark, Andrew; Emtenaes, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">618-624</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A method for the prepn. of the pyrazolylbenzoylcyclohexanecarboxamide I on multi-hundred gram scale was implemented using a one-pot Friedel-Crafts reaction of II with bromobenzene followed by epimerization and ester hydrolysis to yield benzoylcyclohexanecarboxylic acid III, an amidation reaction using propylphosphonic anhydride, and a Suzuki coupling with a tetrahydropyranyl-protected pyrazoleboronate as the key steps.  Crystn. was used to purify III instead of chromatog.; III could then be used to prep. related compds. using amidation and Suzuki coupling reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_kOuKoaHG5rVg90H21EOLACvtfcHk0lgFV606hM80FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlyiu7s%253D&md5=e2c638901253741ed117091e27b242c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00066%26sid%3Dliteratum%253Aachs%26aulast%3DKarlsson%26aufirst%3DS.%26aulast%3DBergman%26aufirst%3DR.%26aulast%3DBroddefalk%26aufirst%3DJ.%26aulast%3DL%25C3%25B6fberg%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DP.%2BR.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DEmten%25C3%25A4s%26aufirst%3DH.%26atitle%3DA%2520practical%2520telescoped%2520three-step%2520sequence%2520for%2520the%2520preparation%2520of%2520%25281R%252C2R%2529-2-%25284-Bromobenzoyl%2529cyclohexanecarboxylic%2520acid%253A%2520a%2520key%2520building%2520block%2520used%2520in%2520one%2520of%2520our%2520drug%2520development%2520projects%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26spage%3D618%26epage%3D624%26doi%3D10.1021%2Facs.oprd.8b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satoshi, I.</span>; <span class="NLM_string-name">Yuji, Y.</span>; <span class="NLM_string-name">Kentaro, I.</span></span> <span> </span><span class="NLM_article-title">(6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide Compound</span>. <span class="NLM_patent">WO/2015/098853</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=I.+Satoshi&author=Y.+Yuji&author=I.+Kentaro&title=%286S%2C9aS%29-N-Benzyl-6-%5B%284-hydroxyphenyl%29methyl%5D-4%2C7-dioxo-8-%28%7B6-%5B3-%28piperazin-1-yl%29azetidin-1-yl%5Dpyridin-2-yl%7Dmethyl%29-2-%28prop-2-en-1-yl%29-octahydro-1H-pyrazino%5B2%2C1-c%5D%5B1%2C2%2C4%5Dtriazine-1-carboxamide+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSatoshi%26aufirst%3DI.%26atitle%3D%25286S%252C9aS%2529-N-Benzyl-6-%255B%25284-hydroxyphenyl%2529methyl%255D-4%252C7-dioxo-8-%2528%257B6-%255B3-%2528piperazin-1-yl%2529azetidin-1-yl%255Dpyridin-2-yl%257Dmethyl%2529-2-%2528prop-2-en-1-yl%2529-octahydro-1H-pyrazino%255B2%252C1-c%255D%255B1%252C2%252C4%255Dtriazine-1-carboxamide%2520Compound%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miles, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naimoli, B. J.</span></span> <span> </span><span class="NLM_article-title">Diels-Alder Reactions of β-Acylacrylic Acids</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1980</span>– <span class="NLM_lpage">1991</span>, <span class="refDoi"> DOI: 10.1080/00397911.2012.686002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1080%2F00397911.2012.686002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=1980-1991&author=W.+H.+Milesauthor=E.+M.+Cohenauthor=B.+J.+Naimoli&title=Diels-Alder+Reactions+of+%CE%B2-Acylacrylic+Acids&doi=10.1080%2F00397911.2012.686002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Diels-Alder Reactions of β-Acylacrylic Acids</span></div><div class="casAuthors">Miles, William H.; Cohen, Evan M.; Naimoli, Barbara J.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1980-1991</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The Diels-Alder reaction of β-acyl acrylic acids with dienes gave good yields with good regio- or stereoselectivity of the corresponding cycloaddn. products with the use of Lewis acids.  E.g., in presence of DIPEA/SnCl4, Diels-Alder reaction of (E)-4-MeC6H4COCH:CHCO2H with cyclopentadiene gave 96% I and II (ratio 93/7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh4KRqTTnGSbVg90H21EOLACvtfcHk0lhOKi08ZWDerQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCgu7Y%253D&md5=dafce0217fb7728fe63d05308521c9b0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F00397911.2012.686002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397911.2012.686002%26sid%3Dliteratum%253Aachs%26aulast%3DMiles%26aufirst%3DW.%2BH.%26aulast%3DCohen%26aufirst%3DE.%2BM.%26aulast%3DNaimoli%26aufirst%3DB.%2BJ.%26atitle%3DDiels-Alder%2520Reactions%2520of%2520%25CE%25B2-Acylacrylic%2520Acids%26jtitle%3DSynth.%2520Commun.%26date%3D2013%26volume%3D43%26spage%3D1980%26epage%3D1991%26doi%3D10.1080%2F00397911.2012.686002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roppe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>640</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.ejphar.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=20519143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=640&publication_year=2010&pages=211-218&author=D.+S.+Lorrainauthor=G.+Bainauthor=L.+D.+Correaauthor=C.+Chapmanauthor=A.+R.+Broadheadauthor=A.+M.+Santiniauthor=P.+P.+Prodanovichauthor=J.+V.+Darlingtonauthor=N.+S.+Stockauthor=J.+Zunicauthor=C.+D.+Kingauthor=C.+Leeauthor=C.+S.+Bacceiauthor=B.+Stearnsauthor=J.+Roppeauthor=J.+H.+Hutchinsonauthor=P.+Prasitauthor=J.+F.+Evans&title=Pharmacology+of+AM803%2C+a+novel+selective+five-lipoxygenase-activating+protein+%28FLAP%29+inhibitor+in+rodent+models+of+acute+inflammation&doi=10.1016%2Fj.ejphar.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation</span></div><div class="casAuthors">Lorrain, Daniel S.; Bain, Gretchen; Correa, Lucia D.; Chapman, Charles; Broadhead, Alex R.; Santini, Angelina M.; Prodanovich, Patricia P.; Darlington, Janice V.; Stock, Nicholas S.; Zunic, Jasmine; King, Christopher D.; Lee, Catherine; Baccei, Christopher S.; Stearns, Brian; Roppe, Jeffrey; Hutchinson, John H.; Prasit, Peppi; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">640</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">211-218</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the in vivo pharmacol. properties of AM803 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, a selective 5-lipoxygenase-activating protein (FLAP) inhibitor, using rat and mouse models of acute inflammation.  Oral administration of AM803 (1 mg/kg) resulted in sustained inhibition of ex vivo ionophore-challenged whole blood LTB4 biosynthesis with > 90% inhibition for up to 12 h and an EC50 of ∼ 7 nM.  When rat lungs were challenged in vivo with calcium-ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) prodn. with ED50s of 0.12 mg/kg and 0.37 mg/kg, resp.  The inhibition measured 16 h following a single oral dose of 3 mg/kg was 86% and 41% for LTB4 and CysLTs, resp.  In an acute inflammation setting, AM803 dose-dependently reduced LTB4, CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection.  Finally, AM803 increased survival time in mice exposed to a lethal i.v. injection of platelet activating factor (PAF).  The magnitude of effect was similar to that of an inhibitor of 5-lipoxygenase (5-LO) and LTA4 hydrolase but superior to a leukotriene CysLT1 receptor antagonist.  In summary, AM803 is a novel, potent and selective FLAP inhibitor that has excellent pharmacodynamic properties in vivo and is effective in animal models of acute inflammation and in a model of lethal shock.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoht19LIcH5qrVg90H21EOLACvtfcHk0lhOKi08ZWDerQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOhurg%253D&md5=5286307a8518fe2c56a2ecbd0296b68f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DBroadhead%26aufirst%3DA.%2BR.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DProdanovich%26aufirst%3DP.%2BP.%26aulast%3DDarlington%26aufirst%3DJ.%2BV.%26aulast%3DStock%26aufirst%3DN.%2BS.%26aulast%3DZunic%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DRoppe%26aufirst%3DJ.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DPharmacology%2520of%2520AM803%252C%2520a%2520novel%2520selective%2520five-lipoxygenase-activating%2520protein%2520%2528FLAP%2529%2520inhibitor%2520in%2520rodent%2520models%2520of%2520acute%2520inflammation%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D640%26spage%3D211%26epage%3D218%26doi%3D10.1016%2Fj.ejphar.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fjellstrom, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Graaf, P. H.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.2174/156802611794480864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.2174%2F156802611794480864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=21320067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=404-418&author=J.+Gabrielssonauthor=O.+Fjellstromauthor=J.+Ulanderauthor=M.+Rowleyauthor=P.+H.+Van+Der%0AGraaf&title=Pharmacodynamic-pharmacokinetic+integration+as+a+guide+to+medicinal+chemistry&doi=10.2174%2F156802611794480864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry</span></div><div class="casAuthors">Gabrielsson, Johan; Fjellstroem, Ola; Ulander, Johan; Rowley, Michael; Van Der Graaf, Piet H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">404-418</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiol. and pathol. conditions in animals and man.  Since the pharmacol. response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concn. or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile.  Hence, the output of PKPD activities extends beyond the provision of quant. measures (models) of results, to the design of future protocols.  Furthermore, because PKPD integrates DMPK (e.g. clearance) and pharmacol. (e.g. potency), it provides an anchor point for compd. selection, and, as such, should be viewed as an important weapon in medicinal chem.  Here we outline key PK concepts relevant to PD, and then consider real-life expts. to illustrate the importance to the medicinal chemist of data obtained by PKPD.  Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations.  By condensing complexity to simplicity, there are not only consequences for exptl. design, and for the ranking and design of compds., but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics.  In short, by using quant. methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compd.'s profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIh-_qK3VZ3LVg90H21EOLACvtfcHk0lh0wdE_xy8iVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnurw%253D&md5=44ac533600b03d728344688033d0e1fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F156802611794480864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480864%26sid%3Dliteratum%253Aachs%26aulast%3DGabrielsson%26aufirst%3DJ.%26aulast%3DFjellstrom%26aufirst%3DO.%26aulast%3DUlander%26aufirst%3DJ.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DVan%2BDer%2BGraaf%26aufirst%3DP.%2BH.%26atitle%3DPharmacodynamic-pharmacokinetic%2520integration%2520as%2520a%2520guide%2520to%2520medicinal%2520chemistry%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D404%26epage%3D418%26doi%3D10.2174%2F156802611794480864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lh0wdE_xy8iVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortelmans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiger, E.</span></span> <span> </span><span class="NLM_article-title">The Ames salmonella/microsome mutagenicity assay</span>. <i>Mutat. Res., Fundam. Mol. Mech. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/s0027-5107(00)00064-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fs0027-5107%2800%2900064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=11113466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslGhtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2000&pages=29-60&author=K.+Mortelmansauthor=E.+Zeiger&title=The+Ames+salmonella%2Fmicrosome+mutagenicity+assay&doi=10.1016%2Fs0027-5107%2800%2900064-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Ames Salmonella/microsome mutagenicity assay</span></div><div class="casAuthors">Mortelmans, K.; Zeiger, E.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">29-60</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review and discussion with 95 refs.  The Ames Salmonella/microsome mutagenicity assay (Salmonella test; Ames test) is a short-term bacterial reverse mutation assay specifically designed to detect a wide range of chem. substances that can produce genetic damage that leads to gene mutations.  The test employs several histidine dependent Salmonella strains each carrying different mutations in various genes in the histidine operon.  These mutations act as hot spots for mutagens that cause DNA damage via different mechanisms.  When the Salmonella tester strains are grown on a minimal media agar plate contg. a trace of histidine, only those bacteria that revert to histidine independence (his+) are able to form colonies.  The no. of spontaneously induced revertant colonies per plate is relatively const.  However, when a mutagen is added to the plate, the no. of revertant colonies per plate is increased, usually in a dose-related manner. The Ames test is used world-wide as an initial screen to det. the mutagenic potential of new chems. and drugs.  The test is also used for submission of data to regulatory agencies for registration or acceptance of many chems., including drugs and biocides.  International guidelines have been developed for use by corporations and testing labs. to ensure uniformity of testing procedures. This review provides historical aspects of how the Ames was developed and detailed procedures for performing the test, including the design and interpretation of results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJOx1kKxVF6LVg90H21EOLACvtfcHk0lh0wdE_xy8iVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslGhtr0%253D&md5=8c4804f0b78e09c6c6609859428a39bf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fs0027-5107%2800%2900064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0027-5107%252800%252900064-6%26sid%3Dliteratum%253Aachs%26aulast%3DMortelmans%26aufirst%3DK.%26aulast%3DZeiger%26aufirst%3DE.%26atitle%3DThe%2520Ames%2520salmonella%252Fmicrosome%2520mutagenicity%2520assay%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D2000%26volume%3D455%26spage%3D29%26epage%3D60%26doi%3D10.1016%2Fs0027-5107%2800%2900064-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börjesson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordén, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasselgren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span></span> <span> </span><span class="NLM_article-title">Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">16168</span>– <span class="NLM_lpage">16185</span>, <span class="refDoi"> DOI: 10.1021/ja206427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+for+main+features+of+structure-genotoxicity+relationships+of+aromatic+amines+by+theoretical+studies+of+their+activation+pathways+in+CYP1A2&doi=10.1021%2Fja206427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Explanation for Main Features of Structure-Genotoxicity Relationships of Aromatic Amines by Theoretical Studies of Their Activation Pathways in CYP1A2</span></div><div class="casAuthors">Shamovsky, Igor; Ripa, Lena; Borjesson, Lena; Mee, Christine; Norden, Bo; Hansen, Peter; Hasselgren, Catrin; O'Donovan, Mike; Sjo, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16168-16185</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arom. and heteroarom. amines (ArNH2) represent a class of potential mutagens that after being metabolically activated covalently modify DNA.  Activation of ArNH2 in many cases starts with N-hydroxylation by P 450 enzymes, primarily CYP1A2.  Poor understanding of structure-mutagenicity relationships of ArNH2 limits their use in drug discovery programs.  Key factors that facilitate activation of ArNH2 are revealed by exploring their reaction intermediates in CYP1A2 using DFT calcns.  On the basis of these calcns. and extensive anal. of structure-mutagenicity data, we suggest that mutagenic metabolites are generated by ferric peroxo intermediate, (CYP1A2)FeIII-OO-, in a three-step heterolytic mechanism.  First, the distal oxygen of the oxidant abstrs. proton from H-bonded ArNH2.  The subsequent proximal protonation of the resulting (CYP1A2)FeIII-OOH weakens both the O-O and the O-H bonds of the oxidant.  Heterolytic cleavage of the O-O bond leads to N-hydroxylation of ArNH- via SN2 mechanism, whereas cleavage of the O-H bond results in release of hydroperoxy radical.  Thus, our proposed reaction offers a mechanistic explanation for previous observations that metab. of arom. amines could cause oxidative stress.  The primary drivers for mutagenic potency of ArNH2 are (i) binding affinity of ArNH2 in the productive binding mode within the CYP1A2 substrate cavity, (ii) resonance stabilization of the anionic forms of ArNH2, and (iii) exothermicity of proton-assisted heterolytic cleavage of N-O bonds of hydroxylamines and their bioconjugates.  This leads to a strategy for designing mutagenicity free ArNH2: Structural alterations in ArNH2, which disrupt geometric compatibility with CYP1A2, hinder proton abstraction, or strongly destabilize the nitrenium ion, in this order of priority, prevent genotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctr81IIN2trVg90H21EOLACvtfcHk0lh0wdE_xy8iVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI&md5=9447ee2144a899b65e9350b712ca2a46</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520for%2520main%2520features%2520of%2520structure-genotoxicity%2520relationships%2520of%2520aromatic%2520amines%2520by%2520theoretical%2520studies%2520of%2520their%2520activation%2520pathways%2520in%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185%26doi%3D10.1021%2Fja206427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">The use of stable isotopes in pharmacological research</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=7029573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADyaL38XlsFGksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1981&pages=81-132&author=T.+A.+Baillie&title=The+use+of+stable+isotopes+in+pharmacological+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The use of stable isotopes in pharmacological research</span></div><div class="casAuthors">Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-132</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    </div><div class="casAbstract">A review with 507 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx_TMoDPwOELVg90H21EOLACvtfcHk0ljTFOsvJ_RTDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFGksLw%253D&md5=fb15a0ef3c0405714ad6c5baa2b9d584</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DThe%2520use%2520of%2520stable%2520isotopes%2520in%2520pharmacological%2520research%26jtitle%3DPharmacol.%2520Rev.%26date%3D1981%26volume%3D33%26spage%3D81%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desbans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgendorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungell, A.-L.</span></span> <span> </span><span class="NLM_article-title">Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.3109/00498254.2013.809617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.3109%2F00498254.2013.809617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=23883428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=17-27&author=C.+Desbansauthor=C.+Hilgendorfauthor=M.+Lutzauthor=P.+Bachellierauthor=T.+Zachariasauthor=J.+C.+Weberauthor=H.+Dolgosauthor=L.+Richertauthor=A.-L.+Ungell&title=Prediction+of+fraction+metabolized+via+CYP3A+in+humans+utilizing+cryopreserved+human+hepatocytes+from+a+set+of+12+single+donors&doi=10.3109%2F00498254.2013.809617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors</span></div><div class="casAuthors">Desbans, C.; Hilgendorf, C.; Lutz, M.; Bachellier, P.; Zacharias, T.; Weber, J. C.; Dolgos, H.; Richert, L.; Ungell, A.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-27</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. It has previously been demonstrated that metab. of drugs via a single enzymic pathway, particularly CYP3A4, is assocd. with increased risk for drug-drug interactions (DDI).  Quant. exptl. systems as well as integrated prediction models to assess such risk during the preclin. phase are highly warranted.  2. The present study was designed to systematically investigate the performance of human cryopreserved hepatocytes in suspension to predict fraction metabolized via CYP3A (fmCYP3A) by assessing the ketoconazole sensitive intrinsic clearance (CLint) for five prototypical CYP3A substrates with varying degree of CYP3A dependent CLint in twelve individual hepatocyte batches.  3. We demonstrate that in contrast to well predicted mean hepatic metabolic clearance (CLH) and mean fmCYP3A data, the variability in CYP3A contribution for compds. having multiple metabolic pathways cannot be predicted from inhibition expts. using ketoconazole as inhibitor.  Instead, data in the present paper indicate that the variability is larger after inhibition of CYP3A for compds. having multiple metabolic pathways.  4. It is therefore recommended to est. the av. CLint and fmCYP3Afor a given test compd. in a series (n = 10) of individual human hepatocyte batches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLabfu1cLLk7Vg90H21EOLACvtfcHk0ljTFOsvJ_RTDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrfK&md5=f241913f7c67ed3e9437dc84e3f8bbef</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3109%2F00498254.2013.809617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2013.809617%26sid%3Dliteratum%253Aachs%26aulast%3DDesbans%26aufirst%3DC.%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DLutz%26aufirst%3DM.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DZacharias%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DJ.%2BC.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DUngell%26aufirst%3DA.-L.%26atitle%3DPrediction%2520of%2520fraction%2520metabolized%2520via%2520CYP3A%2520in%2520humans%2520utilizing%2520cryopreserved%2520human%2520hepatocytes%2520from%2520a%2520set%2520of%252012%2520single%2520donors%26jtitle%3DXenobiotica%26date%3D2014%26volume%3D44%26spage%3D17%26epage%3D27%26doi%3D10.3109%2F00498254.2013.809617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span> <span> </span><span class="NLM_article-title">Validation of early human dose prediction: a key metric for compound progression in drug discovery</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=609-620&author=K.+M.+Page&title=Validation+of+early+human+dose+prediction%3A+a+key+metric+for+compound+progression+in+drug+discovery&doi=10.1021%2Facs.molpharmaceut.5b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery</span></div><div class="casAuthors">Page, Ken M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-620</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human dose prediction is increasingly recognized as an important parameter in Drug Discovery.  Validation of a method using only in vitro and predicted parameters incorporated into a PK model was undertaken by predicting human dose and free Cmax for a no. of marketed drugs and AZ Development compds.  Doses were compared to those most relevant to marketed drugs or to clin. administered doses of AZ compds. normalized either to predicted Cmin or Cmax values.  Av. (AFE) and abs. av. (AAFE) fold-error anal. showed that best predictions were obtained using a QSAR model as the source of Vss, with Fabs set to 1 for acids and 0.5 for all other ion classes; for clearance prediction no binding correction to the well stirred model (WSM) was used for bases, while it was set to Fup/Fup0.5 for all other ion classes.  Using this combination of methods, predicted doses for 45 to 68% of the Cmin- and Cmax-normalized and marketed drug data sets were within 3-fold of the obsd. values, while 82 to 92% of these data sets were within 10-fold.  This method for early human dose prediction is able to rank, identify, and flag risks or optimization opportunities for future development compds. within 10 days of first synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT--CfNq9EGLVg90H21EOLACvtfcHk0ljTFOsvJ_RTDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7%252FO&md5=612ece6c4e2729ab4694b0ae168e4cba</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DK.%2BM.%26atitle%3DValidation%2520of%2520early%2520human%2520dose%2520prediction%253A%2520a%2520key%2520metric%2520for%2520compound%2520progression%2520in%2520drug%2520discovery%26jtitle%3DMol.%2520Pharm.%26date%3D2016%26volume%3D13%26spage%3D609%26epage%3D620%26doi%3D10.1021%2Facs.molpharmaceut.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Quantitative and Qualitative Evaluation of Extrapolation of Intravenous Pharmacokinetic Parameters from Rat, Dog, and Monkey to Humans. I. Clearance</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">603</span>, <span class="refDoi"> DOI: 10.1124/dmd.32.6.603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1124%2Fdmd.32.6.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=15155551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlOgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=603&author=K.+W.+Wardauthor=B.+R.+Smith&title=A+Comprehensive+Quantitative+and+Qualitative+Evaluation+of+Extrapolation+of+Intravenous+Pharmacokinetic+Parameters+from+Rat%2C+Dog%2C+and+Monkey+to+Humans.+I.+Clearance&doi=10.1124%2Fdmd.32.6.603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance</span></div><div class="casAuthors">Ward, Keith W.; Smith, Brian R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-611</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was conducted to comprehensively survey the available literature on i.v. pharmacokinetic parameters in the rat, dog, monkey, and human, and to compare common methods for extrapolation of clearance, to identify the most appropriate species to use in pharmacokinetic lead optimization, and to ascertain whether adequate prospective measures of predictive success are currently available.  One hundred three nonpeptide xenobiotics were identified with i.v. pharmacokinetic data in rat, dog, monkey, and human; both body wt.- and hepatic blood flow-based methods were used for scaling of clearance.  Allometric scaling approaches, particularly those using data from only two of the preclin. species, were less successful at predicting human clearance than methods based on clearance as a set fraction of liver blood flow from an individual species.  Furthermore, commonly used prospective measures of allometric scaling success, including correlation coeff. and allometric exponent, failed to discriminate between successful and failed allometric predictions.  In all instances, the monkey tended to provide the most qual. and quant. accurate predictions of human clearance and also afforded the least biased predictions compared with other species.  Addnl., the availability of data from both common nonrodent species (dog and monkey) did not ensure enhanced predictive quality compared with having only monkey data.  The observations in this investigation have major implications for pharmacokinetic lead optimization and for prediction of human clearance from in vivo preclin. data and support the continued use of nonhuman primates in preclin. pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAonnLuZFTbVg90H21EOLACvtfcHk0lguufWR2-eMVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlOgtro%253D&md5=811ef885c0572fc4235e5d47afddefaf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26atitle%3DA%2520Comprehensive%2520Quantitative%2520and%2520Qualitative%2520Evaluation%2520of%2520Extrapolation%2520of%2520Intravenous%2520Pharmacokinetic%2520Parameters%2520from%2520Rat%252C%2520Dog%252C%2520and%2520Monkey%2520to%2520Humans.%2520I.%2520Clearance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D603%26doi%3D10.1124%2Fdmd.32.6.603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Øie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, T. N.</span></span> <span> </span><span class="NLM_article-title">Effect of altered plasma protein binding on apparent volume of distribution</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1002/jps.2600680948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1002%2Fjps.2600680948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1979&pages=1203-1205&author=S.+%C3%98ieauthor=T.+N.+Tozer&title=Effect+of+altered+plasma+protein+binding+on+apparent+volume+of+distribution&doi=10.1002%2Fjps.2600680948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600680948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600680948%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2598ie%26aufirst%3DS.%26aulast%3DTozer%26aufirst%3DT.%2BN.%26atitle%3DEffect%2520of%2520altered%2520plasma%2520protein%2520binding%2520on%2520apparent%2520volume%2520of%2520distribution%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1979%26volume%3D68%26spage%3D1203%26epage%3D1205%26doi%3D10.1002%2Fjps.2600680948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span>; <span class="NLM_string-name">Emtenäs, H.</span>; <span class="NLM_string-name">Granberg, K.</span>; <span class="NLM_string-name">Lemurell, M.</span>; <span class="NLM_string-name">Pettersen, D.</span>; <span class="NLM_string-name">Plowright, A.</span>; <span class="NLM_string-name">Ulander, J.</span></span> <span> </span><span class="NLM_article-title">Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors</span>. <span class="NLM_patent">WO/2016/177703</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Broddefalk&author=H.+Emten%C3%A4s&author=K.+Granberg&author=M.+Lemurell&author=D.+Pettersen&author=A.+Plowright&author=J.+Ulander&title=Pyrazole+derivatives+useful+as+5-lipoxygenase+activating+protein+%28FLAP%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBroddefalk%26aufirst%3DJ.%26atitle%3DPyrazole%2520derivatives%2520useful%2520as%25205-lipoxygenase%2520activating%2520protein%2520%2528FLAP%2529%2520inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span>; <span class="NLM_string-name">Yamamoto, Y.</span>; <span class="NLM_string-name">Iso, K.</span></span> <span> </span><span class="NLM_article-title">(6S,9AS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-C][1,2,4]triazine-1-carboxamide compound</span>. U.S. Patent <span class="NLM_patent">20,150,175,615</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Inoue&author=Y.+Yamamoto&author=K.+Iso&title=%286S%2C9AS%29-N-Benzyl-6-%5B%284-hydroxyphenyl%29methyl%5D-4%2C7-dioxo-8-%28%7B6-%5B3-%28piperazin-1-yl%29azetidin-1-yl%5Dpyridin-2-yl%7Dmethyl%29-2-%28prop-2-en-1-yl%29-octahydro-1H-pyrazino%5B2%2C1-C%5D%5B1%2C2%2C4%5Dtriazine-1-carboxamide+compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DS.%26atitle%3D%25286S%252C9AS%2529-N-Benzyl-6-%255B%25284-hydroxyphenyl%2529methyl%255D-4%252C7-dioxo-8-%2528%257B6-%255B3-%2528piperazin-1-yl%2529azetidin-1-yl%255Dpyridin-2-yl%257Dmethyl%2529-2-%2528prop-2-en-1-yl%2529-octahydro-1H-pyrazino%255B2%252C1-C%255D%255B1%252C2%252C4%255Dtriazine-1-carboxamide%2520compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Matthew Burns, Dave Perkins, Lai C. Chan, Michael J. Pilling, Anna Jawor-Baczynska, Alexander K. Mullen, Alan Steven, Chris Wimsey, Ahmed Elmekawy, Alex Lamacraft, Benjamin C. Dobson, Angus E. McMillan, David R. J. Hose, Phillip A. Inglesby, Steven A. Raw, <span class="NLM_string-name hlFld-ContribAuthor">Martin F. Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Route Design to Manufacture: Synthesis of the Heterocyclic Fragment of AZD5718 Using a Non-cryogenic Lithiation-Alkoxycarbonylation Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (4)
                                     , 858-870. <a href="https://doi.org/10.1021/acs.oprd.0c00533" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00533%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DRoute%252BDesign%252Bto%252BManufacture%25253A%252BSynthesis%252Bof%252Bthe%252BHeterocyclic%252BFragment%252Bof%252BAZD5718%252BUsing%252Ba%252BNon-cryogenic%252BLithiation-Alkoxycarbonylation%252BReaction%26aulast%3DBurns%26aufirst%3DMatthew%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D10122020%26date%3D29032021%26volume%3D25%26issue%3D4%26spage%3D858%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jenny E.  Ottosson</span>, <span class="hlFld-ContribAuthor ">Malin  Gränfors</span>, <span class="hlFld-ContribAuthor ">Sally  van Pelt</span>, <span class="hlFld-ContribAuthor ">Annika  Langborg Weinmann</span>, <span class="hlFld-ContribAuthor ">Sten O.  Nilsson Lill</span>, <span class="hlFld-ContribAuthor ">Gustaf  Hulthe</span>, <span class="hlFld-ContribAuthor ">Gunnar  Grönberg</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization and demonstration of drug compound ring-chain tautomer formation and its impacts on quality control. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2021,</strong> <em>198 </em>, 114020. <a href="https://doi.org/10.1016/j.jpba.2021.114020" title="DOI URL">https://doi.org/10.1016/j.jpba.2021.114020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2021.114020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2021.114020%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DCharacterization%252Band%252Bdemonstration%252Bof%252Bdrug%252Bcompound%252Bring-chain%252Btautomer%252Bformation%252Band%252Bits%252Bimpacts%252Bon%252Bquality%252Bcontrol%26aulast%3DOttosson%26aufirst%3DJenny%2BE.%26date%3D2021%26volume%3D198%26spage%3D114020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madhuranayaki  Thulasingam</span>, <span class="hlFld-ContribAuthor ">Jesper Z.  Haeggström</span>. </span><span class="cited-content_cbyCitation_article-title">Integral Membrane Enzymes in Eicosanoid Metabolism: Structures, Mechanisms and Inhibitor Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Biology</span><span> <strong>2020,</strong> <em>432 </em>
                                    (18)
                                     , 4999-5022. <a href="https://doi.org/10.1016/j.jmb.2020.07.020" title="DOI URL">https://doi.org/10.1016/j.jmb.2020.07.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmb.2020.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmb.2020.07.020%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Biology%26atitle%3DIntegral%252BMembrane%252BEnzymes%252Bin%252BEicosanoid%252BMetabolism%25253A%252BStructures%25252C%252BMechanisms%252Band%252BInhibitor%252BDesign%26aulast%3DThulasingam%26aufirst%3DMadhuranayaki%26date%3D2020%26volume%3D432%26issue%3D18%26spage%3D4999%26epage%3D5022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. FLAP facilitates the transfer of arachidonic acid from membrane phospholipids to the active site of 5-LO. Inhibition of FLAP attenuates the production of the leukotriene precursor LTA<sub>4</sub> and the formation of the biologically active leukotrienes LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of the most advanced FLAP inhibitors from previously described chemical series, which have later been discontinued during preclinical toxicology studies or in development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Late-Stage Variation of the Amines and Suzuki Reactants To Provide Compounds <b>4a–u</b> Either as Racemates or Pure Enantiomers<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Commonly used reagents and conditions: (a) R<sub>1</sub>-NH<sub>2</sub>, TBTU, DIPEA, DMF or R<sub>1</sub>-NH<sub>2</sub>, T3P, Et<sub>3</sub>N, 50 °C; (b) R<sub>2</sub>-B(OH)<sub>2</sub>/R<sub>2</sub>-Bpin, Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, DMF-H<sub>2</sub>O, 100 °C or R<sub>2</sub>-B(OH)<sub>2</sub>/R<sub>2</sub>-Bpin, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C.</p><p><span class="fn-label"><sup>b</sup></span>See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for synthesis details. No synthesis details given for <b>4a</b> (<i>rac</i>) and <b>4b</b> (<i>rac</i>) as they were identified as hits during the HTS from the AstraZeneca compound collection.</p><p class="last"><span class="fn-label"><sup>c</sup></span>See <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for the chemical structure and stereochemistry.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Variation of the Aryl Ring Introduced by Ring Opening of (3a,7a-<i>trans</i>)-Hexahydro-2-benzofuran-1,3-dione<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (3a,7a<i>-trans</i>)-hexahydro-2-benzofuran-1,3-dione, <i>n</i>-BuLi, Et<sub>2</sub>O and/or THF, −78 °C; 20–32%; (b) 1<i>H</i>-pyrazol-3-ylboronic acid, Pd(dppf), K<sub>3</sub>PO<sub>4</sub> or K<sub>2</sub>CO<sub>3</sub>, DME/EtOH/H<sub>2</sub>O or dioxane/H<sub>2</sub>O, heated in a microwave reactor at 130 °C or reflux, 30–42%; (c) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride, TBTU, NMM or DIPEA, DMF or CH<sub>2</sub>Cl<sub>2</sub>, rt, 6–77%; (d) NH<sub>4</sub>CO<sub>2</sub>H, Pd(OH)<sub>2</sub>, CH<sub>3</sub>OH, heated in a microwave reactor at 100 °C, quant; (e) K<sub>2</sub>CO<sub>3</sub>, PhN(Tf)<sub>2</sub>, DMF, rt, 69%; (f) chiral separation.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>ortho</i>-Fluoro Compounds Using a Diels–Alder Approach<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) oxoacetic acid, CH<sub>3</sub>CO<sub>2</sub>H, CH<sub>3</sub>SO<sub>3</sub>H, 130 °C, 73%; (b) buta-1,3-diene, toluene, 60 °C, 90%; (c) chiral separation; (d) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride, T3P, Et<sub>3</sub>N, EtOAc, 80 °C, 70%; (e) 1<i>H</i>-pyrazol-3-ylboronic acid or 1-(tetrahydro-2<i>H</i>-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 85 °C, 52–58%; (f) Pd/C, CH<sub>3</sub>OH, H<sub>2</sub> (g, 1 atm), rt, 56%; (g) 5% Rh/C, THF, H<sub>2</sub> (g, 2 bar), rt, 91%; (h) 4-amino-1-methyl-1<i>H</i>-pyrazole-3-carboxamide, HATU, DIPEA, DMF, rt; (i) 1.25 M HCl in CH<sub>3</sub>OH, 16 °C, 69%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Introduction of the Bridged Cyclohexyl Ring System<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,3-dimethyl-1<i>H</i>-pyrazol-4-amine hydrogen chloride, CDI, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 91%; (b) 5% Pd/C, THF, H<sub>2</sub>, rt, 99%; (c) 2-fluoro-5-bromo-bromobenzene, <i>n</i>-BuLi, THF, −78 °C, 11%; (d) 1<i>H</i>-pyrazol-5-ylboronic acid, Pd(dppf)<sub>2</sub>CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 14%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Introduction of the Cyclopropyl-Fused Cyclohexyl Ring System<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) buta-1,3-diene, hydroquinone, toluene, 160 °C, 95%; (b) Et<sub>2</sub>Zn, ClCH<sub>2</sub>I, DCE/heptane, 0 °C → rt; (c) LiOH, CH<sub>3</sub>OH–THF–H<sub>2</sub>O, 60 °C; (d) 1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine, T3P, Et<sub>3</sub>N, 50 °C, 64% (from <b>25</b> (<i>rac</i>)); (e) 1<i>H</i>-pyrazol-3-ylboronic acid, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C, 80%. (f) Chiral separation; (g) 1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-4-amine, T3P, Et<sub>3</sub>N, 80 °C, 47% (from <b>25</b>); (h) 1<i>H</i>-pyrazol-3-ylboronic acid, Pd(dtbpf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/water, 80 °C, 63%.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of 1,2-Benzisoxazole Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HONH<sub>2</sub>·HCl, pyridine, 100 °C; (b) NaH, DMF, rt, 59% (over 2 steps); (c) 3-methyl-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 90 °C, 96%; (d) 4-amino-1-methyl-1<i>H</i>-pyrazole-3-carboxamide, HATU, DIPEA, DMF, rt; (e) HCl(aq), dioxane/H<sub>2</sub>O, rt, 74% (over 2 steps); (f) H<sub>2</sub>SO<sub>4</sub>, EtOH, Δ; (g) Et<sub>2</sub>Zn, ClCH<sub>2</sub>I, DCE/heptane, 0 °C → rt; (h) LiOH, CH<sub>3</sub>OH–THF–H<sub>2</sub>O, 50 °C; (i) separation of diastereomers.</p></p></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds with reduced permeability required prolonged incubation time (4 h vs 30 min) in the hWB assay to attenuate the full response on LTB<sub>4</sub> reduction. The dashed line gives the linear fit (residual standard error = 0.32 log units which corresponds to a factor 2), <i>R</i><sup>2</sup> = 0.44; dotted lines correspond to a ratio 4× difference from the fitted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Generic Biotransformation Map of the Compound Series in Human Hepatocytes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Drug plasma concentration vs time (left) and the absolute LTB<sub>4</sub> values vs compound <b>4i</b> exposure (right) is shown for oral repeated dosing (IV data in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>). The circles represent observed PK and mean individual LTB<sub>4</sub> (<i>n</i> = 5, per time point) data from po dosing, and filled and empty circles represent 1 and 0.1 μmol/kg doses, respectively. To the left, the solid and dash blue lines represent the population model fit of 1 and 0.1 μmol/kg po dosing, respectively, and to the right, the black line represents the population model fit including all data from the different oral and IV studies (more information in <a href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf" class="ext-link">Supporting Information</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/medium/jm-2018-02012a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Secondary pharmacology activity of <b>4i</b> was assessed in a screening panel of 180 targets. A margin of >30-fold was predicted for any off-target effects based on the predicted human free <i>C</i><sub>max</sub> of 0.38 μM corresponding to a dose of 280 mg b.i.d. to reach the target of 80% LTB<sub>4</sub> suppression over 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b02012/20190502/images/large/jm-2018-02012a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b02012&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67534" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67534" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters-Golden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, W. R.</span></span> <span> </span><span class="NLM_article-title">Leukotrienes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1056/nejmra071371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1056%2Fnejmra071371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=17978293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=1841-1854&author=M.+Peters-Goldenauthor=W.+R.+Henderson&title=Leukotrienes&doi=10.1056%2Fnejmra071371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotrienes</span></div><div class="casAuthors">Peters-Golden, Marc; Henderson, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1841-1854</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Leukotrienes comprise a family of products of the 5-lipoxygenase pathway of arachidonic acid metab.  The cysteinyl leukotrienes C4, D4, and E4 account for the biol. activity that was previously termed "slow-reacting substance of anaphylaxis", and the efficacy of antagonists to type 1 cysteinyl leukotriene receptor (CysLT1) in asthma validates the importance of cysteinyl leukotrienes and CysLT1 in this disease.  Here, the authors discuss: synthesis of leukotrienes; leukotriene receptors; blockade of leukotriene synthesis and leukotriene receptors; leukotrienes in disease; and leukotrienes in antimicrobial defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjehKHMPz2p7Vg90H21EOLACvtfcHk0ljJYjNFAwtS5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM&md5=4e617e65cf4b1f55f595bc03344fdb55</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2Fnejmra071371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmra071371%26sid%3Dliteratum%253Aachs%26aulast%3DPeters-Golden%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DW.%2BR.%26atitle%3DLeukotrienes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D1841%26epage%3D1854%26doi%3D10.1056%2Fnejmra071371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPheat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herslöf, M.</span></span> <span> </span><span class="NLM_article-title">The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1879</span>– <span class="NLM_lpage">1893</span>, <span class="refDoi"> DOI: 10.1517/13543784.16.12.1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1517%2F13543784.16.12.1879" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1879-1893&author=C.+Whatlingauthor=W.+McPheatauthor=M.+Hersl%C3%B6f&title=The+potential+link+between+atherosclerosis+and+the+5-lipoxygenase+pathway%3A+investigational+agents+with+new+implications+for+the+cardiovascular+field&doi=10.1517%2F13543784.16.12.1879"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.12.1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.12.1879%26sid%3Dliteratum%253Aachs%26aulast%3DWhatling%26aufirst%3DC.%26aulast%3DMcPheat%26aufirst%3DW.%26aulast%3DHersl%25C3%25B6f%26aufirst%3DM.%26atitle%3DThe%2520potential%2520link%2520between%2520atherosclerosis%2520and%2520the%25205-lipoxygenase%2520pathway%253A%2520investigational%2520agents%2520with%2520new%2520implications%2520for%2520the%2520cardiovascular%2520field%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1879%26epage%3D1893%26doi%3D10.1517%2F13543784.16.12.1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J.</span></span> <span> </span><span class="NLM_article-title">What’s all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.tips.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=18187210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=72-78&author=J.+Evansauthor=A.+Fergusonauthor=R.+Mosleyauthor=J.+Hutchinson&title=What%E2%80%99s+all+the+FLAP+about%3F%3A+5-lipoxygenase-activating+protein+inhibitors+for+inflammatory+diseases&doi=10.1016%2Fj.tips.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases</span></div><div class="casAuthors">Evans, Jilly F.; Ferguson, Andrew D.; Mosley, Ralph T.; Hutchinson, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">72-78</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Leukotrienes have physiol. roles in innate immune responses and pathol. roles in inflammatory diseases, such as asthma, allergic rhinitis and atherosclerosis.  Anti-leukotriene therapy has proven benefits in the treatment of respiratory disease, either through the inhibition of leukotriene synthesis or the selective antagonism of leukotriene receptors.  The first committed step in the synthesis of leukotrienes is the oxidn. of arachidonic acid (AA) by 5-lipoxygenase (5-LO), and the integral membrane protein 5-lipoxygenase-activating protein (FLAP) is an essential partner of 5-LO for this process.  FLAP was molecularly identified via a photoaffinity probe and an affinity gel based on MK-886, a selective leukotriene inhibitor that has no activity against broken-cell prepns. of 5-LO.  Several FLAP inhibitors showed efficacy in early clin. trials in asthma but were not developed com. for unpublished reasons.  Recently, the FLAP (ALOX5AP) gene has been linked to risk for myocardial infarction, stroke and restenosis, reigniting pharmaceutical interest in this target.  In addn., the recent detn. of the crystal structure of inhibitor-bound FLAP offers exciting potential for novel FLAP inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQmgWVV5NuILVg90H21EOLACvtfcHk0lg5FoFwSfcBog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLg%253D&md5=332a3d2569c28baeff5dcda2a79377da</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DA.%26aulast%3DMosley%26aufirst%3DR.%26aulast%3DHutchinson%26aufirst%3DJ.%26atitle%3DWhat%25E2%2580%2599s%2520all%2520the%2520FLAP%2520about%253F%253A%25205-lipoxygenase-activating%2520protein%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D72%26epage%3D78%26doi%3D10.1016%2Fj.tips.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaab, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewolinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Wetering de Rooij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04386.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1111%2Fj.1365-2125.2012.04386.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=22803688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Squ70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=779-790&author=G.+Bainauthor=C.+D.+Kingauthor=K.+Schaabauthor=M.+Rewolinskiauthor=V.+Norrisauthor=C.+Amberyauthor=J.+Bentleyauthor=M.+Yamadaauthor=A.+M.+Santiniauthor=J.+van+de+Wetering+de+Rooijauthor=N.+Stockauthor=J.+Zunicauthor=J.+H.+Hutchinsonauthor=J.+F.+Evans&title=Pharmacodynamics%2C+pharmacokinetics+and+safety+of+GSK2190915%2C+a+novel+oral+anti-inflammatory+5-lipoxygenase-activating+protein+inhibitor&doi=10.1111%2Fj.1365-2125.2012.04386.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor</span></div><div class="casAuthors">Bain, Gretchen; King, Christopher D.; Schaab, Kevin; Rewolinski, Melissa; Norris, Virginia; Ambery, Claire; Bentley, Jane; Yamada, Masanori; Santini, Angelina M.; van de Wetering de Rooij, Jeroen; Stock, Nicholas; Zunic, Jasmine; Hutchinson, John H.; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">779-790</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations.  Method : Western European subjects received single (50-1000 mg) or multiple (10-450 mg) oral doses of GSK2190915 or placebo in a dose-escalating manner.  Japanese subjects received three of four GSK2190915 doses (10-200 mg) plus placebo once in a four period crossover design.  Blood samples were collected for GSK2190915 concns. and blood and urine were collected to measure leukotriene B4 and leukotriene E4, resp., as pharmacodynamic markers of drug activity.  Results : There was no clear difference in adverse events between placebo and active drug-treated subjects in either study.  Maximum plasma concns. of GSK2190915 and area under the curve increased in a dose-related manner and mean half-life values ranged from 16-34 h.  Dose-dependent inhibition of blood leukotriene B4 prodn. was obsd. and near complete inhibition of urinary leukotriene E4 excretion was shown at all doses except the lowest dose.  The EC50 values for inhibition of LTB4 were 85 nm and 89 nm in the Western European and Japanese studies, resp.  Conclusion : GSK2190915 is well-tolerated with pharmacokinetics and pharmacodynamics in Western European and Japanese subjects that support once daily dosing for 24 h inhibition of leukotrienes.  Doses of ≥50 mg show near complete inhibition of urinary leukotriene E4 at 24 h post-dose, whereas doses of ≥150 mg are required for 24 h inhibition of blood LTB4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnkQtxs-NZfbVg90H21EOLACvtfcHk0lg5FoFwSfcBog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Squ70%253D&md5=c0b4858ea6d2f13b5b3245b92e38aaee</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04386.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04386.x%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DSchaab%26aufirst%3DK.%26aulast%3DRewolinski%26aufirst%3DM.%26aulast%3DNorris%26aufirst%3DV.%26aulast%3DAmbery%26aufirst%3DC.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bde%2BWetering%2Bde%2BRooij%26aufirst%3DJ.%26aulast%3DStock%26aufirst%3DN.%26aulast%3DZunic%26aufirst%3DJ.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%2520and%2520safety%2520of%2520GSK2190915%252C%2520a%2520novel%2520oral%2520anti-inflammatory%25205-lipoxygenase-activating%2520protein%2520inhibitor%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D779%26epage%3D790%26doi%3D10.1111%2Fj.1365-2125.2012.04386.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drajesk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awni, W. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/s0009-9236(98)90164-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fs0009-9236%2898%2990164-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=9542476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADyaK1cXisVWnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=324-331&author=S.+L.+Wongauthor=J.+Drajeskauthor=M.+Changauthor=C.+Lanniauthor=G.+Wittauthor=R.+Hansenauthor=W.+M.+Awni&title=Pharmacokinetics+and+pharmacodynamics+of+single+and+multiple+oral+doses+of+a+novel+5-lipoxygenase+inhibitor+%28ABT-761%29+in+healthy+volunteers&doi=10.1016%2Fs0009-9236%2898%2990164-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers</span></div><div class="casAuthors">Wong, Shekman L.; Drajesk, Jeffrey; Chang, Min; Lanni, Carmine; Witt, Galen; Hansen, Robert; Awni, Walid M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology and Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-331</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">This study evaluated the safety, pharmacokinetics and pharmacodynamics of ABT-761 [R(+)-N-[3-[5-(4-fluorophenylmethyl)-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea], a new N-hydroxyurea analog.  This was a randomized, double-blind, placebo-controlled, single- and multiple-dose (15-day) study of ABT-761 (50 to 200 mg/day) in healthy, nonsmoking adult male volunteers.  The pharmacokinetics were evaluated by investigation of the time- and dose-dependent effects of ABT-761, and the pharmacol. selectivity of ABT-761 was evaluated based on calcium ionophore-stimulated leukotriene B4 (LTB4) and thromboxane B2 (TXB2) biosynthesis ex vivo in whole blood.  After single and multiple doses, mean obsd. time to reach max. concn. values of ABT-761 ranged from 4.0 to 7.5 h.  Mean values for max. concn. and area under the plasma concn.-time curve from 0 to 24 h increased approx. linearly with dose.  Mean terminal half-life and apparent vol. of distribution during the terminal elimination phase of ABT-761 ranged from 15.4 to 17.8 h and 69.5 to 78.9 L, resp., and was dose independent.  Steady state was reached on day 11 after multiple dosing.  Less than 0.05% of unchanged ABT-761 was recovered in urine within the 24-h period after day 15 dosing.  Population ABT-761 plasma concn. at which 50% of the max. possible inhibition was obsd. for LTB4 inhibition was 0.24 μg/mL.  No differences in mean TXB2 inhibition were obsd. between the subjects receiving ABT-761 and placebo.  These results indicate that ABT-761 is a potent and selective inhibitor of 5-lipoxygenase and the pharmacokinetics of ABT-761 are time and dose independent between 50 and 200 mg/day after single and multiple dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTZfiiiAa-7Vg90H21EOLACvtfcHk0liEAiahCso5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVWnu70%253D&md5=2d561a945ff6360736789690f8e02a5c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fs0009-9236%2898%2990164-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0009-9236%252898%252990164-3%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BL.%26aulast%3DDrajesk%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DLanni%26aufirst%3DC.%26aulast%3DWitt%26aufirst%3DG.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DAwni%26aufirst%3DW.%2BM.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520single%2520and%2520multiple%2520oral%2520doses%2520of%2520a%2520novel%25205-lipoxygenase%2520inhibitor%2520%2528ABT-761%2529%2520in%2520healthy%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1998%26volume%3D63%26spage%3D324%26epage%3D331%26doi%3D10.1016%2Fs0009-9236%2898%2990164-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tardif, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">L’Allier, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grégoire, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotz, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pressacco, J.</span></span> <span> </span><span class="NLM_article-title">Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with recent acute coronary syndrome</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1161/circimaging.110.937169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1161%2Fcircimaging.110.937169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=20190281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A280%3ADC%252BC3czksVarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=298-307&author=J.-C.+Tardifauthor=P.+L.+L%E2%80%99Allierauthor=R.+Ibrahimauthor=J.+C.+Gr%C3%A9goireauthor=A.+Nozzaauthor=M.+Cossetteauthor=S.+Kouzauthor=M.-A.+Lavoieauthor=J.+Paquinauthor=T.+M.+Brotzauthor=R.+Taubauthor=J.+Pressacco&title=Treatment+with+5-lipoxygenase+inhibitor+VIA-2291+%28atreleuton%29+in+patients+with+recent+acute+coronary+syndrome&doi=10.1161%2Fcircimaging.110.937169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome</span></div><div class="casAuthors">Tardif Jean-Claude; L'allier Philippe L; Ibrahim Reda; Gregoire Jean C; Nozza Anna; Cossette Marieve; Kouz Simon; Lavoie Marc-Andre; Paquin Janie; Brotz Tilmann M; Taub Rebecca; Pressacco Josephine</div><div class="citationInfo"><span class="NLM_cas:title">Circulation. Cardiovascular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">298-307</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Production of leukotrienes by 5-lipoxygenase (5-LO) has been linked to unstable atherosclerotic plaques and cardiovascular events.  VIA-2291 is a potent 5-LO inhibitor.  METHODS AND RESULTS:  In a double-blinded study, 191 patients were randomly assigned 3 weeks after an acute coronary syndrome to receive 25, 50, or 100 mg VIA-2291 or placebo daily for 12 weeks.  The primary study end point, whole blood stimulated leukotriene LTB4 at trough drug level, was reduced in all VIA-2291 groups (P<0.0001) in a dose-dependent fashion, with approximately 80% inhibition in >90% of patients in the 100-mg group.  A significant reduction of urine leukotriene LTE4 was obtained in all dose groups.  No serious adverse events were considered related to study drug.  A subset of 93 patients who had undergone a 64-slice coronary CT examination at baseline continued on study medication for a total of 24 weeks and underwent a repeat scan.  Five of these patients withdrew or were noncompliant and 28 had nonevaluable scans.  Among the 60 remaining patients, new coronary plaques were observed in 5 of 18 (27.8%) placebo-treated patients and in 2 of 42 (4.8%) VIA-2291-treated patients (P=0.01).  A reduction in noncalcified plaque volume at 24 weeks versus placebo was observed in VIA-2291-treated groups in the 34 of these 60 patients in whom this end point was analyzable (P<0.01).  CONCLUSIONS:  VIA-2291 reduces leukotriene production at 12 weeks after an acute coronary syndrome.  Preliminary data from the CT substudy suggest that such a reduction in leukotriene production may influence atherosclerosis; however, this requires confirmation in a larger study.  Clinical Trial Registration- URL: http://www.clinicaltrials.gov.  Unique identifier: NCT00358826.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrLYXMby2XrySm0e6ZOaemfW6udTcc2eYzSnj_xd8Zorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czksVarsw%253D%253D&md5=2b668946b510c248724b4df82176deb3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1161%2Fcircimaging.110.937169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fcircimaging.110.937169%26sid%3Dliteratum%253Aachs%26aulast%3DTardif%26aufirst%3DJ.-C.%26aulast%3DL%25E2%2580%2599Allier%26aufirst%3DP.%2BL.%26aulast%3DIbrahim%26aufirst%3DR.%26aulast%3DGr%25C3%25A9goire%26aufirst%3DJ.%2BC.%26aulast%3DNozza%26aufirst%3DA.%26aulast%3DCossette%26aufirst%3DM.%26aulast%3DKouz%26aufirst%3DS.%26aulast%3DLavoie%26aufirst%3DM.-A.%26aulast%3DPaquin%26aufirst%3DJ.%26aulast%3DBrotz%26aufirst%3DT.%2BM.%26aulast%3DTaub%26aufirst%3DR.%26aulast%3DPressacco%26aufirst%3DJ.%26atitle%3DTreatment%2520with%25205-lipoxygenase%2520inhibitor%2520VIA-2291%2520%2528atreleuton%2529%2520in%2520patients%2520with%2520recent%2520acute%2520coronary%2520syndrome%26jtitle%3DCirculation%26date%3D2010%26volume%3D3%26spage%3D298%26epage%3D307%26doi%3D10.1161%2Fcircimaging.110.937169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsson, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span> <span> </span><span class="NLM_article-title">Recent advances for FLAP inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2607</span>– <span class="NLM_lpage">2612</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.bmcl.2015.04.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=26004579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFWgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2607-2612&author=D.+Pettersenauthor=%C3%96.+Davidssonauthor=C.+Whatling&title=Recent+advances+for+FLAP+inhibitors&doi=10.1016%2Fj.bmcl.2015.04.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances for FLAP inhibitors</span></div><div class="casAuthors">Pettersen, Daniel; Davidsson, Oejvind; Whatling, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2607-2612</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. A no. of FLAP inhibitors have been progressed to clin. trials for respiratory and other inflammatory indications but so far no drug has reached the market.  With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease.  We also show how recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP inhibitors paving the way for new compd. classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_be1PSARIkLVg90H21EOLACvtfcHk0liEAiahCso5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFWgtrs%253D&md5=f6eab0befa0ce24c17ff5e153a3b4907</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.090%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DD.%26aulast%3DDavidsson%26aufirst%3D%25C3%2596.%26aulast%3DWhatling%26aufirst%3DC.%26atitle%3DRecent%2520advances%2520for%2520FLAP%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2607%26epage%3D2612%26doi%3D10.1016%2Fj.bmcl.2015.04.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roppe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span> <span> </span><span class="NLM_article-title">5-lipoxygenase-activating protein (FLAP) inhibitors. part 4: development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8013</span>– <span class="NLM_lpage">8029</span>, <span class="refDoi"> DOI: 10.1021/jm2008369</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2008369" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVaisLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8013-8029&author=N.+S.+Stockauthor=G.+Bainauthor=J.+Zunicauthor=Y.+Liauthor=J.+Ziffauthor=J.+Roppeauthor=A.+Santiniauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=C.+D.+Kingauthor=C.+Bacceiauthor=C.+Leeauthor=H.+Rongauthor=C.+Chapmanauthor=A.+Broadheadauthor=D.+Lorrainauthor=L.+Correaauthor=J.+H.+Hutchinsonauthor=J.+F.+Evansauthor=P.+Prasit&title=5-lipoxygenase-activating+protein+%28FLAP%29+inhibitors.+part+4%3A+development+of+3-%5B3-tert-Butylsulfanyl-1-%5B4-%286-ethoxypyridin-3-yl%29benzyl%5D-5-%285-methylpyridin-2-ylmethoxy%29-1H-indol-2-yl%5D-2%2C2-dimethylpropionic+acid+%28AM803%29%2C+a+potent%2C+oral%2C+once+daily+FLAP+inhibitor&doi=10.1021%2Fjm2008369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor</span></div><div class="casAuthors">Stock, Nicholas S.; Bain, Gretchen; Zunic, Jasmine; Li, Yiwei; Ziff, Jeannie; Roppe, Jeffrey; Santini, Angelina; Darlington, Janice; Prodanovich, Pat; King, Christopher D.; Baccei, Christopher; Lee, Catherine; Rong, Haojing; Chapman, Charles; Broadhead, Alex; Lorrain, Dan; Correa, Lucia; Hutchinson, John H.; Evans, Jilly F.; Prasit, Peppi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8013-8029</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc (I) is described (AM803, now GSK2190915).  Building upon AM103, SAR studies centering around the pyridine moiety led to the discovery of compds. that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h).  Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclin. toxicol. and pharmacokinetics in rat and dog.  11Cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model.  This compd. has successfully completed phase 1 clin. studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph6QQEmUcpHbVg90H21EOLACvtfcHk0lhkXwbSbcCGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVaisLrP&md5=603c7ee09513152640d3e2b91177db0b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm2008369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008369%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DN.%2BS.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DZunic%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZiff%26aufirst%3DJ.%26aulast%3DRoppe%26aufirst%3DJ.%26aulast%3DSantini%26aufirst%3DA.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DBaccei%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DBroadhead%26aufirst%3DA.%26aulast%3DLorrain%26aufirst%3DD.%26aulast%3DCorrea%26aufirst%3DL.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DPrasit%26aufirst%3DP.%26atitle%3D5-lipoxygenase-activating%2520protein%2520%2528FLAP%2529%2520inhibitors.%2520part%25204%253A%2520development%2520of%25203-%255B3-tert-Butylsulfanyl-1-%255B4-%25286-ethoxypyridin-3-yl%2529benzyl%255D-5-%25285-methylpyridin-2-ylmethoxy%2529-1H-indol-2-yl%255D-2%252C2-dimethylpropionic%2520acid%2520%2528AM803%2529%252C%2520a%2520potent%252C%2520oral%252C%2520once%2520daily%2520FLAP%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8013%26epage%3D8029%26doi%3D10.1021%2Fjm2008369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, H.</span>; <span class="NLM_string-name">Bartolozzi, A.</span>; <span class="NLM_string-name">Simpson, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the novel oxadiazole-containing 5-lipoxygenase activating protein (FLAP) inhibitor BI 665915</span>.  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_publisher-name">American Chemical Society</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1239</span>, pp  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">119</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=101-119&author=H.+Takahashi&author=A.+Bartolozzi&author=T.+Simpson&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch004%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520the%2520novel%2520oxadiazole-containing%25205-lipoxygenase%2520activating%2520protein%2520%2528FLAP%2529%2520inhibitor%2520BI%2520665915%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2016%26volume%3D1239%26spage%3D101%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gür, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Çalışkan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banoglu, E.</span></span> <span> </span><span class="NLM_article-title">Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.ejmech.2017.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=28784429" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2018&pages=34-48&author=Z.+T.+G%C3%BCrauthor=B.+%C3%87al%C4%B1%C5%9Fkanauthor=E.+Banoglu&title=Drug+discovery+approaches+targeting+5-lipoxygenase-activating+protein+%28FLAP%29+for+inhibition+of+cellular+leukotriene+biosynthesis&doi=10.1016%2Fj.ejmech.2017.07.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCr%26aufirst%3DZ.%2BT.%26aulast%3D%25C3%2587al%25C4%25B1%25C5%259Fkan%26aufirst%3DB.%26aulast%3DBanoglu%26aufirst%3DE.%26atitle%3DDrug%2520discovery%2520approaches%2520targeting%25205-lipoxygenase-activating%2520protein%2520%2528FLAP%2529%2520for%2520inhibition%2520of%2520cellular%2520leukotriene%2520biosynthesis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D153%26spage%3D34%26epage%3D48%26doi%3D10.1016%2Fj.ejmech.2017.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemurell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winiwarter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsson, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtenäs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hovdal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydén-Landergren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlind, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herslöf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drmota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigfridsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1021/jm501531v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501531v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=897-911&author=M.+Lemurellauthor=J.+Ulanderauthor=S.+Winiwarterauthor=A.+Dahl%C3%A9nauthor=%C3%96.+Davidssonauthor=H.+Emten%C3%A4sauthor=J.+Broddefalkauthor=M.+Swansonauthor=D.+Hovdalauthor=A.+T.+Plowrightauthor=A.+Pettersenauthor=M.+Ryd%C3%A9n-Landergrenauthor=J.+Barlindauthor=A.+Llinasauthor=M.+Hersl%C3%B6fauthor=T.+Drmotaauthor=K.+Sigfridssonauthor=S.+Mosesauthor=C.+Whatling&title=Discovery+of+AZD6642%2C+an+inhibitor+of+5-lipoxygenase+activating+protein+%28FLAP%29+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Fjm501531v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm501531v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501531v%26sid%3Dliteratum%253Aachs%26aulast%3DLemurell%26aufirst%3DM.%26aulast%3DUlander%26aufirst%3DJ.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DDahl%25C3%25A9n%26aufirst%3DA.%26aulast%3DDavidsson%26aufirst%3D%25C3%2596.%26aulast%3DEmten%25C3%25A4s%26aufirst%3DH.%26aulast%3DBroddefalk%26aufirst%3DJ.%26aulast%3DSwanson%26aufirst%3DM.%26aulast%3DHovdal%26aufirst%3DD.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26aulast%3DPettersen%26aufirst%3DA.%26aulast%3DRyd%25C3%25A9n-Landergren%26aufirst%3DM.%26aulast%3DBarlind%26aufirst%3DJ.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DHersl%25C3%25B6f%26aufirst%3DM.%26aulast%3DDrmota%26aufirst%3DT.%26aulast%3DSigfridsson%26aufirst%3DK.%26aulast%3DMoses%26aufirst%3DS.%26aulast%3DWhatling%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520AZD6642%252C%2520an%2520inhibitor%2520of%25205-lipoxygenase%2520activating%2520protein%2520%2528FLAP%2529%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D897%26epage%3D911%26doi%3D10.1021%2Fjm501531v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spade, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altemus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boekelheide, K.</span></span> <span> </span><span class="NLM_article-title">Identification of sperm mRNA biomarkers associated with testis injury during preclinical testing of pharmaceutical compounds</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2017.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.taap.2017.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=28167222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFSntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2017&pages=1-7&author=E.+Dereauthor=D.+J.+Spadeauthor=S.+J.+Hallauthor=A.+Altemusauthor=J.+D.+Smithauthor=J.+A.+Phillipsauthor=J.+S.+Moffitauthor=K.+T.+Blanchardauthor=K.+Boekelheide&title=Identification+of+sperm+mRNA+biomarkers+associated+with+testis+injury+during+preclinical+testing+of+pharmaceutical+compounds&doi=10.1016%2Fj.taap.2017.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of sperm mRNA biomarkers associated with testis injury during preclinical testing of pharmaceutical compounds</span></div><div class="casAuthors">Dere, Edward; Spade, Daniel J.; Hall, Susan J.; Altemus, Aimee; Smith, James D.; Phillips, Jonathan A.; Moffit, Jeffrey S.; Blanchard, Kerry T.; Boekelheide, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The human testis is sensitive to toxicant-induced injury but current methods for detecting adverse effects are limited, insensitive and unreliable.  Animal studies use sensitive histopathol. endpoints to assess toxicity, but require testicular tissue that is not available during human clin. trials.  More sensitive and reliable mol. biomarkers of testicular injury are needed to better monitor testicular toxicity in both clin. and preclin.  Adult male Wistar Han rats were exposed for 4 wk to compds. previously assocd. with testicular injury, including cisplatin (0, 0.2, 0.3, or 0.4 mg/kg/day), BI665915 (0, 20, 70, 100 mg/kg/d), BI665636 (0, 20, 100 mg/kg/d) or BI163538 (0, 70, 150, 300 mg/kg/d) to evaluate reproductive toxicity and assess changes in sperm mRNA levels.  None of the compds. resulted in any significant changes in body, testis or epididymis wts., nor were there decreases in testicular homogenization resistant spermatid head counts.  Histopathol. evaluation found that only BI665915 treatment caused any testicular effects, including minor germ cell loss and disorganization of the seminiferous tubule epithelium, and an increase in the no. of retained spermatid heads.  A custom PCR-array panel was used to assess induced changes in sperm mRNA.  BI665915 treatment resulted in a significant increase in clusterin (Clu) levels and decreases in GTPase, IMAP family member 4 (Gimap4), prostaglandin D2 synthase (Ptgds) and transmembrane protein with EGF like and two follistatin like domains 1 (Tmeff1) levels.  Correlation anal. between transcript levels and quant. histopathol. endpoints found a modest assocn. between Clu with retained spermatid heads.  These results demonstrate that sperm mRNA levels are sensitive mol. indicators of testicular injury that can potentially be translated into a clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo2LNsJ2tYnbVg90H21EOLACvtfcHk0liNWeb_iA3qyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFSntbw%253D&md5=4fa08092dda1ef77af1f05e33b00ee5e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2017.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2017.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DDere%26aufirst%3DE.%26aulast%3DSpade%26aufirst%3DD.%2BJ.%26aulast%3DHall%26aufirst%3DS.%2BJ.%26aulast%3DAltemus%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DJ.%2BD.%26aulast%3DPhillips%26aufirst%3DJ.%2BA.%26aulast%3DMoffit%26aufirst%3DJ.%2BS.%26aulast%3DBlanchard%26aufirst%3DK.%2BT.%26aulast%3DBoekelheide%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520sperm%2520mRNA%2520biomarkers%2520associated%2520with%2520testis%2520injury%2520during%2520preclinical%2520testing%2520of%2520pharmaceutical%2520compounds%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2017%26volume%3D320%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.taap.2017.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. C.</span></span> <span> </span><span class="NLM_article-title">Eicosanoid transcellular biosynthesis: from cell-cell Interactions to in vivo tissue responses</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">375</span>, <span class="refDoi"> DOI: 10.1124/pr.58.3.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1124%2Fpr.58.3.8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=375&author=G.+Folcoauthor=R.+C.+Murphy&title=Eicosanoid+transcellular+biosynthesis%3A+from+cell-cell+Interactions+to+in+vivo+tissue+responses&doi=10.1124%2Fpr.58.3.8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.8%26sid%3Dliteratum%253Aachs%26aulast%3DFolco%26aufirst%3DG.%26aulast%3DMurphy%26aufirst%3DR.%2BC.%26atitle%3DEicosanoid%2520transcellular%2520biosynthesis%253A%2520from%2520cell-cell%2520Interactions%2520to%2520in%2520vivo%2520tissue%2520responses%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D375%26doi%3D10.1124%2Fpr.58.3.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamin, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujjainwalla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. W.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1126/science.1144346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1126%2Fscience.1144346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=17600184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFylur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2007&pages=510-512&author=A.+D.+Fergusonauthor=B.+M.+McKeeverauthor=S.+Xuauthor=D.+Wisniewskiauthor=D.+K.+Millerauthor=T.-T.+Yaminauthor=R.+H.+Spencerauthor=L.+Chuauthor=F.+Ujjainwallaauthor=B.+R.+Cunninghamauthor=J.+F.+Evansauthor=J.+W.+Becker&title=Crystal+structure+of+inhibitor-bound+human+5-lipoxygenase-activating+protein&doi=10.1126%2Fscience.1144346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein</span></div><div class="casAuthors">Ferguson, Andrew D.; McKeever, Brian M.; Xu, Shihua; Wisniewski, Douglas; Miller, Douglas K.; Yamin, Ting-Ting; Spencer, Robert H.; Chu, Lin; Ujjainwalla, Feroze; Cunningham, Barry R.; Evans, Jilly F.; Becker, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">5837</span>),
    <span class="NLM_cas:pages">510-512</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Leukotrienes are proinflammatory products of arachidonic acid oxidn. by 5-lipoxygenase that have been shown to be involved in respiratory and cardiovascular diseases.  The integral membrane protein 5-lipoxygenase-activating protein (FLAP) is essential for leukotriene biosynthesis.  We describe the x-ray crystal structures of human FLAP in complex with two leukotriene biosynthesis inhibitors at 4.0 and 4.2 angstrom resoln., resp.  The structures show that inhibitors bind in membrane-embedded pockets of FLAP, which suggests how these inhibitors prevent arachidonic acid (AA) from binding to FLAP and subsequently being transferred to 5-lipoxygenase (5-LO), thereby preventing leukotriene biosynthesis.  This structural information provides a platform for the development of therapeutics for respiratory and cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SUG1wwYenLVg90H21EOLACvtfcHk0liNWeb_iA3qyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFylur4%253D&md5=63a64a92c9c07b4543a4ec93a239031f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1144346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1144346%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DMcKeever%26aufirst%3DB.%2BM.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DWisniewski%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DYamin%26aufirst%3DT.-T.%26aulast%3DSpencer%26aufirst%3DR.%2BH.%26aulast%3DChu%26aufirst%3DL.%26aulast%3DUjjainwalla%26aufirst%3DF.%26aulast%3DCunningham%26aufirst%3DB.%2BR.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DBecker%26aufirst%3DJ.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520inhibitor-bound%2520human%25205-lipoxygenase-activating%2520protein%26jtitle%3DScience%26date%3D2007%26volume%3D317%26spage%3D510%26epage%3D512%26doi%3D10.1126%2Fscience.1144346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span> </span><span class="NLM_article-title">Pipeline Pilot</span>.  <i>Basic Chemistry User Guide</i>; <span class="NLM_publisher-name">Scitegic Inc.</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pipeline+Pilot.+Basic+Chemistry+User+Guide%3B+Scitegic+Inc.%3A+San+Diego%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DPipeline%2520Pilot%26btitle%3DBasic%2520Chemistry%2520User%2520Guide%26pub%3DScitegic%2520Inc%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickup, B. T.</span></span> <span> </span><span class="NLM_article-title">A gaussian description of molecular shape</span>. <i>J. Phys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">3503</span>– <span class="NLM_lpage">3510</span>, <span class="refDoi"> DOI: 10.1021/j100011a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/j100011a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1995&pages=3503-3510&author=J.+A.+Grantauthor=B.+T.+Pickup&title=A+gaussian+description+of+molecular+shape&doi=10.1021%2Fj100011a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fj100011a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100011a016%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DJ.%2BA.%26aulast%3DPickup%26aufirst%3DB.%2BT.%26atitle%3DA%2520gaussian%2520description%2520of%2520molecular%2520shape%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1995%26volume%3D99%26spage%3D3503%26epage%3D3510%26doi%3D10.1021%2Fj100011a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krejsa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogalski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penzotti, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migeon, J. C.</span></span> <span> </span><span class="NLM_article-title">Predicting ADME properties and side effects: the BioPrint approach</span>. <i>Curr. Opin. Drug Discov. Devel.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=12951810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=470-480&author=C.+M.+Krejsaauthor=D.+Horvathauthor=S.+L.+Rogalskiauthor=J.+E.+Penzottiauthor=B.+Maoauthor=F.+Barbosaauthor=J.+C.+Migeon&title=Predicting+ADME+properties+and+side+effects%3A+the+BioPrint+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting ADME properties and side effects: The BioPrint approach</span></div><div class="casAuthors">Krejsa, Cecile M.; Horvath, Dragos; Rogalski, Sherri L.; Penzotti, Julie E.; Mao, Boryeu; Barbosa, Frederique; Migeon, Jacques C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Current Drugs</span>)
        </div><div class="casAbstract">A review.  Computational methods are increasingly used to streamline and enhance the lead discovery and optimization process.  However, accurate prediction of absorption, distribution, metab. and excretion (ADME) and adverse drug reactions (ADR) is often difficult, due to the complexity of underlying physiol. mechanisms.  Modeling approaches have been hampered by the lack of large, robust and standardized training datasets.  In an extensive effort to build such a dataset, the BioPrint database was constructed by systematic profiling of nearly all drugs available on the market, as well as numerous ref. compds.  The database is composed of several large datasets: compd. structures and mol. descriptors, in vitro ADME and pharmacol. profiles, and complementary clin. data including therapeutic use information, pharmacokinetics profiles and ADR profiles.  These data have allowed the development of computational tools designed to integrate a program of computational chem. into library design and lead development.  Models based on chem. structure are strengthened by in vitro results that can be used as addnl. compd. descriptors to predict complex in vivo endpoints.  The BioPrint pharmacoinformatics platform represents a systematic effort to accelerate the process of drug discovery, improve quant. structure-activity relationships and develop in vitro/in vivo assocns.  In this review, we will discuss the importance of training set size and diversity in model development, the implementation of linear and neighborhood modeling approaches, and the use of in silico methods to predict potential clin. liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQ71juUoErrVg90H21EOLACvtfcHk0liAspS1Ft77pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFymsLw%253D&md5=f8db4e37cc895d67bf4a82efe021c5c2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrejsa%26aufirst%3DC.%2BM.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRogalski%26aufirst%3DS.%2BL.%26aulast%3DPenzotti%26aufirst%3DJ.%2BE.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DBarbosa%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%2BC.%26atitle%3DPredicting%2520ADME%2520properties%2520and%2520side%2520effects%253A%2520the%2520BioPrint%2520approach%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discov.%2520Devel.%26date%3D2003%26volume%3D6%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span> <i>MOE
Molecular
Operating Environment</i>; <span class="NLM_publisher-name">Chemical Computing
Group, Inc.</span>: <span class="NLM_publisher-loc">Montreal,
Canada</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MOE%0AMolecular%0AOperating+Environment%3B+Chemical+Computing%0AGroup%2C+Inc.%3A+Montreal%2C%0ACanada%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMOE%250AMolecular%250AOperating%2520Environment%26pub%3DChemical%2520Computing%250AGroup%252C%2520Inc%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">OpenEye</span>.  <i>ROCS</i>; <span class="NLM_publisher-name">OpenEye</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=OpenEye&title=ROCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DROCS%26pub%3DOpenEye%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löfberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtenäs, H.</span></span> <span> </span><span class="NLM_article-title">A practical telescoped three-step sequence for the preparation of (1R,2R)-2-(4-Bromobenzoyl)cyclohexanecarboxylic acid: a key building block used in one of our drug development projects</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlyiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=618-624&author=S.+Karlssonauthor=R.+Bergmanauthor=J.+Broddefalkauthor=C.+L%C3%B6fbergauthor=P.+R.+Mooreauthor=A.+Starkauthor=H.+Emten%C3%A4s&title=A+practical+telescoped+three-step+sequence+for+the+preparation+of+%281R%2C2R%29-2-%284-Bromobenzoyl%29cyclohexanecarboxylic+acid%3A+a+key+building+block+used+in+one+of+our+drug+development+projects&doi=10.1021%2Facs.oprd.8b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical Telescoped Three-Step Sequence for the Preparation of (1R,2R)-2-(4-Bromobenzoyl)cyclohexanecarboxylic Acid: A Key Building Block Used in One of Our Drug Development Projects</span></div><div class="casAuthors">Karlsson, Staffan; Bergman, Rolf; Broddefalk, Johan; Loefberg, Christian; Moore, Peter R.; Stark, Andrew; Emtenaes, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">618-624</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A method for the prepn. of the pyrazolylbenzoylcyclohexanecarboxamide I on multi-hundred gram scale was implemented using a one-pot Friedel-Crafts reaction of II with bromobenzene followed by epimerization and ester hydrolysis to yield benzoylcyclohexanecarboxylic acid III, an amidation reaction using propylphosphonic anhydride, and a Suzuki coupling with a tetrahydropyranyl-protected pyrazoleboronate as the key steps.  Crystn. was used to purify III instead of chromatog.; III could then be used to prep. related compds. using amidation and Suzuki coupling reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_kOuKoaHG5rVg90H21EOLACvtfcHk0liAspS1Ft77pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlyiu7s%253D&md5=e2c638901253741ed117091e27b242c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00066%26sid%3Dliteratum%253Aachs%26aulast%3DKarlsson%26aufirst%3DS.%26aulast%3DBergman%26aufirst%3DR.%26aulast%3DBroddefalk%26aufirst%3DJ.%26aulast%3DL%25C3%25B6fberg%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DP.%2BR.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DEmten%25C3%25A4s%26aufirst%3DH.%26atitle%3DA%2520practical%2520telescoped%2520three-step%2520sequence%2520for%2520the%2520preparation%2520of%2520%25281R%252C2R%2529-2-%25284-Bromobenzoyl%2529cyclohexanecarboxylic%2520acid%253A%2520a%2520key%2520building%2520block%2520used%2520in%2520one%2520of%2520our%2520drug%2520development%2520projects%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26spage%3D618%26epage%3D624%26doi%3D10.1021%2Facs.oprd.8b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satoshi, I.</span>; <span class="NLM_string-name">Yuji, Y.</span>; <span class="NLM_string-name">Kentaro, I.</span></span> <span> </span><span class="NLM_article-title">(6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide Compound</span>. <span class="NLM_patent">WO/2015/098853</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=I.+Satoshi&author=Y.+Yuji&author=I.+Kentaro&title=%286S%2C9aS%29-N-Benzyl-6-%5B%284-hydroxyphenyl%29methyl%5D-4%2C7-dioxo-8-%28%7B6-%5B3-%28piperazin-1-yl%29azetidin-1-yl%5Dpyridin-2-yl%7Dmethyl%29-2-%28prop-2-en-1-yl%29-octahydro-1H-pyrazino%5B2%2C1-c%5D%5B1%2C2%2C4%5Dtriazine-1-carboxamide+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSatoshi%26aufirst%3DI.%26atitle%3D%25286S%252C9aS%2529-N-Benzyl-6-%255B%25284-hydroxyphenyl%2529methyl%255D-4%252C7-dioxo-8-%2528%257B6-%255B3-%2528piperazin-1-yl%2529azetidin-1-yl%255Dpyridin-2-yl%257Dmethyl%2529-2-%2528prop-2-en-1-yl%2529-octahydro-1H-pyrazino%255B2%252C1-c%255D%255B1%252C2%252C4%255Dtriazine-1-carboxamide%2520Compound%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miles, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naimoli, B. J.</span></span> <span> </span><span class="NLM_article-title">Diels-Alder Reactions of β-Acylacrylic Acids</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1980</span>– <span class="NLM_lpage">1991</span>, <span class="refDoi"> DOI: 10.1080/00397911.2012.686002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1080%2F00397911.2012.686002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2013&pages=1980-1991&author=W.+H.+Milesauthor=E.+M.+Cohenauthor=B.+J.+Naimoli&title=Diels-Alder+Reactions+of+%CE%B2-Acylacrylic+Acids&doi=10.1080%2F00397911.2012.686002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Diels-Alder Reactions of β-Acylacrylic Acids</span></div><div class="casAuthors">Miles, William H.; Cohen, Evan M.; Naimoli, Barbara J.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1980-1991</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The Diels-Alder reaction of β-acyl acrylic acids with dienes gave good yields with good regio- or stereoselectivity of the corresponding cycloaddn. products with the use of Lewis acids.  E.g., in presence of DIPEA/SnCl4, Diels-Alder reaction of (E)-4-MeC6H4COCH:CHCO2H with cyclopentadiene gave 96% I and II (ratio 93/7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh4KRqTTnGSbVg90H21EOLACvtfcHk0liAspS1Ft77pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCgu7Y%253D&md5=dafce0217fb7728fe63d05308521c9b0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F00397911.2012.686002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397911.2012.686002%26sid%3Dliteratum%253Aachs%26aulast%3DMiles%26aufirst%3DW.%2BH.%26aulast%3DCohen%26aufirst%3DE.%2BM.%26aulast%3DNaimoli%26aufirst%3DB.%2BJ.%26atitle%3DDiels-Alder%2520Reactions%2520of%2520%25CE%25B2-Acylacrylic%2520Acids%26jtitle%3DSynth.%2520Commun.%26date%3D2013%26volume%3D43%26spage%3D1980%26epage%3D1991%26doi%3D10.1080%2F00397911.2012.686002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roppe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>640</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fj.ejphar.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=20519143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=640&publication_year=2010&pages=211-218&author=D.+S.+Lorrainauthor=G.+Bainauthor=L.+D.+Correaauthor=C.+Chapmanauthor=A.+R.+Broadheadauthor=A.+M.+Santiniauthor=P.+P.+Prodanovichauthor=J.+V.+Darlingtonauthor=N.+S.+Stockauthor=J.+Zunicauthor=C.+D.+Kingauthor=C.+Leeauthor=C.+S.+Bacceiauthor=B.+Stearnsauthor=J.+Roppeauthor=J.+H.+Hutchinsonauthor=P.+Prasitauthor=J.+F.+Evans&title=Pharmacology+of+AM803%2C+a+novel+selective+five-lipoxygenase-activating+protein+%28FLAP%29+inhibitor+in+rodent+models+of+acute+inflammation&doi=10.1016%2Fj.ejphar.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation</span></div><div class="casAuthors">Lorrain, Daniel S.; Bain, Gretchen; Correa, Lucia D.; Chapman, Charles; Broadhead, Alex R.; Santini, Angelina M.; Prodanovich, Patricia P.; Darlington, Janice V.; Stock, Nicholas S.; Zunic, Jasmine; King, Christopher D.; Lee, Catherine; Baccei, Christopher S.; Stearns, Brian; Roppe, Jeffrey; Hutchinson, John H.; Prasit, Peppi; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">640</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">211-218</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the in vivo pharmacol. properties of AM803 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, a selective 5-lipoxygenase-activating protein (FLAP) inhibitor, using rat and mouse models of acute inflammation.  Oral administration of AM803 (1 mg/kg) resulted in sustained inhibition of ex vivo ionophore-challenged whole blood LTB4 biosynthesis with > 90% inhibition for up to 12 h and an EC50 of ∼ 7 nM.  When rat lungs were challenged in vivo with calcium-ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) prodn. with ED50s of 0.12 mg/kg and 0.37 mg/kg, resp.  The inhibition measured 16 h following a single oral dose of 3 mg/kg was 86% and 41% for LTB4 and CysLTs, resp.  In an acute inflammation setting, AM803 dose-dependently reduced LTB4, CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection.  Finally, AM803 increased survival time in mice exposed to a lethal i.v. injection of platelet activating factor (PAF).  The magnitude of effect was similar to that of an inhibitor of 5-lipoxygenase (5-LO) and LTA4 hydrolase but superior to a leukotriene CysLT1 receptor antagonist.  In summary, AM803 is a novel, potent and selective FLAP inhibitor that has excellent pharmacodynamic properties in vivo and is effective in animal models of acute inflammation and in a model of lethal shock.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoht19LIcH5qrVg90H21EOLACvtfcHk0lj31ozU4GACGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOhurg%253D&md5=5286307a8518fe2c56a2ecbd0296b68f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DBroadhead%26aufirst%3DA.%2BR.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DProdanovich%26aufirst%3DP.%2BP.%26aulast%3DDarlington%26aufirst%3DJ.%2BV.%26aulast%3DStock%26aufirst%3DN.%2BS.%26aulast%3DZunic%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DRoppe%26aufirst%3DJ.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DPharmacology%2520of%2520AM803%252C%2520a%2520novel%2520selective%2520five-lipoxygenase-activating%2520protein%2520%2528FLAP%2529%2520inhibitor%2520in%2520rodent%2520models%2520of%2520acute%2520inflammation%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D640%26spage%3D211%26epage%3D218%26doi%3D10.1016%2Fj.ejphar.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fjellstrom, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Graaf, P. H.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.2174/156802611794480864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.2174%2F156802611794480864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=21320067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=404-418&author=J.+Gabrielssonauthor=O.+Fjellstromauthor=J.+Ulanderauthor=M.+Rowleyauthor=P.+H.+Van+Der%0AGraaf&title=Pharmacodynamic-pharmacokinetic+integration+as+a+guide+to+medicinal+chemistry&doi=10.2174%2F156802611794480864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry</span></div><div class="casAuthors">Gabrielsson, Johan; Fjellstroem, Ola; Ulander, Johan; Rowley, Michael; Van Der Graaf, Piet H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">404-418</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiol. and pathol. conditions in animals and man.  Since the pharmacol. response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concn. or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile.  Hence, the output of PKPD activities extends beyond the provision of quant. measures (models) of results, to the design of future protocols.  Furthermore, because PKPD integrates DMPK (e.g. clearance) and pharmacol. (e.g. potency), it provides an anchor point for compd. selection, and, as such, should be viewed as an important weapon in medicinal chem.  Here we outline key PK concepts relevant to PD, and then consider real-life expts. to illustrate the importance to the medicinal chemist of data obtained by PKPD.  Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations.  By condensing complexity to simplicity, there are not only consequences for exptl. design, and for the ranking and design of compds., but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics.  In short, by using quant. methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compd.'s profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIh-_qK3VZ3LVg90H21EOLACvtfcHk0lj31ozU4GACGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnurw%253D&md5=44ac533600b03d728344688033d0e1fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F156802611794480864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480864%26sid%3Dliteratum%253Aachs%26aulast%3DGabrielsson%26aufirst%3DJ.%26aulast%3DFjellstrom%26aufirst%3DO.%26aulast%3DUlander%26aufirst%3DJ.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DVan%2BDer%2BGraaf%26aufirst%3DP.%2BH.%26atitle%3DPharmacodynamic-pharmacokinetic%2520integration%2520as%2520a%2520guide%2520to%2520medicinal%2520chemistry%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D404%26epage%3D418%26doi%3D10.2174%2F156802611794480864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lj31ozU4GACGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortelmans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiger, E.</span></span> <span> </span><span class="NLM_article-title">The Ames salmonella/microsome mutagenicity assay</span>. <i>Mutat. Res., Fundam. Mol. Mech. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/s0027-5107(00)00064-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1016%2Fs0027-5107%2800%2900064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=11113466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslGhtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2000&pages=29-60&author=K.+Mortelmansauthor=E.+Zeiger&title=The+Ames+salmonella%2Fmicrosome+mutagenicity+assay&doi=10.1016%2Fs0027-5107%2800%2900064-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Ames Salmonella/microsome mutagenicity assay</span></div><div class="casAuthors">Mortelmans, K.; Zeiger, E.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">29-60</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review and discussion with 95 refs.  The Ames Salmonella/microsome mutagenicity assay (Salmonella test; Ames test) is a short-term bacterial reverse mutation assay specifically designed to detect a wide range of chem. substances that can produce genetic damage that leads to gene mutations.  The test employs several histidine dependent Salmonella strains each carrying different mutations in various genes in the histidine operon.  These mutations act as hot spots for mutagens that cause DNA damage via different mechanisms.  When the Salmonella tester strains are grown on a minimal media agar plate contg. a trace of histidine, only those bacteria that revert to histidine independence (his+) are able to form colonies.  The no. of spontaneously induced revertant colonies per plate is relatively const.  However, when a mutagen is added to the plate, the no. of revertant colonies per plate is increased, usually in a dose-related manner. The Ames test is used world-wide as an initial screen to det. the mutagenic potential of new chems. and drugs.  The test is also used for submission of data to regulatory agencies for registration or acceptance of many chems., including drugs and biocides.  International guidelines have been developed for use by corporations and testing labs. to ensure uniformity of testing procedures. This review provides historical aspects of how the Ames was developed and detailed procedures for performing the test, including the design and interpretation of results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJOx1kKxVF6LVg90H21EOLACvtfcHk0lgbE3l3Pfehgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslGhtr0%253D&md5=8c4804f0b78e09c6c6609859428a39bf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fs0027-5107%2800%2900064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0027-5107%252800%252900064-6%26sid%3Dliteratum%253Aachs%26aulast%3DMortelmans%26aufirst%3DK.%26aulast%3DZeiger%26aufirst%3DE.%26atitle%3DThe%2520Ames%2520salmonella%252Fmicrosome%2520mutagenicity%2520assay%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D2000%26volume%3D455%26spage%3D29%26epage%3D60%26doi%3D10.1016%2Fs0027-5107%2800%2900064-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börjesson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordén, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasselgren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span></span> <span> </span><span class="NLM_article-title">Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">16168</span>– <span class="NLM_lpage">16185</span>, <span class="refDoi"> DOI: 10.1021/ja206427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+for+main+features+of+structure-genotoxicity+relationships+of+aromatic+amines+by+theoretical+studies+of+their+activation+pathways+in+CYP1A2&doi=10.1021%2Fja206427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Explanation for Main Features of Structure-Genotoxicity Relationships of Aromatic Amines by Theoretical Studies of Their Activation Pathways in CYP1A2</span></div><div class="casAuthors">Shamovsky, Igor; Ripa, Lena; Borjesson, Lena; Mee, Christine; Norden, Bo; Hansen, Peter; Hasselgren, Catrin; O'Donovan, Mike; Sjo, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16168-16185</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arom. and heteroarom. amines (ArNH2) represent a class of potential mutagens that after being metabolically activated covalently modify DNA.  Activation of ArNH2 in many cases starts with N-hydroxylation by P 450 enzymes, primarily CYP1A2.  Poor understanding of structure-mutagenicity relationships of ArNH2 limits their use in drug discovery programs.  Key factors that facilitate activation of ArNH2 are revealed by exploring their reaction intermediates in CYP1A2 using DFT calcns.  On the basis of these calcns. and extensive anal. of structure-mutagenicity data, we suggest that mutagenic metabolites are generated by ferric peroxo intermediate, (CYP1A2)FeIII-OO-, in a three-step heterolytic mechanism.  First, the distal oxygen of the oxidant abstrs. proton from H-bonded ArNH2.  The subsequent proximal protonation of the resulting (CYP1A2)FeIII-OOH weakens both the O-O and the O-H bonds of the oxidant.  Heterolytic cleavage of the O-O bond leads to N-hydroxylation of ArNH- via SN2 mechanism, whereas cleavage of the O-H bond results in release of hydroperoxy radical.  Thus, our proposed reaction offers a mechanistic explanation for previous observations that metab. of arom. amines could cause oxidative stress.  The primary drivers for mutagenic potency of ArNH2 are (i) binding affinity of ArNH2 in the productive binding mode within the CYP1A2 substrate cavity, (ii) resonance stabilization of the anionic forms of ArNH2, and (iii) exothermicity of proton-assisted heterolytic cleavage of N-O bonds of hydroxylamines and their bioconjugates.  This leads to a strategy for designing mutagenicity free ArNH2: Structural alterations in ArNH2, which disrupt geometric compatibility with CYP1A2, hinder proton abstraction, or strongly destabilize the nitrenium ion, in this order of priority, prevent genotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctr81IIN2trVg90H21EOLACvtfcHk0lgbE3l3Pfehgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI&md5=9447ee2144a899b65e9350b712ca2a46</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520for%2520main%2520features%2520of%2520structure-genotoxicity%2520relationships%2520of%2520aromatic%2520amines%2520by%2520theoretical%2520studies%2520of%2520their%2520activation%2520pathways%2520in%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185%26doi%3D10.1021%2Fja206427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">The use of stable isotopes in pharmacological research</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=7029573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADyaL38XlsFGksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1981&pages=81-132&author=T.+A.+Baillie&title=The+use+of+stable+isotopes+in+pharmacological+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The use of stable isotopes in pharmacological research</span></div><div class="casAuthors">Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-132</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    </div><div class="casAbstract">A review with 507 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx_TMoDPwOELVg90H21EOLACvtfcHk0lglbMH-gx0Eew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlsFGksLw%253D&md5=fb15a0ef3c0405714ad6c5baa2b9d584</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DThe%2520use%2520of%2520stable%2520isotopes%2520in%2520pharmacological%2520research%26jtitle%3DPharmacol.%2520Rev.%26date%3D1981%26volume%3D33%26spage%3D81%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desbans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgendorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungell, A.-L.</span></span> <span> </span><span class="NLM_article-title">Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.3109/00498254.2013.809617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.3109%2F00498254.2013.809617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=23883428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=17-27&author=C.+Desbansauthor=C.+Hilgendorfauthor=M.+Lutzauthor=P.+Bachellierauthor=T.+Zachariasauthor=J.+C.+Weberauthor=H.+Dolgosauthor=L.+Richertauthor=A.-L.+Ungell&title=Prediction+of+fraction+metabolized+via+CYP3A+in+humans+utilizing+cryopreserved+human+hepatocytes+from+a+set+of+12+single+donors&doi=10.3109%2F00498254.2013.809617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors</span></div><div class="casAuthors">Desbans, C.; Hilgendorf, C.; Lutz, M.; Bachellier, P.; Zacharias, T.; Weber, J. C.; Dolgos, H.; Richert, L.; Ungell, A.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-27</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. It has previously been demonstrated that metab. of drugs via a single enzymic pathway, particularly CYP3A4, is assocd. with increased risk for drug-drug interactions (DDI).  Quant. exptl. systems as well as integrated prediction models to assess such risk during the preclin. phase are highly warranted.  2. The present study was designed to systematically investigate the performance of human cryopreserved hepatocytes in suspension to predict fraction metabolized via CYP3A (fmCYP3A) by assessing the ketoconazole sensitive intrinsic clearance (CLint) for five prototypical CYP3A substrates with varying degree of CYP3A dependent CLint in twelve individual hepatocyte batches.  3. We demonstrate that in contrast to well predicted mean hepatic metabolic clearance (CLH) and mean fmCYP3A data, the variability in CYP3A contribution for compds. having multiple metabolic pathways cannot be predicted from inhibition expts. using ketoconazole as inhibitor.  Instead, data in the present paper indicate that the variability is larger after inhibition of CYP3A for compds. having multiple metabolic pathways.  4. It is therefore recommended to est. the av. CLint and fmCYP3Afor a given test compd. in a series (n = 10) of individual human hepatocyte batches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLabfu1cLLk7Vg90H21EOLACvtfcHk0lglbMH-gx0Eew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrfK&md5=f241913f7c67ed3e9437dc84e3f8bbef</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3109%2F00498254.2013.809617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2013.809617%26sid%3Dliteratum%253Aachs%26aulast%3DDesbans%26aufirst%3DC.%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DLutz%26aufirst%3DM.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DZacharias%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DJ.%2BC.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DUngell%26aufirst%3DA.-L.%26atitle%3DPrediction%2520of%2520fraction%2520metabolized%2520via%2520CYP3A%2520in%2520humans%2520utilizing%2520cryopreserved%2520human%2520hepatocytes%2520from%2520a%2520set%2520of%252012%2520single%2520donors%26jtitle%3DXenobiotica%26date%3D2014%26volume%3D44%26spage%3D17%26epage%3D27%26doi%3D10.3109%2F00498254.2013.809617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span> <span> </span><span class="NLM_article-title">Validation of early human dose prediction: a key metric for compound progression in drug discovery</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=609-620&author=K.+M.+Page&title=Validation+of+early+human+dose+prediction%3A+a+key+metric+for+compound+progression+in+drug+discovery&doi=10.1021%2Facs.molpharmaceut.5b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery</span></div><div class="casAuthors">Page, Ken M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-620</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human dose prediction is increasingly recognized as an important parameter in Drug Discovery.  Validation of a method using only in vitro and predicted parameters incorporated into a PK model was undertaken by predicting human dose and free Cmax for a no. of marketed drugs and AZ Development compds.  Doses were compared to those most relevant to marketed drugs or to clin. administered doses of AZ compds. normalized either to predicted Cmin or Cmax values.  Av. (AFE) and abs. av. (AAFE) fold-error anal. showed that best predictions were obtained using a QSAR model as the source of Vss, with Fabs set to 1 for acids and 0.5 for all other ion classes; for clearance prediction no binding correction to the well stirred model (WSM) was used for bases, while it was set to Fup/Fup0.5 for all other ion classes.  Using this combination of methods, predicted doses for 45 to 68% of the Cmin- and Cmax-normalized and marketed drug data sets were within 3-fold of the obsd. values, while 82 to 92% of these data sets were within 10-fold.  This method for early human dose prediction is able to rank, identify, and flag risks or optimization opportunities for future development compds. within 10 days of first synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT--CfNq9EGLVg90H21EOLACvtfcHk0lglbMH-gx0Eew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrs7%252FO&md5=612ece6c4e2729ab4694b0ae168e4cba</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DPage%26aufirst%3DK.%2BM.%26atitle%3DValidation%2520of%2520early%2520human%2520dose%2520prediction%253A%2520a%2520key%2520metric%2520for%2520compound%2520progression%2520in%2520drug%2520discovery%26jtitle%3DMol.%2520Pharm.%26date%3D2016%26volume%3D13%26spage%3D609%26epage%3D620%26doi%3D10.1021%2Facs.molpharmaceut.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Quantitative and Qualitative Evaluation of Extrapolation of Intravenous Pharmacokinetic Parameters from Rat, Dog, and Monkey to Humans. I. Clearance</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">603</span>, <span class="refDoi"> DOI: 10.1124/dmd.32.6.603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1124%2Fdmd.32.6.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=15155551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlOgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=603&author=K.+W.+Wardauthor=B.+R.+Smith&title=A+Comprehensive+Quantitative+and+Qualitative+Evaluation+of+Extrapolation+of+Intravenous+Pharmacokinetic+Parameters+from+Rat%2C+Dog%2C+and+Monkey+to+Humans.+I.+Clearance&doi=10.1124%2Fdmd.32.6.603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance</span></div><div class="casAuthors">Ward, Keith W.; Smith, Brian R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-611</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was conducted to comprehensively survey the available literature on i.v. pharmacokinetic parameters in the rat, dog, monkey, and human, and to compare common methods for extrapolation of clearance, to identify the most appropriate species to use in pharmacokinetic lead optimization, and to ascertain whether adequate prospective measures of predictive success are currently available.  One hundred three nonpeptide xenobiotics were identified with i.v. pharmacokinetic data in rat, dog, monkey, and human; both body wt.- and hepatic blood flow-based methods were used for scaling of clearance.  Allometric scaling approaches, particularly those using data from only two of the preclin. species, were less successful at predicting human clearance than methods based on clearance as a set fraction of liver blood flow from an individual species.  Furthermore, commonly used prospective measures of allometric scaling success, including correlation coeff. and allometric exponent, failed to discriminate between successful and failed allometric predictions.  In all instances, the monkey tended to provide the most qual. and quant. accurate predictions of human clearance and also afforded the least biased predictions compared with other species.  Addnl., the availability of data from both common nonrodent species (dog and monkey) did not ensure enhanced predictive quality compared with having only monkey data.  The observations in this investigation have major implications for pharmacokinetic lead optimization and for prediction of human clearance from in vivo preclin. data and support the continued use of nonhuman primates in preclin. pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAonnLuZFTbVg90H21EOLACvtfcHk0litEom4VlGmcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlOgtro%253D&md5=811ef885c0572fc4235e5d47afddefaf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26atitle%3DA%2520Comprehensive%2520Quantitative%2520and%2520Qualitative%2520Evaluation%2520of%2520Extrapolation%2520of%2520Intravenous%2520Pharmacokinetic%2520Parameters%2520from%2520Rat%252C%2520Dog%252C%2520and%2520Monkey%2520to%2520Humans.%2520I.%2520Clearance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D603%26doi%3D10.1124%2Fdmd.32.6.603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Øie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, T. N.</span></span> <span> </span><span class="NLM_article-title">Effect of altered plasma protein binding on apparent volume of distribution</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1002/jps.2600680948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;key=10.1002%2Fjps.2600680948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1979&pages=1203-1205&author=S.+%C3%98ieauthor=T.+N.+Tozer&title=Effect+of+altered+plasma+protein+binding+on+apparent+volume+of+distribution&doi=10.1002%2Fjps.2600680948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600680948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600680948%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2598ie%26aufirst%3DS.%26aulast%3DTozer%26aufirst%3DT.%2BN.%26atitle%3DEffect%2520of%2520altered%2520plasma%2520protein%2520binding%2520on%2520apparent%2520volume%2520of%2520distribution%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1979%26volume%3D68%26spage%3D1203%26epage%3D1205%26doi%3D10.1002%2Fjps.2600680948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span>; <span class="NLM_string-name">Emtenäs, H.</span>; <span class="NLM_string-name">Granberg, K.</span>; <span class="NLM_string-name">Lemurell, M.</span>; <span class="NLM_string-name">Pettersen, D.</span>; <span class="NLM_string-name">Plowright, A.</span>; <span class="NLM_string-name">Ulander, J.</span></span> <span> </span><span class="NLM_article-title">Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors</span>. <span class="NLM_patent">WO/2016/177703</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Broddefalk&author=H.+Emten%C3%A4s&author=K.+Granberg&author=M.+Lemurell&author=D.+Pettersen&author=A.+Plowright&author=J.+Ulander&title=Pyrazole+derivatives+useful+as+5-lipoxygenase+activating+protein+%28FLAP%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBroddefalk%26aufirst%3DJ.%26atitle%3DPyrazole%2520derivatives%2520useful%2520as%25205-lipoxygenase%2520activating%2520protein%2520%2528FLAP%2529%2520inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span>; <span class="NLM_string-name">Yamamoto, Y.</span>; <span class="NLM_string-name">Iso, K.</span></span> <span> </span><span class="NLM_article-title">(6S,9AS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-C][1,2,4]triazine-1-carboxamide compound</span>. U.S. Patent <span class="NLM_patent">20,150,175,615</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Inoue&author=Y.+Yamamoto&author=K.+Iso&title=%286S%2C9AS%29-N-Benzyl-6-%5B%284-hydroxyphenyl%29methyl%5D-4%2C7-dioxo-8-%28%7B6-%5B3-%28piperazin-1-yl%29azetidin-1-yl%5Dpyridin-2-yl%7Dmethyl%29-2-%28prop-2-en-1-yl%29-octahydro-1H-pyrazino%5B2%2C1-C%5D%5B1%2C2%2C4%5Dtriazine-1-carboxamide+compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DS.%26atitle%3D%25286S%252C9AS%2529-N-Benzyl-6-%255B%25284-hydroxyphenyl%2529methyl%255D-4%252C7-dioxo-8-%2528%257B6-%255B3-%2528piperazin-1-yl%2529azetidin-1-yl%255Dpyridin-2-yl%257Dmethyl%2529-2-%2528prop-2-en-1-yl%2529-octahydro-1H-pyrazino%255B2%252C1-C%255D%255B1%252C2%252C4%255Dtriazine-1-carboxamide%2520compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q7M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q7M','PDB','2Q7M'); return false;">PDB: 2Q7M</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q7R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Q7R','PDB','2Q7R'); return false;">PDB: 2Q7R</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i65"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02012">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18274"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b02012">10.1021/acs.jmedchem.8b02012</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_001.csv">CSV</a>)</p></li><li><p class="inline">General experimental setup for analysis and characterization, FLAP binding assay, whole blood LTB<sub>4</sub> assay, assays related to ADME and safety profiling (log <i>D</i>, solubility, CYP inhibition, hepatocyte CL<sub>int</sub> (human, rat, dog), Caco-2 <i>P</i><sub>app</sub> assay, RM trapping (GSH and CH<sub>3</sub>ONH<sub>2</sub>), CYP reaction profiling (CYP3A4 contribution and fraction metabolised), plasma protein binding (human, rat, dog), fraction unbound in the incubation, blood/plasma ratio, hERG inhibition, inhibition of other cardiac ion channels, liver panel, phospholipidosis, hAhR activation, Ames test, in vitro micronucleus assay, whole blood COX-1 and COX-2 assays), MetID experimental details, in vivo PK and PK/PD experimental details, and dose prediction equations (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_001.csv">jm8b02012_si_001.csv (2.46 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b02012/suppl_file/jm8b02012_si_002.pdf">jm8b02012_si_002.pdf (974.0 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b02012&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-9%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b02012" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b02012" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997eacbfaed1fb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
